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Abstract
Penalized mixed-effects ordinal response models for high-dimensional genomic data in
twins and families
Amanda Elswick Gentry, B.A.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosphy at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Advisor: Kellie J. Archer, Ph.D.
Professor and Chair
College of Public Health at The Ohio State University

The Brisbane Longitudinal Twin Study (BLTS) was being conducted in Australia and was
funded by the US National Institute on Drug Abuse (NIDA). Adolescent twins were
sampled as a part of this study and surveyed about their substance use as part of the
Pathways to Cannabis Use, Abuse and Dependence project. The methods developed in this
dissertation were designed for the purpose of analyzing a subset of the Pathways data that
includes demographics, cannabis use metrics, personality measures, and imputed genotypes
(SNPs) for 493 complete twin pairs (986 subjects.) The primary goal was to determine
what combination of SNPs and additional covariates may predict cannabis use, measured
on an ordinal scale as: “never tried,” “used moderately,” or “used frequently”. To conduct
this analysis, we extended the ordinal Generalized Monotone Incremental Forward
Stagewise (GMIFS) method for mixed models. This extension includes allowance for a
unpenalized set of covariates to be coerced into the model as well as flexibility for
user-specified correlation patterns between twins in a family. The proposed methods are
applicable to high-dimensional (genomic or otherwise) data with ordinal response and
specific, known covariance structure within clusters.
Keywords: ordinal regression, penalization, mixed models, twin modeling, cannabis use,
GWAS, genomics

Chapter 1
Introduction
1.1

Motivation

The National Institute on Drug Abuse (NIDA) reported that only 36.1% of American high
school seniors perceive daily use of cannabis (marijuana) to be harmful 103 . This percentage
is representative of a trend; over the last several years, teens report less concern about the
dangers of cannabis use. In contrast, research continues to show that regular use of marijuana is associated with anxiety and depression and worsening of symptoms in those with
schizophrenia 104 . In answer to this public health concern, the NIDA has funded the Pathways to Cannabis Use, Abuse, and Dependence (Pathways) project to uncover, among other
things, the genetic and environmental factors influencing cannabis use among adolescents 56 .
This study utilizes data from the Brisbane Longitudinal Twin Study (BLTS) that sampled
thousands of Australian adolescents. Of primary research interest for this dissertation project
is determining what genetic variants, personality factors, and demographic measures are associated with ordinal level of cannabis use. From a statistical analysis perspective, detecting
these associations is not straight-forward since the covariate space is high-dimensional. Covariates include categorical measures (e.g. sex, zygosity), ordinal measures (e.g. alcohol
use), and continuous imputed allelic dosage values for over 8 million single nucleotide poly-
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morphism (SNP) loci. Additionally, the sample population includes twins and their siblings,
resulting in correlations among observations for which the model must account.
These data modeling challenges (high-dimensionality, correlated observations, and an ordinal outcome) are not unique to the Pathways to Cannabis Use, Abuse, and Dependence
project. As high-throughput genomic technologies become less expensive and more accessible, more researchers are utilizing them. SNP arrays, as well as methylation profiles and gene
expression technologies produce thousands, or even millions of data values for each subject,
meaning that studies including these measures will nearly always face the problem of more
covariates than subjects in the sample. Clustered data, including family and longitudinal
data as specific cases, are also a common data structure in health-related research. Currently,
there is no available statistical method which can appropriately model the data to answer
some relevant research questions. The primary goal in this dissertation is to address some
portion of this gap in statistical knowledge and develop a modeling strategy to efficiently
analyze the Pathways data.
This dissertation research is described in the following chapters and sections:
• Chapter 1: Introduction
– In order to properly explain the motivation for this research, it is necessary to
present an overview of the motivating dataset. The introduction will therefore
include a full description of the BLTS and Pathways data as well as a survey
of currently available ordinal regression methods for handling high-dimensional
and/or correlated data.
• Chapter 2: No-Penalty Subset
– The first method developed applies to an ordinal-response, penalized regression
method designed to model high-dimensional data. Many of these penalized methods require that the full set of covariates be included in the penalized set, i.e.,
that the penalization scheme be allowed to select (or not select) any of the avail2

able predictors for the final model. This presents a challenge when some subset
of covariates are considered clinically relevant and investigators wish to ensure
they are included in a final predictive model. Our proposed method allows some
subset of covariates, a “no penalty”subset, to be coerced into the model.
• Chapter 3: Mixed Model
– The second and primary method developed is an ordinal-response, penalized
mixed-model with a random effect that accounts for the specific genetic correlations between twins. By specifying the covariance structure between observations
in the same family (twin pair), the model is able to estimate the proportion of the
variance that may be attributed to genetic factors, shared environmental factors,
and/or subject-specific environmental factors. This proposed model includes a
no penalty subset, as developed in the previous chapter. Simulation studies are
conducted to evaluate the performance of the model.
• Chapter 4: Data Application
– This chapter includes an analysis of the primary, motivating data. The proposed
method is applied to the BLTS and Pathways data and the findings interpreted.
• Chapter 5: Conclusion and Future Directions
– The conclusion discusses the overall contribution the proposed method makes to
the field. Future research directions and goals are also presented.
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1.2
1.2.1

Data Description
The Brisbane Longitudinal Twin Study and the Pathways
to Cannabis Use, Abuse, and Dependence Project

The Queensland Institute of Medical Research (QIMR) initiated the Brisbane Longitudinal
Twin Study (BLTS) in 1992. The BLTS sample includes Australian monozygotic (identical)
and dizygotic (fraternal) twins (3,408 total twins), their siblings (1,572 total individuals), and
their parents, representing 1,703 total families. Data collected since 1992 has focused on some
common diseases, such as melanoma and asthma, psychiatric conditions, such as anxiety,
depression, schizophrenia, and use and abuse of a range of both legal and illicit substances.
The US National Institute on Drug Abuse (NIDA) funded the Pathways to Cannabis Use,
Abuse, and Dependence (Pathways) project which collected data from the BLTS for the
purpose of discovering genetic and environmental factors associated with marijuana use
in adolescents 56 . As part of the Pathways project, alcohol and drug (including cannabis)
use was surveyed among BLTS Australian adolescent twins and their non-twin siblings.
Genome-wide association (GWA) data was collected for 8,809,012 typed and imputed single
nucleotide polymorphisms (SNPs), obtained via the Illumina 610k SNP array. In addition,
personality was measured with the Junior Eysenck Personality Questionnaire (JEPQ) 46 . We
will describe each of these three data collections, the drug use data, the SNP data, and the
personality data, in greater detail. It is important to note that the subset of participants
in each of these three data collections varies slightly; the final analysis will therefore include
fewer subjects (the subset that participated in all three data collections) that each dataset
contains individually.

1.2.2

Drug Use Dataset

Under funding from the NIH/NIDA Pathways project, BLTS subjects where administered
questionnaires surveying, among other things, their general health, activities, personality,
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and drug and alcohol use. Participants were asked about each of the following substances:
Alcohol, Nicotine, Cannabis, Cocaine, Amphetamine-type stimulants, Inhalants, Sedatives
or Sleeping Pills, Hallucinogens, Opiods, Ecstasy, Ketamine, GHB or party drugs, and overthe-counter and prescription Analgesics and Stimulants for non-medical purposes. Questions
about these substances asked about age of initiation, past three-month and lifetime use, as
well as any concurrent use of any of these substances with alcohol. For each of alcohol,
nicotine, and cannabis, measures referred to as “stem items” were calculated based on the
substance use questionnaire responses. If responses to Diagnostic and Statistical Manual of
Mental Disorders, version 4 and 5 (DSM-IV and DSM-V) use questions in each of these three
substance categories met certain criteria, then the DSM-IV/V abuse and dependence items
where administered to the participant. Participants were asked the abuse and dependence
item if they reported smoking at least 100 cigarettes in their lifetime, consuming five or more
drinks (for males) or four or more drinks (for females) at least once a week for a month or
more, or using marijuana at least six times in their lifetime for each of nicotine, alcohol, and
cannabis, respectively. The stem items for each of these three categories indicates use on an
ordinal scale as described in Table 1.1.
Ordinal Level
0
1
2

Ordinal Description
“Never tried”
“Used moderately”
“Used frequently”

Explanation
Never tried
Used, but not enough to meet the threshold
for use and dependence survey
Met or exceded use threshold

Table 1.1: Ordinal scale for stem items.
The drug use data are available for 3104 subjects, 2384 twins and 720 siblings. There
were 1360 male and 1744 female participants. The median age was 25 (mean 25.60), with
minimum of 18 and maximum of 38 (age not reported for 205 subjects). Table 1.2 below
shows a breakdown of twins by sex and zygosity.
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Female
Male
Total

MZ
564 (57.32%)
420 (42.68%)
984

DZ (same sex)
421 (57.12%)
316 (42.88%)
737

DZ (opposite sex)
356 (53.70%)
307 (46.30%)
663

Siblings
403 (55.97%)
317 (44.03%)
720

Total
1744 (56.19%)
1360 (43.81%)
3104

Table 1.2: Drug use questionnaire participant sex by zygosity.
Notice that Table 1.2 shows counts for individuals and not for pairs. In some cases, the
individual counts for twins may be odd numbers reflecting the fact that on some occassions,
only one twin from the pair chose to participate in the study. There were 429 complete
monozygotic (MZ) pairs, 577 complete DZ pairs, 313 complete same-sex dizygotic (DZ)
pairs and 264 complete opposite-sex DZ pairs. Table 1.3 below gives the full breakdown of
same-sex pairs.

Female
Male

MZ
255 (59.44%)
174 (40.56%)

DZ (same sex)
189 (60.38%)
124 (39.62%)

Table 1.3: Number of same-sex twin pairs by zygosity.
Among the drug use questions were items asking participants if they had ever, in their
lifetime, used tobacco products, alcohol, and/or cannabis. A summary of these binary use
statistics, by sex, is given in Table 1.4 and includes the number of subjects who did not
respond to the question.

Tobacco

Alcohol

Cannabis

Used
Never used
Did not answer
Used
Never used
Did not answer
Used
Never used
Did not answer

Female
775 (44.44%)
787 (45.13%)
182 (10.44%)
1537 (88.13%)
26 (1.49%)
181 (10.38%)
830 (47.59%)
783 (44.90%)
131 (7.51%)

Male
744 (54.71%)
437 (32.13%)
179 (13.16%)
1165 (85.66%)
16 (1.18%)
179 (13.16%)
776 (57.06%)
442 (32.50%)
142(10.44%)

Table 1.4: Number of subjects reporting level of tobacco, alcohol, and cannabis use by sex.
If a participant indicated that they had used one of alcohol, tobacco, and/or cannabis,
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then the participant was subsequently asked at what age they initiated this use. The mean
and standard deviation of the age of initiation for each of the three substances are given in
Table 1.5.
Alcohol
Tobacco
Cannabis

Female
15.97 (1.77)
16.53 (2.53)
17.83 (2.68)

Male
15.71 (1.98)
16.99 (3.05)
17.66 (2.87)

Table 1.5: Mean and standard deviation of age of initiation for alcohol, tobacco, and cannabis
by sex.

1.2.3

Personality Data

The Junior Eysenck Personality Questionnaire (JEPQ) was administered to a subset of the
study participants in order to measure personality. The JEPQ assesses personality along
three primary dimensions, neuroticism, psychoticism, and extroversion 41 . Neuroticism measures elements such as self-esteem, anxiety, and depression, psychoticism measures empathy
and sensitivy such that a high score would indicate a liability towards psychotic illnesses,
and extroversion is a general measure of “sociability” 57 , A lie scale is also measured by the
JEPQ; this scale is intended to detect a pattern of “socially desirable”responses 41 . Each
dimension is assessed via a series of Yes/No questions to which the participant may choose
to answer, “Yes”, “No”, or “I don’t know”. The “I don’t know” responses are coded as
missing while “Yes” is coded as 1 and “No” is coded as 0. Typically, the missing values are
imputed prior to analysis 29 . The JEPQ consists of 81 questions, 20 for neuroticism, 17 for
psychoticism, 24 for extroversion, and 20 for lie. Generally speaking, it is appropriate to
include and impute missing values for subjects missing no more than 1/3 of the responses
from each dimension. The highest proportion missingness for an individual participant from
our dataset was 0.15, 0.12, 0.17, and 0.15, for neuroticism, psychoticism, extroversion, and
lie, respectively. Given these low proportions of missingness by subject, it was reasonable not
to exclude any subject on the basis of missing responses. Where a response was missing, the
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Figure 1.1: Histograms of scores for each JEPQ dimension.
subject- and dimension-specific median was obtained. This subject and dimension-specific
median was rounded to the closest value (either 0 or 1), and that rounded value imputed
for the missing value. A total, dimension-specific score for each subject is then found by
summing the responses for each subject across each dimension. The distributions of the four
dimensions are given in Figure 1.1.
JEPQ scores were available for a total of 3563 subjects. Among those, 1909 also had
drug use data.
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1.2.4

Genome-Wide Association Data

Gentic variants are of great interest in many research areas, including behavior genetics and
substance use research. Typically, genetic variants between individuals are measured by
Single Nucleotide Polymorphisms (SNPs). While all humans have over 99% of their DNA in
common, the small proportion of differences between humans DNA sequences are responsible
for the many of the visible and invisible differences between them. One genetic difference
often studied within human populations are SNPs. DNA is composed of 4 nucleotide bases,
adenine (A), thymine (T), cytosine (C), and guanine (G), arranged along two strands that
bind together in a specific way and coil to form the familiar double-helix shape. The specific
sequence of these 4 bases varies from person to person, however, as stated, 99% of the
sequence is the same for all humans. As illustrated in Figure 1.2, SNPs are the single
nucleotide base differences commonly occurring in the human population (generally speaking,
in greater than 1% of the population.) The figure shows a segment of one strand of DNA from
three individuals. These segments contain the same sequence of nucleotide bases everywhere
except for the location captured in the box labeled “SNP”, illustrating a single nucleotide
base difference that might occur along the sequences.

Figure 1.2: Illustration of a SNP, a single nucleotide base difference that commonly occurs
in the human population 89 .
9

It is approximated that there are around 10 million SNPs in the human genome. Humans
are diploid organisms and therefore have two complete sets of chromosomes. For each locus,
or location on the DNA strand, there are two copies. For SNPs, there are generally only two
possible alleles, or nucleotide base possibilities observed. One allele is often more commonly
observed in the population and is traditionally referred to as the “major allele”, while the
alternate form is referred to as the “minor allele”. And so, although more than two alleles
are possible for a given locus, for most loci, there are only two variations observed. Figure
1.3 shows the possible combinations of these alleles on a chromosome.

Figure 1.3: Illustration of the possible pairings of two alleles on a chromosome to form
homozygous or heterozygous loci 14 .
The two forms, in the figure, are denoted as “A” and “a”. When the two alleles are the
same, the form may be said to be homozygous and heterzygous when they are not. Genotype
is reported as the number of copies of the minor allele, therefore, considering “A” to be the
major allele, when two copies of the major allele are present, the genotype is 0. It is 1 when
both alleles are present and 2 when two copies of the minor allele appear.
As part of the Pathways project, subjects were genotyped using the Illumina 610K array.
The 610K utilizes Beadchip technology. This Beadchip array is comprised of beads which
are covered in DNA oligonucleotide probes. The appropriately named Human 610-Quad
array contains 4 arrays per slide and each array interrogates over 610,000 loci. Each 50bp
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probe ends one base short of the loci, or SNP location, of interest and after the DNA is
hybridized to the array, fluorescent antibodies labeling single-base extensions are used to
stain the array 59,73,74 . The relative proportions of red and green at each locus indicates the
genotype for that locus. Illumina’s Infinium II technology is illustrated in Figure 1.4, which
shows three different probes and illustrates the nucleotide bases attaching to the end of the
probes and emitting their fluorescent dye signals.

Figure 1.4: Illustration of the Infinium II technology interrogating three different loci on a
Beadchip array. Probe 1 has been covered in cytosine bases that have attached and probe 3
has been covered by thymine bases that have attached and these homozygous loci will emit
predominantly green and red signals respectively. Probe 2 is a heterozygous loci to which
guamine and adenine bases have attached and an approximately equally green and red signal
will emit from this probe.
The Beadchip array directly types fewer than one million SNPs while there are estimated
to be approximately 10 million SNPs across the human genome. SNPs on the genome,
however, are not independent of one another. A phenomenon known as linkage disequilibrium
is defined as, “the nonrandom association between the alleles at two or more genetic loci in
a natural breeding population.” 28 SNPs close together on the genome tend to be inherited
as a set, referred to as a haplotype. SNPs within a haplotype block have a certain, wellstudied correlation pattern. Large-scale projects, such as the International HapMap Project
were undertaken in order to create a map of the haplotype blocks present in the human
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genome. Owing to this and other mapping projects, a small number of tag SNPs (around a
half-million or so) may be directly typed and several million more inferred, or imputed, with
a high degree of certainty. Software such as Plink 114 leverage this haplotype and linkage
disequilibrium information to take the 610K array output and impute several million more
SNPs than the array is able to directly type. Because this imputation involves some level
of uncertainty, instead of reporting the imputed SNPs as hard call genotypes, the software
outputs imputed so-called “dosage”data. While hard call genotyping records a SNP as
having 0, 1, or 2 copies of the minor allele, the imputed dosage data gives a continuous value
between 0 and 2 as the estimated minor allele frequency. The genotype imputation for this
sample was accomplished with the University of Michigan’s Imputation Server 34 which at
the time of imputation, implemented ShapeIt 38 for the phasing step (haplotype estimation)
and minimac2 for the actual imputation 52,70 .

1.2.5

Final Analysis Set

The subset of subjects included in the final analysis is described here. In order to be included
in the final analysis, a subject had to be a member of a complete twin pair (complete data
had to be available for the co-twin), have taken the JEPQ, and have non-missing responses
for gender, zygosity, and the stem items for cannabis, alcohol, and nicotine. A total of 986
subjects (493 twin pairs) met these criteria. The distribution of participant sex and zygosity
is described in Table 1.6
Female
Male
Total

MZ
218 (59.89%)
146 (40.11%)
364

DZ (same sex)
214 (59.78%)
144 (40.22%)
358

DZ (opposite sex)
132 (50%)
132 (50%)
264

Total
564 (57.20%)
422 (42.80%)
986

Table 1.6: Participants in the final application analysis set sex by zygosity.
Table 1.7 shows the number and proportions of responses in each ordinal “stem” item, for
male and female participants. Recall that an ordinal level of use of “0” indicates never tried
or never used the substance, “1” indicates tried but did not use enough of the substance
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to meet the threshold levels to be administered the use and dependence survey, and “2”
indicates used frequently.

Tobacco

Alcohol

Cannabis

Total

0
1
2
0
1
2
0
1
2

Female
258 (45.74%)
196 (34.75%)
110 (19.50%)
13 (2.30%)
247 (43.79%)
304 (53.90%)
302 (53.55%)
152 (26.95%)
110 (19.50%)
564

Male
147 (34.83%)
150 (35.55%)
125 (29.62%)
4 (0.95%)
118 (27.96%)
300 (71.09%)
167 (39.57%)
80 (18.96%)
175 (41.47%)
422

Total
405 (41.08%)
346 (35.09%)
235 (23.83%)
17 (1.72%)
365 (37.02%)
604 (61.26%)
469 (47.57%)
232 (23.53%)
285 (28.90%)
986

Table 1.7: Number of subjects in the final application analysis set reporting level of tobacco,
alcohol, and cannabis use by sex.

1.3
1.3.1

Currently Available Methods
Biometric Twin Model

For decades, the classical twin design has been an important model in behavioral genetics and
it has traditionally been analyzed with the biometric twin model. We know that monozygotic (MZ) twins, or “identical” twins, share essentially identical genomes, while dizygotic
(DZ) twins, or “fraternal” twins, share approximately 50% of their genomes. Knowledge of
these approximate proportions of shared DNA is extremely useful from a modeling perspective. Even without measured genotypes, the biometrical twin model implements structural
equation modeling methods to estimate proportions of phenotypic variance due to additive
genetic effects, unique environmental effects, and either shared environmental or dominance
genetic effects 99 . This approach is especially powerful given that twins reared together live
in the same shared environment and share a (approximately) known proportion of their
genes. The biometric model framework is comprehensive and flexible to effectively answer
carefully constructed questions concerning latent factors that affect phenotypic variance in
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one or many variables at once; it may be used to parse out the true number and relationship
of latent genetic or environmental factors contributing to traits of interest.
The general biometric model for a continuous phenotype parses the variance of a phenotype according to the following formula 115 :

yij = µ + Aij + Dij + Cij + ij , where

(1.1)

yij is the observed phenotype for member j from family i,
µ is the overall mean,
Aij ∼ N (0, σA2 ) is an additive genetic component,
2
) is a dominance genetic component,
Dij ∼ N (0, σD

Cij ∼ N (0, σC2 ) is a common environment component,
ij ∼ N (0, σE2 ) is a unique (individual) environment component, and
these four variance components are mutually independent so that,
2
+ σE2 .
var(yij ) = σA2 + σC2 + σD

This model, referred to as the ACDE model, is often fit as a path model under the framework
of structural equation modeling. The OpenMX software 23,100,113 in R is the most popular
and effective means of fitting such a model. For many twin study samples, observations are
only available for pairs of MZ and DZ twins. When this is true, the model is not identifiable
because all four variance components cannot be simultaneously estimated. Generally, a
researcher may determine whether additive genetic or dominance genetics effects are more
likely to influence the phenotypic trait under study and choose to fit either an ACE or an
ADE model. Either an ACE or an ADE model may be indicated by examination of the
intracluster correlations (ICCs) of the phenotype or outcome of interest between MZ and
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DZ pairs. Allowing r to indicate the ICC, the following equations show what sort of variance
components are likely to be influencing an outcome, based on comparisons between MZ and
DZ ICCs:

rM Z = rDZ, shared environment,

(1.2)

rM Z = 2rDZ, additive genetics,

(1.3)

rM Z > 2rDZ, additive genetics and dominance genetics,

(1.4)

1
rDZ > rM Z, additive genetics and shared environment.
2

(1.5)

Variance components may be selectively dropped and nested models may be compared with
likelihood ratio tests. For example, if the shared environmental component is estimated to
be small, an AE model may be compared to an ACE model. One drawback of the biometric
approach is that it is not designed to accomodate a large number of covariates, such as
genome-wide SNP data.

1.3.2

Regression Tests for Association

When molecular genetic data are present, one of the simplest analyses is a single locus association test (SLAT). In the early days of single nucleotide polymorphism genotyping, SLAT
was the most common method for assessing quantitative trait loci. Under this framework,
each loci is entered as a covariate into a regression equation modeling a phenotype as the
outcome. As SNPs are typically typed or imputed to number in the thousands or even millions of loci, these were traditionally entered into a model one at a time so that each SNP
was tested individually. Then, these single-SNP model p-values were adjusted to account
for multiple testing 24 using, for example, a Bonferroni correction 77 or the Benjamini and
Hochberg false discovery rate (FDR) correction 20 . This approach was reliant on the theory
that a few SNPs with large effect size were driving many observable phenotypes. Although
this has been found to be true in some areas of research, success has also been found in
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using multivariable models with sets of SNPs or genes predicting phenotypes 25,98 . In general, as the research has matured, it has been concluded that most complex and/or common
diseases are likely to be caused by a larger number of SNPs with smaller effect, working in
concert 45,83,137 .
Around this same time, it was proposed that perhaps some combination of moderately
“suggestive” markers from the univariate SNP analyses might be used to identify some disease risk 45 . Even though such an approach was unlikely to identify a single SNP or very small
set of SNPs responsible for a given phenotype, the combination of information from many
SNPs might confer some information regarding the phenotype. Under these assumptions, the
polygenic risk score (PRS) approach was born. PRS analyses have been successful in psychiatric and behavior genetics in particular 58 and have successfully created and applied scores
that explained significant proportions of genetic variance in substance use applications 27,127 .
Somewhat related to the idea of the PRS is the approach taken by GCTA. Genome-wide
Complex Trait Analysis (GCTA) is a GWAS data analysis software, first designed as a computational tool for approximating the amount of phenotype variation explained by a large
number of SNPs all at once 138,139 . GCTA estimates the genetic relatedness matrices (GRMs)
explicitly for all individuals in the sample set and uses these to account for all genetic relatedness between subjects. The method fits all measured SNPs (either genome-wide or
chromosome-by-chromosome) as random effects in a regression model of a phentoype of interest. It therefore estimates the proportion of phenotypic variance attributable to all (typed
or imputed) available SNP markers.

1.3.3

Penalized Ordinal Regression Methods

The PRS or GCTA approaches are not necessarily ideal for the research goals of the Pathways
study. It is of interest to parse out some subset or group of markers which may be predictive
of cannabis use, and neither PRS nor GCTA accomplish this task since they are not designed
with covariate selection in mind. GCTA in particular is based on the idea that all measured
16

SNPs will contribute to the phenotype of interest. One goal in analyzing the Pathways data is
to identify some set of SNPs that are related to cannabis use. As mentioned previously, given
the high-dimensional and correlated nature of the GWA data, this is not a task that is readily
accomplished with existing statistical methodology. The first of the modeling considerations
to address is the high-dimensional nature of the data. Many penalized regression methods
have been developed, some of which apply to the ordinal regression setting.
One popular regularization approach is ridge regression. Ridge regression introduces
an L2-penalty term to the regression equation and is therefore more useful for addressing
multicollinearity than dimension reduction 68 . The nature of the ridge penalty prevents any
coefficient estimate to shrink to exactly zero. Although a ridge penalty has been adapted
for ordinal regression 39,87 and has been implemented for GWAS applications in quantitative
genetics, 36 such a regularization scheme does not directly address the need for variable selection. The widely-used Least Absolute Skrinkage and Selection Operator (LASSO) method,
originally developed for linear regression, penalizes the likelihood by introducing an L1penalty into the regression equation 122 . With the LASSO penalty, sparsity is encouraged
and the coefficients of some covariates are allowed to shrink to exactly zero, making it a
useful tool for variable selection. The elastic net penalty was introduced as a combination
of the ridge regression and LASSO approaches; it includes both an L1- and an L2-penalty
term 148 .
The LASSO was applied to the Bayesian setting 111 and the adaptive LASSO was developed to address the situations in which the LASSO solution is not consistent using adaptive
weights 147 . These have all been further expanded to methods such as the Bayesian adaptive
LASSO 86 and later, the Bayesian adaptive LASSO for ordinal regression 47 . Other variations of the general L1- and L2-penalties have also been applied to unordered multinomial
models 124,143 . The Dantzig selector 26 is another penalization scheme, similar to the LASSO,
that works by including in the likelihood formulation an L1-penalty term with specific constaints. The Dantzig selector was extended to allowing fitting of all generalized linear models
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and concurrently modified to address overshrinkage common with the implementation of the
original Dantzig selector 75 .
The LASSO was extended to apply more broadly to generalized linear regression 109 .
This methodology included a fitting algorithm that calculated the full penalized solution
path and has been implemented in the R packages glmpath 110 and glmnet 49 . One very
useful feature of glmpath is that the function allows the user to specify some subset of
covariates to be coerced into the model without penalization. The elastic net penalization
scheme (of which ridge regression and the LASSO are two special cases) may be found using
glmpath or glmnet via a linear, logistic, multinomial, Poisson, or Cox regression model and
the user may set the so-called “mixing parameter”to define the proportions of the L1- and
L2-penalty terms. Both packages implement fitting through slightly different algorithms,
although both use coordinate descent 50 . The glmpath and glmnet packages were both
extended for the continuation ratio method for ordinal outcomes in the glmpathcr 9,12 and
glmnetcr 8,12 packages, respectively. The ordinalNet package is another package that fits
an elastic net penalty via coordinate descent to ordinal response data using a variety of link
functions 135,136 .
A related penalized methodology is the Bayesian Sparse Linear Mixed Model (BSLMM) 144,145,146 .
Implemented in the software package GEMMA, the BSLMM is a so-called “hybrid” between
the linear mixed model and Bayesian variable selection regression models. Similar in nature
to the LASSO, BSLMM is based on the idea that some small, subset of variables may be
responsible for the outcome phenotype and the remaining variables are allowed to drop out
of the model alltogether. GEMMA does not, however, allow for ordinal response models.

Fitting Methods
Multiple methods for fitting the LASSO penalized model solution have been proposed and
some of these have led to the development of other penalized model forms. For example,
Least Angle Regression (LAR) was designed as an algorithm to solve the entire LASSO
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solution path (i.e., the solution for every possible tuning parameter) simultaneously 42 . A
similar fitting algorithm, Incremental Forward Stagewise (IFS) also solves the entire LASSO
solution path for a continuous response, but does so in a smoother fashion by forcing the path
to be monotone 64,123 . A more general form of IFS, the Generalized Monotone Incremental
Stagewise Regression (GMIFS) method is an extension that allows for a binary response to
be modeled using a logistic regression framework 64 . Consider a general likehood of the form:

L(β) = −

n
X

[yi log(pi + (1 − yi ) log(1 − pi )],

(1.6)

exp(xi β)
,
1 + exp(xi β)

(1.7)

i=1

where pi =

and yi is a binary response for subject i, pi is the probability of response, xi is a vector of
penalized predictors and β is the associated vector of penalized coefficients. Then the X
matrix is augmented to include the negative version of itself, so that {X}, with dimensions
n × p, becomes {X : −X}, with dimensions n × 2p. The GMIFS is an “incremental” fitting
method, meaning that in every iteration, or fitting “step,”the algorithm updates a single
parameter estimate by a small, incremental amount. Augmenting the covariate space in this
way saves computation time because the calculation of the second derivative is not necessary
in order to determine if the parameter to be updated should be incremented in the positive
or negative direction. By avoiding the additional calculation to determine the direction of
the update, the model may be fit more efficiently. The GMIFS fits a penalized solution
according to the following algorithm:
Step 1: Start with β1 , β2 , ..., β2p = 0.
Step 2: Find the predictor xm with the largest negative gradient element,

−δL
.
δβ

Step 3: Update βm = βm + , where  is some small increment, such as 0.01.
Step 4: Repeat steps 2-3 many times.
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This was updated to allow for ordinal responses and the inclusion of an unpenalized set of
covariates 11,55 . The details of the method and its development appear in Chapter 2. This
work has been incorporated into the R package ordinalgmifs.

1.3.4

Mixed-Effects Ordinal Regression Methods

A second consideration for modeling the cannabis use data is the correlated nature of the
data. Observations and responses in twins are expected to show greater correlation than
would be expected between two otherwise unrelated subjects. Owing to this, standard
regression which assumes all observations to be independent of one another is inappropriate
for these data. The mixed-effects model offers a solution; while fixed-effects (fixed, but
unknown) estimates are made for most model covariates, a random-effect (that is, a varying)
effect term may be added for a family identifier covariate in order to account and adjust for
the expected correlation in the data between twins in the same family.
Many mixed-effects models have been developed and are available in various R packages.
Two popular linear mixed-effects model fitting packages are glmm 82 and lme4 15,16 . For ordinal
responses, the ordinal package provides a cumulative logit model that will fit one or two
random effects 33 . The mixor package fits general mixed-effects ordinal and binary response
models 65 . The Vignette associated with the package includes an example of how the package
may be used to fit separate random effects to account for zygosity when modeling twin data,
although the methodology extends only to families that include either one set of MZ or one
set of DZ twins 10 . The mixcat package offers ordinal regression with non-parametric random
effect distributions 107 . Bayesian mixed-effects regression is available in the arm package 54 .
Bayesian mixed-effects models for ordinal regression are implemented in both the MCMCpack
and MCMCglmm packages 61,62,90,91 . All of the methods mentioned in this section apply only to
the low-dimensional setting.
The penalization methods and R packages described are not a comprehensive list of all
available methods and software. They are, however, representative of currently available
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models and techniques. At the time of this writing, no single method includes all the
capabilities desired in order to adequately describe and answer the research questions relating
to the cannabis use data, namely, a regularized ordinal regression model with mixed-effects
that allow specifically for a twin cluster situation. This dissertation work proposes one such
model. The next chapter presents the first portion of this work in which a penalized fitting
algorithm is adapted for ordinal response regression with inclusion of a no-penalty subset of
covariates. Chapter 3 incorporates this methodology into a mixed-effects ordinal regression
model which accounts for the specific familial correlations present in the cannabis use data.
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Chapter 2
No-penalty Subset
2.1

Introduction and Context

Most penalized or regularized regression methods subject the full set of covariates to the
penalization scheme. In other words, in many cases, once a penalized fitting method is implemented, the model is allowed to penalize the coefficients in an automated manner. It was
of interest to develop a penalized ordinal regression method that would allow some subset of
covariates to be coerced into the model without being subject to penalization. A so-called
“no-penalty” subset would be useful in a variety of modeling situations. In certain epidemiological studies, for example, researchers prefer to include predictors such as age and/or sex in
population models. For the current application of interest, some measures are known to be
associated with cannabis use. Age of initiation of cannabis use has been found to be related
to greater use later in life 116,130 . It is also well understood that cannabis use is associated
with both alcohol and tobacco use 5,108 . For our analysis, it will therefore be advantageous to
utilize a model that allows certain variables to be adjusted for without penalization. At the
time of this portion of original work, no available method allowed for a no-penalty subset
in a regularized ordinal regression model. The research described in this chapter has been
published in Cancer Informatics under the title “Penalized Ordinal Regression Methods for
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Predicting Stage of Cancer in High-Dimensional Covariate Spaces” in 2015 by Amanda Elswick Gentry, Colleen K. Jackson-Cook, Debra E. Lyon, and Kellie J. Archer 55 . This portion
of the method was designed for the purpose of analyzing a methylation study conducted on
breast cancer patients. In the following chapter, this study itself, the proposed and published
method, and the application of the method to the study data are described in detail. This
work is incorporated into the model formulation proposed in Chapter 3 and applied to the
cannabis use data in Chapter 4.

2.2
2.2.1

Motivating Data
Primary Outcome of Interest

For our original paper, we worked with one dataset from a breast cancer study conducted
at Virginia Commonwealth University. The dataset included 73 women with breast cancer
and included baseline clinical and demographic covariates such as Estrogen-Receptor (ER),
Progesterone-Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2)
status, age, race (white or African American), prior breast cancer surgery (lumpectomy, segmental, or simple surgery prior to study enrollment), and smoking status (currently smoking,
yes or no). The primary outcome of interest in this study was stage of cancer. Stage of cancer is a pathological description of a tumor and for breast cancer it considers the following:
size of tumor, number of cells in the tumor, location of tumor with respect to the chest wall
and skin, amount of cancer in mammary, axillary, and sentinal lymph nodes, the number of
lymph nodes involved, and the spread of cancer to other organs 6 . Stage of cancer typically
determines the course of therapy and is most often ascertained through a biopsy of the cancerous tissue. For stage of cancer, it may be of interest to predict which response level a
patient may exhibit, given some set of explanatory variables. Ordinal regression may be used
to model the probability of exhibiting a specific ordinal response, given some set of relevant
covariates. As previously discussed, most ordinal regression methods require either that the
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sample size exceeds the number of features or that all covariate parameters be penalized.
For this project, the aim was to develop a method that allowed the model to penalize some
covariates without penalizing others (such as demographic covariates).

2.2.2

Sample Description

All 73 subjects in the study were women. The overall median age of the participants was
53 (minimum of 23, maximum of 71); 52 of the women were white and 21 were AfricanAmerican. ER, PR, and HER2 status were collapsed into a single, categorical measure of
breast cancer subtype, 120 defined in Table 2.1; the number of patients in each category is
also given.
Subtype
Luminal A
Luminal B
Triple Negative
HER2 Type

ER+ and/or PR+, HER2ER+ and/or PR+, HER2+
ER-, PR-, HER2ER-, PR-, HER2+

Number of Patients
37
8
21
7

Table 2.1: Criteria for breast cancer subtype classification and count for each category. Note
that breast cancer subtype classification typically considers proportion of tumor cells positive
for the Ki67 protein. This measurement was not collected in our study and therefore could
not be used for classification.
Patients in this study had stages of cancer ranging from I to IIIA. The distributions of
age, BMI, race, smoking status, and prior surgery are shown for each cancer stage in Table
2.2.
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Stage
Age (median)
BMI (median)
Race (Black)
Currently Smoking (Y)
Prior Surgery (Y)

I
n=21
55
29.58
5/21
3/21
21/21

IIA
IIB
n=29 n=15
48
56
25.79 31.01
10/29 6/15
5/29 6/15
26/29 12/15

IIIA
n=8
49
29.25
0/8
1/8
7/8

Total
n=73
53
28.34
21/73
15/73
66/73

Table 2.2: Demographic characteristics by stage of cancer. The medians are reported for
continuous variables (age and BMI) and the frequencies are reported for categorical variables
(race, smoking status, and prior surgery).

The distribution of patients according to cancer subtype and stage is shown in Table 2.3.
Stage
Luminal A
Luminal B
Triple Negative
HER2 Type

I
n=21
7
2
11
1

IIA
n=29
16
3
7
3

IIB IIIA
n=15 n=8
7
7
3
0
2
1
3
0

Total
n=73
37
8
21
7

Table 2.3: Frequencies of breast cancer subtype by stage of cancer.

2.2.3

Methylation Data

For this analysis, we had as covariates high-dimensional methylation data from the Illumina
Human Methylation 450K technology. The primary goal was to construct a model that
would allow us to use the methylation data and other relevent covariates to predict stage of
cancer in a sample of women with breast cancer. Methylation is an epigenetic event, which
alters gene expression without altering the DNA sequence itself. It is the process by which
a cytosine molecule on the DNA strand becomes a 5-methylcytosine through the addition
of a methyl group (as illustrated in Figure 2.1) or a 5-hydroxymethylcytosine through the
addition of a methyl group followed by a hydroxy group.
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Figure 2.1: Illustration of the methylation process of a cytosine 2 .
Profound methylation changes are known to occur in the context of cancer; well-documented
changes include the hypermethylation of tumor-suppressor genes 44 and the hypomethylation
of proto-oncogenes 43 . Specific patterns of methylation exhibited in tumors are thought to
not only detect cancer, 17 but also predict tumor behavior 18 and illuminate differences and
similarities across and within tumor types 44 . Jones and Laird stated that perhaps methylation patterns in cells could serve as “a rough blueprint for the expression profile of that
cell”and envisioned that future development of science and technology might produce a useful methylation analysis to generate a “DNA methylation fingerprint for a tumor biopsy.” 78
Studies of methylation patterns in peripheral blood specimens from people diagnosed with
cancer have also shown alterations. Of particular relevance, DNA methylation analysis from
peripheral blood samples identified an association between methylation of the HYAL2 gene
and breast cancer, 140 suggesting that methylation patterns in blood might be useful as a
screening tool for evaluating tumors in other tissues. Because epigenetic changes, such as
methylation, are reversible, identification of specific methylation changes occuring in specific
cancers may lead to targeted therapies to return normal function to the cells 78 . Given this
evidence, we hypothesized that differential methylation may be predictive of stage of cancer
in women with breast cancer.
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2.2.4

Data Pre-processing

In this particular study, peripheral blood samples were collected at study entry and DNA
was subsequently extracted from these samples using standard methods, bisulphite converted (Zymo Research EZ Methylation Kit), and hybridized to Illumina’s Human Methylation 450K array according to the manufacturer’s protocol. To assess assay reliability, some
samples were hybridized multiple times, resulting in a total of 82 methylation profiles.
The scanned arrays were processed using the minfi 13 Bioconductor package in R to obtain
the β values for each probe, where βij represents proportion methylated for the ith probe
and the j th array, defined here as:

β=

M
, where
M + U + offset

M : Methylated signal for a given CpG site
U : Unmethylated signal for a given CpG site
offset: 100, to avoid division by small numbers 22
Some pre-processing of the methylation data was necessary prior to statistical analysis.
Our first pre-processing step was to look at the distribution of β values by GC content (relative proportion of nucleotide bases, G and C). This is important because previous research
has established that methylation may not be accurately measured in regions of high GC
content 84 . Illumina’s design for the 450K array includes two separate assays, Type I and
Type II, for estimating methylation at a given locus. GC content was calculated as the
proportion of the probe sequence comprised of C’s and G’s and reported separately for Type
I and Type II design types. We then examined the boxplots of average β values (across
all samples) by GC content for each of the assay types separately. The resulting boxplots
were used to determine a GC proportion cutoff value beyond which methylation seems to no
longer be reliably measured. The choice of such a cutoff is clearly subjective, however, it is
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important to remove the CpG sites beyond the cutoff because inclusion of unreliable probes
may distort the analysis.
The original, unfiltered data had 485,512 CpG sites. The boxplots of GC content by CpG
site (Figures 2.2 and 2.3) indicated that methylation may not be accurately measured beyond
42% for Type I probes or beyond 40% for Type II probes. After examining these boxplots,
we chose the more conservative of the two values and excluded CpG sites with greater than
40% GC content from further analysis. This GC content filtering criteria removed 52,077
CpG sites, leaving 433,435 CpG sites.
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Figure 2.2: Boxplot of mean β values by percent GC content across all samples, for type I
probes.
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Figure 2.3: Boxplot of mean β values by percent GC content across all samples, for type II
probes.
We also removed CpG sites within which there were known Single Nucleotide Polymorphisms (SNPs) according to the Illumina-provided annotation files 22 . There were 80,104
CpG sites that included SNPs, after these were removed, 353,331 CpG sites remained.
The Type I design includes two bead types for each CpG site, one which detects methylated CpG sites and one which detects unmethylated CpG sites. The Type II design includes
a single bead with a two color readout; a different color is used to indicate whether the CpG
site is methylated or unmethylated. In 2011, Dedeurwaerder et al. examined the distribution
of β values produced by the Type I and Type II bead types used in the 450K technology 37 .
They noted that the distribution of β values from both bead types, across the whole array,
exhibited two distinct peaks, one close to 0 for the unmethylated CpGs and one close to 1
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for the methylated CpGs. These peaks however, when modeled separately by bead type, did
not not align exactly; the peaks for the β values from the Type II beads were shifted inwards
when compared to the Type I beads. This shift is attributed to chemistry differences between the beads and is acknowledged by Illumina in a Tecnical Note for the 450K technology
on their website 72 . To correct this issue, we implemented the peak correction method by
Dedeurwaurder et al. on our β values as a preprocessing step; this method adjusts the Type
II peaks so that they align to the locations of the Type I peaks. The peak correction method
uses the M-values, the logit of the β values,

Mij = log

βij
.
(1 − βij )

Prior to the logit transformation and peak correction, we modified the β values slightly by
adding or subtracting 0.001 to any β values exactly equal to 0 or 1, respectively, in order
to prevent errors during the logit transformation. There were 1,742 βs exactly equal to zero
(while none were exactly equal to one). We imputed those equal to 0 to be 0.001 before
applying the logit transform.
Finally, there were five patients having n1 = 4, n2 = 4, n3 = 2, n4 = 2, and n5 = 2
hybridized samples each. For each of these patients, we averaged the final, peak-corrected
M-values across the replicate samples and used this single, mean signal for each of these
five patients in our analysis. All data analysis was conducted in R (version 3.1.0) utilizing the minfi 13 (version 1.10.2), limma 119 (version 3.16.8), VGAM (version 0.9-4) 141 , and
ordinalgmifs 7 (version 1.0.2) packages. In our analysis, we used the 450K annotation file
version 1.2 1 .

2.3

Background: Previously Described Methods

In genomic research, traditional modeling methods are often inappropriate. Traditional
ordinal regression methods, for example, require that the number of predictors (p) be smaller
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than the sample size (n) and that the predictors be independent. After filtering, our breast
cancer study included 353,331 CpG sites and only 73 patients; such a situation, where
p  n, is typical when analyzing high-throughput genomic data. Furthermore, we know that
methylation levels of CpG sites in close proximity to one another are highly correlated. To
handle these challenges, we implemented penalized regression methods. Penalized regression
introduces bias into the model in exchange for reducing variability 123 . The resulting model
is sparse which is an attractive feature when we are dealing with an overly large predictor
space and are interested in producing a parsimonious model.
There are a variety of algorithms available for finding a penalized solution, as discussed in
Chapter 1. One particular algorithm of relevence for the development of our proposed model
is the Incremental Forward Stagewise (IFS) method, which provides the monotone Least
Absolute Shrinkage and Selection Operator (LASSO) solution in a linear regression setting 64 .
Hastie et al. modified and extended the IFS procedure, creating the Generalized Monotone
Incremental Forward Stagewise (GMIFS) method which provides a penalized solution in a
logistic regression setting 64 . Archer et al. further extended the GMIFS method to provide
the penalized solution in an ordinal regression setting 11 . In our work, we extended the
ordinal GMIFS algorithm to allow a subset of covariates to be included in the model without
penalization.

2.4
2.4.1

Data Filtering
Likelihood Ratio Tests to Determine No-Penalty Subset

This so-called no-penalty subset, the subset of demographic variables not penalized, is included in the final model and the fitting algorithm is not allowed to shrink any of these
coefficients to 0. This no-penalty subset option is important in many scientific investigations
where some biologically-relevent demographic information should be retained in the model,
regardless of statistical significance ascribed to the given covariates. For our breast cancer
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dataset, we fit univariate ordinal response models predicting stage for each of the following:
age, race, BMI, smoking status, prior surgery related to the management of breast cancer,
and subtype, to see which of these will be important for inclusion in the full ordinal model.
A likelihood ratio test (LRT) was conducted for each of the demographic covariates comparing the intercepts-only model to each of the univariate models when fitting cumulative logit
models to predict stage of cancer. The results of these tests are given in Table 2.4.

Deviance
χ21 statistic
P-Value

Intercepts
Only
188.72

Age

BMI

Race

187.57
1.15
0.2834

188.70
0.02
0.8787

188.69
0.03
0.8611

Currently
Smoking
187.56
1.16
0.2821

Prior
Surgery
185.70
3.02
0.0824

Subtype
179.91
8.81*
0.0319

*χ23 statistic

Table 2.4: LRT and resulting p-values from univariate cumulative logit models predicting
stage of cancer.
In the interest of developing a parsimonious model, we used a p-value cutoff of 0.05. At
this significance level, it was clear that only subtype (e.g. Luminal A; Luminal B; HER2+;
triple negative) was significantly related to stage of breast cancer in this univariate sense.

2.4.2

Likelihood Ratio Tests to Filter Methylation Data

Given the large number of CpG sites in the 450K array, we first filtered the M-values by
significance in order to reduce the number of penalized coefficients considered by the model.
We fit a model predicting stage with only the demographic covariates found to be important
from the previous LRTs and each of the CpG sites individually. We then conducted a series
of LRTs between the demographic-only model and each of the CpG site models. Using a
liberal p-value threhold of 0.25, we included in the penalized model only those CpG sites with
a p-value< 0.25. After excluding CpG sites with p-values greater than 0.25, 103,001 CpG
sites remained. Additionally, we removed CpG sites which were universally unmethylated
(β < 0.1) across all samples and those which were universally methylated (β > 0.9) in all
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samples. Removing these CpG sites constituted no loss of information since all the samples
were either fully unmethylated or fully methylated. After excluding CpG sites for which β
was < 0.1 or > 0.9 in all samples, 27,110 CpG sites remained.

2.5

Proposed Method

The primary outcome measure of interest, as mentioned, was stage of cancer. Stage of cancer
is measured as 0-IV and may be further subdivided into 0, IA-B, IIA-B, IIIA-C, and IV.
The patients in our study, which focused on ascertaining participants with early stage breast
cancer, were classified as stage I (n=21), IIA (n=29), IIB (n=15), or IIIA (n=8); for this
application, therefore, the response is composed of C = 4 ordered classes. We constructed
a response matrix Y which was an n × C matrix representing class membership. Each of
i = 1, ..., n subjects may take one of c = 1, ..., C stages (ordinal levels), and the elements of
the matrix are

yic =




1, if observation i is in stage c


0, otherwise.

We also constructed a matrix of non-penalized predictors, W and a matrix of penalized
predictors, X. Using a cumulative logit model to model the C − 1 logits of ordinal categories
at or below a given level, the probability of interest may be expressed as follows:

P (yi ≤ c | xi , wi ) =

exp(αc + xTi β + wiT θ)
,
1 + exp(αc + xTi β + wiT θ)

where αc ’s represent the intercepts and β and θ represent the coefficients for the penalized
and non-penalized predictors, respectively. The intercept terms are constrained such that
−∞ = α0 < α1 < ... < αC−1 < αC = ∞. In this way, we modeled the conditional probability
that, given values of the demographic and methylation covariates, the cancer classification
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for a patient would fall at or below a certain stage. The conditional probability that the
cancer classification would fall exactly at a certain stage may be written:

πc (xi , wi ) = P (Yi = c | xi , wi )
=

exp(αc + xTi β + wiT θ)
exp(αc−1 + xTi β + wiT θ)
−
1 + exp(αc + xTi β + wiT θ) 1 + exp(αc−1 + xTi β + wiT θ)

Therefore, the likelihood is given by:
n Y
C
Y

L=

πc (xi , wi )yic

i=1 c=1

and the log-likelihood is given by:

log(L) =

n X
C
X

yic log(πc (xi , wi ))

i=1 c=1

which can be more formally expressed:

log(L) =

n X
C
X
i


yic log

c

exp(αc + xTi β + wiT θ)
exp(αc−1 + xTi β + wiT θ)
−
1 + exp(αc + xTi β + wiT θ) 1 + exp(αc−1 + xTi β + wiT θ)


.

The specific steps of the modified GMIFS algorithm to obtain this solution are implemented in the ordinalgmifs package in R 7 . We outline the steps for the cumulative logit
form of the model here.

1. Beginning at step s = 0,
Augment the X covariate space by appending the negative of the covariate space so
that X becomes [X : −X].*
*We augment the covariate space in this way so that we may avoid calculation of the
second derivative to determine the direction of the update. 64
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2. Set all of the β terms to 0 so that β̂

(s)

= 0.

(The β vector is of length 2p)
3. Initialize the α terms as αc = logit(

Pn PC
i=1

yic
c=1 n ).

4. Holding the β terms fixed, update α and θ by maximum likelihood
5. Holding α and θ fixed, find m = argmin −
2p

δ
δβp


logL

s+1
s
6. Update β̂m
to be β̂m
+ , where  is some small value, such as  = 0.01.

7. Repeat steps 4-6 until logL(s+1) − logL(s) < τ , where τ is some small value, such as
τ = 0.00001.
Once the algorithm converges, the parameter estimates achieved constitute the “converged
model.” For each step of the algorithm, we calculated the log likelihood, Akaike Information
Criterion (AIC), and the Bayesian Information Criterion (BIC) for the model at that iteration
of the algorithm. The AIC and BIC are measures of the relative quality or appropriateness of
a statistical model and are calculated as follows, for n observations, k estimated parameters
in the model, and a maximized likelihood value of L∗ ,

AIC = 2k − 2 log(L∗ ), and

(2.1)

BIC = log(n)k − 2 log(L∗ ).

(2.2)

AIC and BIC are fit criteria and the model with minimum AIC or BIC may be regarded
as the model that balances parsimony and minimization of the log-likelihood. Generally,
the minimum BIC model will be more parsimonious (contain fewer parameters) than the
minimum AIC model. For this application, we then extracted the parameter estimates at
the step that minimized the AIC.
The penalized covariates are given by x with β denoting the corresponding parameter
estimates. As indicated in item 2 of the algorithm, at the first step all the βs are set to zero.
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For each consecutive step of the algorithm, only one β is updated by a very small incremental
amount. As indicated in items 5-6 of the algorithm, this β that is updated is that which
corresponds to the predictor having the largest negative derivative of the log-likelihood. After
a β has been updated, the thresholds and unpenalized predictors are estimated by maximum
likelihood keeping the β fixed (see item 4 of the algorithm). For this reason, some predictors
are penalized (x) while others are not penalized (w). The P penalized β estimates are found
when the log likelihood is minimized with respect to the following constraints:

βp+ , βp−

P
X
≥ 0 and
(βp+ + βp− ) ≤ s
p=1

The value of s is not specified by the user. Rather, each of the s values corresponds to
a specific solution 64 so that both the AIC-slected and the converged model will have an
associated s value. Note that this method is an incremental forward stagewise method
which differs from preselecting a tuning parameter, or set of tuning parameters, against
which the model is fit then subsequently selecting the best fitting model by some model
fitting criterion.
For our selected model, we were interested in how the blood methylation values predicted
the stage of the actual tumor. For the non-zero coefficient estimates, we investigated whether
any of the differentially methylated loci had been previously associated with breast cancer
or other types of cancer.

2.6

Simulation Study

We also conducted a simulation study to further test the performance of the method. At
the time of this writing and publication, there existed no comparative method which fit a
penalized cumulative logit model so we had no method against which to test the GMIFS
cumulative logit model performance. For our simulation study, we used a sample size of 80
subjects, where 100 predictor variables were generated from a uniform distribution on the
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[-1, 1] interval. Thereafter, the latent response, yi? for i = 1, . . . , 80, was generated using
the first four predictors (X1 , . . . , X4 ) as covariates truly associated with the response where
the coefficients were (0.5, -0.5, 0.5, -0.5) and adding a Gaussian error term with mean 0
and standard deviation of 0.15. The observed response was generated by referencing the
probabilities of the generated latent response using a standard normal distribution where
the observed class was taken to be:

yi =





1 if P (yi? ) ≤ 0.25







2 if 0.25 < P (yi? ) ≤ 0.50

.

(2.3)




3 if 0.50 < P (yi? ) ≤ 0.75







4 if P (yi? ) > 0.75
Thereafter, a cumulative logit GMIFS model was fit using X1 as an unpenalized predictor and
X2 , X3 , X4 as penalized predictors and the AIC selected model was examined. This entire
process was repeated 50 times. Characteristics of the fitted models examined included: the
number of times the coefficients for X2 , X3 , and X4 were non-zero (true positive rate); the
number of times the coefficients for X5 , . . . , X100 were non-zero (false positive rate); and the
misclassification rate.
Our simulation study indicated that the method performed well. The true positive rate
was 100% as all models returned non-zero coefficient estimates for X2 , X3 , and X4 . The
median false positive rate was 5.2% (range 0 - 33%). The median misclassification rate was
13.75% (range 1.25 - 30.00%).

2.7

Application Results

The ordinal cumulative logit GMIFS model was fit to the subtype covariate, as a nonpenalized predictor, and to the M values for the 27,110 CpG sites, as penalized predictors.
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Figure 2.4: Boxplot of β-values for CpG site cg19149522 (ZDHHC4), for all subjects, by
stage of cancer.
The model attaining minimum AIC included 35 non-zero CpG sites (Table 2.5) while the
fully converged model estimated 107 non-zero CpG sites. Subsequently, we ran the model
again, this time filtering to exclude CpG sites with p-values greater than 0.05. Fitting the
same GMIFS model to this smaller set of CpG sites resulted in the exact same parameter
estimates and class predictions as the previous model, which used a p-value cutoff of 0.25.
Boxplots (Figures 2.4 and 2.5) are shown for the two CpG sites from Table 2.5 with the
largest absolute coefficient. The plots display the distribution of β values for all subjects
according to stage of cancer. The β values for cg19149522 (ZDHHC4) seem to be monotonically decreasing while the β values for cg16807687 (PCDH21) seem to be monotonically
increasing.
The fully converged model predicted stage without error while the minimum AIC model
had an error rate of 15.1%. Table 2.6 shows the cross-tabulation of observed versus predicted
class. The fully converged model was without error, however, it included 107 non-zero
parameter estimates indicating that it is likely overfit. The AIC model was less accurate for
prediction, particularly for patients with stage IIIA cancer. This is likely due to the fact
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CpG Site
cg01393985
cg02873991
cg02990147
cg03478356
cg03604519
cg03642328
cg04315214
cg05898699
cg06159404
cg06618740
cg07068358
cg07078747
cg07850592
cg08314875
cg08407901
cg08615372
cg08833952
cg09667394
cg10139947
cg10467557
cg12386614
cg12440927
cg13033971
cg14468658
cg14884760
cg16807687
cg19009644
cg19149522
cg19893664
cg20418394
cg21156276
cg24493834
cg25099892
cg26479305
cg27161197

Chromosome
6
12
X
9
X
11
1
18
10
1
16
12
1
Y
21
19
22
1
2
13
1
7
13
5
22
10
3
7
14
10
9
6
13
12
12

Location (start)
89927651
25151263
24329623
45726913
70150242
69624925
2043799
15197299
43846376
1100126
25879737
34177660
231299396
15015601
43989901
18699234
22469409
78011748
105274650
21893614
33608005
157791673
46291925
140723461
50164389
85973970
10553211
6616375
105619634
72254335
4491869
129250963
113313857
52470979
47224649

Location (end)
89927700
25151312
24329672
45726962
70150291
69624974
2043848
15197348
43846425
1100175
25879786
34177709
231299445
15015650
43989950
18699283
22469458
78011797
105274699
21893663
33608054
157791722
46291974
140723510
50164438
85974019
10553260
6616424
105619683
72254384
4491918
129251012
113313906
52471028
47224698

UCSC Ref Gene
GABRR1
C12orf77
FAM48B2
FAM27A
SLC7A3
FGF3
PRKCZ

HS3ST4
ALG10
TRIM67
DDX3Y
SLC37A1
C19orf60
AK5

PTPRN2
PCDHGA2, PCDHGA3, PCDHGA1
PCDH21
ZDHHC4
JAG2
KIAA1274
SLC1A1
LAMA2
C13orf35
C12orf44

Table 2.5: AIC selected CpG sites listed with their chromosome, position, and associated
UCSC ref genes, where appropriate.
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Figure 2.5: Boxplot of β-values for CpG site cg16807687 (PCDH21), for all subjects, by
stage of cancer.
that our patient sample is unbalanced across the stages and is biased towards stages I-IIB.
AIC
I
IIA
IIB
IIIA

I IIA
20 1
0 29
0
4
0
0

IIB
0
0
11
6

IIIA
0
0
0
2

Converged
I
IIA
IIB
IIIA

I IIA
21 0
0 29
0
0
0
0

IIB
0
0
15
0

IIIA
0
0
0
8

Table 2.6: Cross-tabulation of the observed (rows) versus predicted (columns) class for the
AIC and the fully-converged models.

2.8

Discussion

In this Chapter, we described our published paper in which we presented an ordinal response model for high-dimensional covariate spaces that allows for the inclusion of both
non-penalized and penalized covariates. While our simulations and case study were performed using a cumulative logit model, this method can be applied to any cumulative link,
forward continuation ratio, backward continuation ratio, adjacent category, or stereotype
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logit model using the ordinalgmifs R package 7 . While the fully converged model had
100% accuracy in predicting stage of cancer, there were several misclassifications for the
AIC selected model. This may be partially attributed to the imbalance and small class
size, particularly for stage IIIA. It should be noted that the fully converged model is likely
overfit and that classification of the training data used to fit the model is not the fairest
measure of predictive ability. A better assessment of model performance could be made via
cross-validation or bootstrapping. However, several of the CpG sites included in the models
were located within genes that have previously been associated with breast cancer. AK5,
PTPRN2, LAMA2, FGF3, SLC37A1, and SLC1A1 have all been previously associated with
breast cancer 19,71,85,92,95,101,118 . SLC7A3, PRKCZ, JAG2, GABRR1, DDX3Y and PCDHGA3
have been previously associated with other types of cancer 48,76,79,93,102,105 . Our results, which
agree with previously published results, indicate that methylation patterns of the tumor itself may impact methylation patterns present in peripheral blood. Development of a model
that can accurately predict stage of cancer from DNA methylation or other genomic profiles
from peripheral blood samples and demographic information may have important healthcare
implications.
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Chapter 3
Mixed-Model
3.1
3.1.1

Previous Research
Additive genetic, common environmental, and unique environmental components of cannabis use and dependence

Previous research has been conducted in cannabis use within the context of behavior genetics.
In 1998, one of the early classical twin design studies in cannabis use estimated 40% of the
variance in cannabis use among a sample of female twins was due to additive genetic factors
while 35% was due to common environmental factors 81 . The same study used AE models to
estimate the heritability of heavy use of cannabis at 79% and heritability of cannabis abuse
at 72%. The same year, another study used ACE models for cannabis use in both genders
and estimated additive genetic effects, common environmental effects, and individual effects
of 17%, 62%, and 21% respectively in males and 53%, 38%, and 10% in females 125 . In 2000,
a study of male twins indicated estimates of ACE factors of 33%, 34%, and 33% respectively
for cannabis use 80 . In the same study, AE models were used to estimate variance factors
for heavy use, abuse, and dependence and the additive genetic and shared environmental
factors were found to be 84% and 17%, 76% and 24%, and 58% and 42% for the three use
categories respectively.
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Another study employed GCTA to investigate the association between common SNPs
and a factor score that represented liability to cannabis use disorder, as defined in the
DSM-V 3 . While they estimated that 21% of the phenotypic variance could be explained by
genomic factors, this estimate was not statistically significant. Additionally, they identified
11 SNPs on chromosome 17 which achieved nominal genome-wide significance for cannabis
use disorder although none of these met the established p-value threshold of 5 × 10−8 . This
agrees with previous research conducted in 2011 which had linked SNPs along chromosome
17 to DSM-IV cannabis dependence 4 .

3.1.2

Cannabis Initiation

A 2010 study implemented a traditional ACE model to estimate that 44% of liability to
cannabis initiation was due to genes, while 31% was attributed to shared environmental
factors and 24% to unique environmental factors 128 . In 2013, a study used GCTA 138 to
estimate the proportion of variance in cannabis use initiation attributable to the combined
effect of all measured common SNPs 126 . It was discovered that only about 6% of the variance
in initiation could be explained by the common variants. While small, it should also be noted
that this study included 4,612 unrelated individuals but less than one million imputed SNPs.
Another study implemented GCTA to estimate that 25% of the variance observed in cannabis
initiation could be attributed to the cumulative effect of SNPs; 94 the majority of these effects
were found in chromosomes 4 and 18. A SNP-based analysis of initiation conducted in the
same study found several suggestive SNPs contained within genes on chromosome 19 and a
SNP on chromosome 5 was found to be associated with age of initiation.

3.1.3

Relationship between Cannabis and other substances

Other research has indicated that dependence and addiction to substances such as cannabis,
alcohol, and tobacco may share some amount of “common liability.”One study capitalized
on this relationship by using GCTA to estimate the additive genetic portion of the variance
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of dependence vulnerability, a summary score of dependence symptoms for alcohol, tobacco,
and a variety of illicit drugs, including cannabis 106 . The combined effect of all measured
SNPs was found to explain 36% of the variability in polysubstance dependence.

3.2

Twin Models

3.2.1

The Mixed Model

Another common approach to twin data analysis is the mixed model. Mixed models are
useful in longitudinal or repeated-measures modeling situations where a study participant
has, for example, the same test performed at multiple time points, such as a heart rate taken
at weekly appointments over several weeks. Mixed models are also applicable for clustered
data when, for example, study participants come from a similar unit (such as a family) or
share certain unmeasurable variables in common. For example, in a multisite clinical trial,
a mixed model might be used to adjust for unmeasured similarities among patients from
the same clinic location. In these cases, measurements over time within a single subject
or measurements between family members, the measurements cannot be assumed to be
independent of one another. Including a random effect in the regression equation allows the
model to account for this lack of independence. The general form of a mixed linear regression
model for clustered or longitudinal data is 66 :

yi = Xi β + Zi ui + i , where

(3.1)

yi is the ni × 1 response vector for cluster (or individual, in the longitudinal case) i
with j = 1, ..., ni observations on i = 1, ..., N total clusters,
Xi is an ni × p covariate matrix,
β is a p × 1 vector of fixed-effect regression parameters,
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Zi is an ni × r design matrix for the random effects,
ui is an r × 1 vector of random cluster effects, and
i is an ni × 1 error vector.
This parameterization allows for r random effects. Generally, there are 1-2 random effects
including a random, cluster-specific intercept and a random slope term. For longitudinal
analysis, the random slope typically models a time effect. Usually, it is assumed that i ∼
N (0, σ 2 Ini ) and ui ∼ N (0, Σi ). The general idea behind the mixed model is to capture both
the correlation within observations in a cluster (or timepoints within an individual) and
between individuals in different clusters.

Kinship Matrix
When molecular genetic data is being modeled in a sample of related subjects, a kinship
matrix is often used to express the expected correlations between members of a single family.
Monozygotic twins may be expected to share all of their genes, since, as the name implies,
MZ twins developed from a single zygote. Dizygotic twins and full siblings are expected to
share approximately half of their genes, on average. These theoretical values are based on
an assumption of no inbreeding, i.e. assuming the parents are unrelated. As discussed in
Section 1.2.4 and shown in Figure 1.3, as diploid organisms, humans have two alleles at each
locus. The probability that two individuals have the same allele at a single locus is referred
to the “coefficient of kinship” or the “coefficient of coancestry” for those two individuals
and its theoretical value is based on genetic and probability theory. More specifically, the
coefficient of kinship is the probability that two related individuals share the same allele
“identical by descent” (IBD), meaning that they directly inherited the same allele. This is
easily understood in the context of a parent-child relationship; for example, a child receives
50% of its DNA from its father and 50% from its mother, so at conception, each parent
gives one of two alleles, for each genetic locus. With two possibilities from the mother and
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two from the father, the probability that a child will share a locus IBD with one parent is
1/4 132 . Extending this logic, the coefficient of kinship between MZ twins is 1/2 and between
DZ twins or full siblings is 1/4.
The “additive genetic relationship” between two individuals describes the probability
that two alleles sampled between related individuals will be IBD for the same locus. This
additive genetic coefficient of relationship is twice the kinship coefficient and therefore is
often called the “double coancestry matrix” 67 . This additive genetic coefficient describes
the expected correlation then between SNP loci of related subjects and is 1 for MZ twins,
1/2 for DZ twins and siblings, and also 1/2 for parent-offspring pairs. The terms “kinship”
and “coancestry”matrices are used somewhat inconsistently interchangeably for the additive
genetic relationship matrix and often “kinship matrix” is used to describe either the true
kinship matrix (of kinship coefficients) or the double coancestry matrix.

3.2.2

The Mixed Model for Behavior Genetics Analysis

The application of the mixed model to twin data for genomic analysis is not new. In 2002,
Guo and Wang described a linear mixed model for clustered, genetically informative data 60
which allowed for 5 types of relatedness (where relatedness is indicated by t), MZ twins (m),
DZ twins (d), siblings (f ), half-siblings (h), and/or cousins (c), as follows:

yi = Xi β + Zi u + ei , where,

(3.2)

yi is the ni × 1 continuous response vector for the ni members of the ith family,
Xi is the ni × (p + 1) matrix of p covariates and β is the (p + 1) × 1 vector of coefficient
estimates for the intercept plus p covariates,
Zi is the ni ×5 matrix of relatedness indicators where, for a family with j members, the
j th row of Zi is given as (zj(m) , zj(d) , zj(f ) , zj(h) , zj(c) ) and the corresponding indicator is
1 where the individual is in each type of cluster
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ui is the family-specific 5×1 vector of random effects given as (ui(m) , ui(d) , ui(f ) , ui(h) , ui(c) )
2
2
2
2
2
and is distributed as N (0, G), where G is a 5×5 diagonal matrix with (σu(m)
, σu(d)
, σu(f
) , σu(h) , σu(c) , )

and ei is an ni × 1 vector of random error components and is distributed as N (0, R),
P
where R is an M × M diagonal matrix with k th diagonal element, rk = t zk(t) σ 2e(t)
and zk(t) represents the indicator for the t relationship types in the k th family group
P
and M = N
j=1 nj .
Then the within-cluster (or within-family) correlation may be calculated as: ρt =

2
σu(t)
2
2
σu(t) +σe(t)

.

The variances of the random effects are dependent on the type of genetic relatedness within
the family cluster because genetic theory expects that the within-cluster variance will be
generally smaller, the greater the genetic relatedness 60 . Guo and Wang also describe a more
complex model in which some of the environmental covariates (the xs) are also allowed to
have random effects. Regardless, the variances may be partitioned into additive genetic and
shared environmental components as follows:

h2x + c2(md),x = ρ(m),x ,
1 2
h + c2(md),x = ρ(d),x ,
2 x
1 2
h + c2(f ),x = ρ(f ),x ,
2 x
1 2
hx + c2(h),x = ρ(h),x ,
4
1 2
hx + c2(c),x = ρ(c),x , where
8

(3.3)
(3.4)
(3.5)
(3.6)
(3.7)

h2x is the heritability in the environment described by x and the c2(t),x are the proportions of
the variance due to shared environment for the tth relationship type. The authors suggest
that this model may be fit using commercial software packages such as SAS and note that
one limitation of the model is that hypothesis testing for the h2 and c2 terms is not possible
under the given formulation.
The Guo and Wang method was applied and extended by Cho et al. in 2006 32 . They used
the following mixed-model to estimate the heritability, shared environmental, and unshared
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environmental components (ACE) of a variety of suicide risk factors:

yi = Xi β + λi ai + ci + ei , where

(3.8)

yi is a vector of outcomes for j sibling in pair i,
Xi is a matrix of predictors,
β is a vector of predictor effects,
ai and ci are the genetic and shared environmental random effects, respectively, for
pair i,
λi = 1, for MZ pairs or

p
1/2 for DZ pairs, and

ei is the random vector of residual terms.
Although the authors give no details regarding estimation methods or software used to fit
these models, they state that this model was estimated and compared to AE and CE models
via likelihood ratio tests.
Visscher, Benyamin, and White proposed a more detailed linear mixed model formulation
for twin and family data 129 . They formulate the traditional ACE model in the regression
framework as follows:

yi = µ + apa(i) + ci + mi + ei

(3.9)

= µ + pairi + mi + ei , where

(3.10)

yi is the continuous response vector for ni individuals from family group i,
µ is the overall mean of the response,
a represents additive genetic component and may be partitioned into effects inherited
from mother, from father, and deviation from those, so that ai = 1/2adad + 1/2amum +
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mi = apa + mi where the adad and amum terms may be combined into the parental
average term, apa , and mi is the deviation from the parental average,
ci is the shared environmental component,
ei is a vector of length ni of the individual, non-shared environmental components (also
called the “residual” components),
and the pairi term respresents the combination of apa + ci , and is common between
both members of a twin pair.
According to this formulation, the covariance between the members of a twin pair is defined
as follows:

Cov(yij , yik ) = mi var(Mi ) + var(P airi )

(3.11)

= mi ∗ 1/2 ∗ var(Ai ) + var(P airi )

(3.12)

= mi ∗ 1/2 ∗ var(Ai ) + 1/2 ∗ var(Ai ) + var(Ci )

(3.13)

(where mi = 1 for MZ twins and 0 otherwise)

(3.14)

= var(Ai ) + var(Ci ), for MZ twins,

(3.15)

= 1/2 ∗ var(Ai ) + var(Ci ), for DZ twins.

(3.16)

The authors point out that this model lends itself more readily to likelihood ratio testing
for significance of different variance terms than the Guo and Wang formulation 60,129 . For
example, testing an AE model against an ACE model is more straightforward using this
model. Model-fitting was demonstrated through residual maximum likelihood estimation in
the ASREML software.
Eaves et al. 40 suggested an ordinal response model that combined elements of a psychometric model and a model for individual differences. Their model describes the probability
of a response exceeding the kth out of K ordered categories on the jth item to follow the
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cumulative logit distribution:

Pi,j,k =

1
, where
1 + exp[−βj (θi − αj,k )]

(3.17)

βj is the discriminating power of the jth item,
αj,k is the item difficulty, and
θ is the so-called latent trait and is hypothesized to comprise two components, a fixed
covariate effect and a random residual effect that captures individual differences so
that θi = ai + δi , where ai is age (in this application) and δi is a random effect assumed
to be N (0, σ 2 ).
This model was fit using MCMC for Bayesian estimation with the Gibbs sampler. Although
few details were provided in this publication regarding the fitting procedure such as initial
values, it was stated that the model was fit in WinBUGS1.3, a Windows version of the BUGS
program.
Yu et al 142 . crafted a more complex model that accounts not only for familial relatedness
but also population structure. Their method was designed to handle a high degree of familial
relatedness and a moderate to high degree of population structure. The mixed-model is given
as:
y = Xβ + Sα + Qv + Zu + e, where

(3.18)

y is an n × 1 vector of continuous phenotypic observations for all n subjects,
Xβ represents non-genetic fixed-effects and associated coefficient estimates,
Sα represents SNP effects,
Q is a matrix that accounts for population structure and is estimated via STRUCTURE
software; it relates y to v,
v is a vector of population effects,
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Z is a design matrix,
u is a vector of random effects,
e is a vector of residuals,
Var(u) = 2KVg where K is an n × n matrix of relative kinship coefficients and Vg is
the genetic variance,
Var(e) = RVR where R is an n × n diagonal matrix with diagonal elements equal to
the reciprocal of the number of observations for which each phenotypic data point was
obtained and VR is the residual variance.
This model was fit using Proc Mixed in SAS and a software developed by the authors called
TASSEL.
More recently, Wang et al 131 . proposed a generalized linear mixed model formulation
that allows for estimation of fixed environmental effects, genetic variant effects, and variance
components for additive and dominance genetic effects, shared environments effects, and
individual effects. Their contribution specified a re-formulation of the traditional GLMM
that included a Cholesky decomposition of the random effects which allowed the model to be
fit using existing programs in SAS (proc “nlmixed”) or R (BRugs package) for the continuous
or dichotomous outcome cases. Their model is specified as follows:

g(µi ) = m + Zi α + x(gi )β + vi + ei , where

(3.19)

g() is a known link function, and µi = E(yi |vi , ei ) is an ni × 1 continuous or binary
response vector for the members of family i,
m is an intercept for the baseline,
Zi is a ni × p matrix of environmental covariates,
α is a p × 1 vector of fixed-effect estimates for the environmental effects,
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x(gi ) is a q × nj matrix of coded genotypes (the “g”here is not be confused with the
link function),
β is a p × 1 vector of fixed-effect estimates for the genetic effects,
vi is an ni ×1 vector of random effects which is distributed N (0, Σi ) for the ni members
of family i,
ei ∼ N (0, σc2 ), and ei ⊥vi , and
2
Σi = 2Φi σA2 + ∆i σD
where Φi and ∆i are the kinship matrix (accounting for additive

genetic effects) and the matrix accounting for dominance genetic effects, respectively,
for family i.
This GLMM was re-formulated to incorporate the Cholesky decompositions of the kinship
and double coancestry matrices. A standard Cholesky decomposition may be used to define
2Φi = LΦi L|Φi and ∆i = L∆i L|∆i so that the random genetic effects for each family may be
re-parameterized as:

vi = LΦi ai + L∆i di , where

(3.20)

ai = (ai1 , ..., airi )| ∼ N (0, σA2 Iri )with ri = rank(Φi ), and
2
di = (di1 , ..., disi )| ∼ N (0, σD
Isi )with si = rank(∆i ), so that
2
Cov(vi ) = Cov(LΦi ai + L∆i di ) = 2Φi σA2 + ∆i σD
= Σi .

3.3

Proposed Model

Of all the mixed-models available for complex, genomic data in families, none meets all of
our specific modeling needs. None of the models presented in section 3.2.2 are applicable in
high-dimensional scenarios. To answer the research questions of interest requires an ordinal
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response mixed regression model that allows for a set of penalized variables, a set of unpenalized variables, user-specified covariances for the random effects, and efficient implementation
in software. For this reason, we introduce the following model. The proposed cumulative
logit model for an ordinal response with C levels for the ith cluster or family is given as
follows:



 γ
P (Yi ≤ c|Xi , wi , ui )
ic
= log
log
1 − γ ic
P (Yi > c|Xi , wi , ui )

(3.21)

= αc + Xi β + Wi θ + zi ui ,

(3.22)

γ ic is an ni ×1 vector of probabilities that the observation for each member from family
i will fall at or below level c of the outcome phenotype,
αc is the intercept for ordinal level c,
Xi is an ni × p matrix of penalized predictors for ni members in the ith family,
β is a p × 1 vector of fixed-effects parameters,
Wi is an ni × q matrix of unpenalized predictors for ni members in the ith family,
θ is a q × 1 vector of fixed-effects parameters,
zi is an ni × 1 design vector for the random effects, and
ui is a family-specific random effect and zi ui ∼ N (0, Σi ) where the form of Σi is
dependent on the structure of the ith family.
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When the ith family contains one set of MZ twins, Σi is given as:




1 1 
2
Σi = σA2 ∗ Ki + σC2 ∗ 
 + σE ∗ I2
1 1






1 1
1 1
1 0
2
2
= σA2 ∗ 
 + σC ∗ 
 + σE ∗ 

1 1
1 1
0 1

(3.23)

(3.24)

When the ith family contains one set of DZ twins, Σi is given as:

Σi = σA2 ∗ Ki + σC2




 1 0.5
1
2
= σA2 ∗ 
 + σC ∗ 
0.5 1
1



1 1
2
∗
 + σE ∗ I2
1 1



1
1 0
2
 + σE ∗ 

1
0 1

(3.25)

(3.26)

According to this specification, Ki is the theoretical kinship matrix and it is different for MZ
and DZ pairs. The kinship matrix is multiplied by the additive genetic variance term σA2 ,
which is the same across all clusters. Similarly, the shared environmental variance term σC2 is
the same for all clusters (twin pairs, in this application.) The shared environmental variance
term is multiplied by the same matrix for both MZ and DZ pairs since twins, regardless of
zygosity, are assumed to share the same, communal environment. It represents individual,
non-shared variation and is estimated for each participant. This model was developed for
the purpose of application to the Pathways data from the BLTS participants. Although the
study population contains families of various sizes with both twins and non-twin siblings, we
will apply it only to complete twin pairs. The model and fitting method are valid for any
family size but so far, R code has been developed for fitting only complete twin pairs.
Then πc (Xij , Wij , ui ) represents the probability that the response for the j th member of
the ith family falls into category c. Because the link function is cumulative, the individual
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probabilities for all ordinal levels are found through subtraction and may be expressed:

=

πc (Xij , Wij , ui ) = P (Yij ≤ c|Xij , Wij , ui ) − P (Yij ≤ c − 1|Xij , Wij , ui )

(3.27)

exp(αc + Xij β + Wij θ + zi ui )
exp(αc−1 + Xij β + Wij θ + zi ui )
−
1 + exp(αc + Xij β + Wij θ + zi ui ) 1 + exp(αc−1 + Xij β + Wij θ + zi ui )

(3.28)

By definition, α0 = −∞ and αC = ∞, therefore, when c = 1,
exp(α1 + Xij β + Wij θ + zi ui )
,
1 + exp(α1 + Xij β + Wij θ + zi ui )
h exp(α + X β + W θ + z u ) i
0
ij
ij
i i
because lim
= 0.
α0 →−∞ 1 + exp(α0 + Xij β + Wij θ + zi ui )
π1 (Xij , Wij , ui ) =

(3.29)
(3.30)

Similarly, when c = C,
exp(αC−1 + Xij β + Wij θ + zi ui )
,
1 + exp(αC−1 + Xij β + Wij θ + zi ui )
h exp(α + X β + W θ + z u ) i
C
ij
ij
i i
because lim
= 1.
αC →∞ 1 + exp(αC + Xij β + Wij θ + zi ui )

π1 (Xij , Wij , ui ) = 1 −

(3.31)
(3.32)

The distribution of the random vector ui may be expressed as:

f (ui ) =

1 0
1
p
exp[− ui Σ−1
i ui ]
2
2π |Σi |

(3.33)

It is worth noting here that the random effect ui is a random intercept and is the same for
all j members of the ith family. The random vector ui is of length j and may be re-expressed
as ui = ui ∗ ji , where ji is a vector of 1’s and is of length j. The distribution of the random
effect may therefore be expressed as:

f (ui ) =

1
1
0
p
exp[− u2i ∗ ji Σ−1
i ji ]
2
2π |Σi |
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(3.34)

Then the conditional likelihood for family i is:
n

0

L∗i (α, β, θ, ui , Σi |Xi , Wi )

C

i Y
Y
exp(− 21 ui Σ−1
i ui )
p
πc (Xij , Wij , ui )yijc .
=
2π |Σi |
j=1 c=1

(3.35)

The marginal likelihood may be achieved by integrating out the random effect, ui . The
marginal likelihood for family i is:
Z h

1
p
2π |Σi |

ni Y
C
i
1 0 −1 Y
exp(− ui Σi ui )
πc (Xij , Wij , ui )yijc dui .
2
j=1 c=1

(3.36)

As this integral has no closed form solution, we employ Gauss-Hermite quadrature to estimate
a solution. This quadrature rule estimates integrals of a general form in the following way 35 :
Z

∞
2

f (x) exp(−x )dx ≈
−∞

m
X

wm f (zm ),

(3.37)

i=1

where the wm and the zm are the weights and abscissa (respectively) as dictated by the
Hermite polynomials 35 and M represents the number of nodes, or points, being used. An
adaptive version of Gauss-Hermite quadrature involves a transformation which ensures that
the integrand will be sampled across the most suitable range of values 88,97 . Following the
derivations of Liu and Pierce, consider expressing:
Z

∞

Z

2

∞

f (x) exp(−x )dx as
−∞

f (t)φ(t; µ, σ)dt,

(3.38)

−∞

where φ(t; µ, σ) is an arbitrary normal density. The nodes zm are transformed to be located
√
√
√
at tm = µ + 2σ 2 zm so (dtm = 2σ 2 dzm ) and the weights wm are modified to wm / π. Then
µ̂ is set to equal the mode of g(t) where,
ni Y
C
1 0 −1 Y
g(ti ) = exp(− ui Σi ui )
πc (Xij , Wij , ui )yijc ,
2
j=1 c=1
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(3.39)

2

the integrand from equation 3.36. And σ̂ = 1ĵ , where ĵ = − δtδ 2 log g(ti )
i

h(ti ) =

and define:
ti =µ̂

g(ti )
.
φ(ti ; µ̂i , σ̂i )

(3.40)

And then,
Z

∞

Z

∞

g(ti )dti =
−∞

h(ti )(φ(ti ; µ̂i , σ̂i ))dti

(3.41)

−∞
Z ∞

 (t − µ̂ )2 
1
i
i
exp −
h(ti ) q
dti
ˆ2
−∞
2
ˆ
2
σ
i
2σi π
q
M
X
wm
√
h(µ̂i + 2σˆi2 zm )
≈
π
m=1
q
M
X
g(
µ̂
+
2σˆi2 zm )
i
wm


√
=
π q 1 exp − (ti −µˆi )2
m=1

=

=

=

m=1
M
X

q
wm 2σˆi2

(3.43)

(3.44)
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Applying this approximation to the likelihood stated above gives:
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q
πc (Xij , Wij , (µ̂i + 2σˆi2 zm ))yijc . (3.47)

Note that the likelihood given above includes the i subscript on the µ̂ and the σˆ2 since an
empirical Bayes estimate must be found for each cluster, i. The µ̂i is the mode of g(ti ),
the integrand from 3.36, for each family. It may be calculated by maximizing g(ti ) or,
equivalently, minimizing -log(g(ti )) as follows:

µ̂i = arg min − log(g(ti ))

(3.48)

ni Y
C
i
h
1 0 −1 Y
yijc
πc (Xij , Wij , ui )
.
= arg min − log exp(− ui Σi ui )
2
j=1 c=1

(3.49)

Computation of this mode is made simpler and faster when the derivative is provided to the
optimization function. The derivative of the objective function log(g(t)) is shown below.
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Then, looking at just
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πc (Xij , Wij , ui ) , and allowing the expression:
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Xij β + Wij θ + zi ui be represented as ∗, we see:
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And, when c = C and αC = ∞, see that
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These derivative calculations decrease computational burden, therefore decreasing the amount
of time it takes to find a solution.

3.4

Alternate Model Formulations

Our proposed mixed-model explicitly estimates the additive genetic, shared environmental,
and unique environental components of the variance, in keeping with the traditional additive
genetic assumptions in biometric model form. In many applications, however, one of either
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the additive genetic or the shared environmental components will account for only a negligible
proportion of the total variance. In these cases, it is helpful to drop one of these terms (the
σa2 or the σc2 ) and use a likelihood ratio test to determine its neccesity. The proposed model
was designed with this flexibility in mind and either the σa2 or the σc2 may be easily dropped
in order to perform a likelihood ratio test.
The previously proposed model represents a mixed-effects regression formulation most
similar to that seen in much of the behavior genetics and other molecular genetics twinmodeling literature. Many other mixed-model formulations, however, have been applied.
Hedeker and Gibbons suggested a general mixed-effects model with heterogeneous random
effect variance terms to account for correlations between twins in a pair 66 . Their logisticregression random-intercept model was given as follows:



log

pi 
= Xi β + M Z i
1 − pi



σδ(M Z) 
 θi , where
DZi 
σδ(DZ)


(3.50)

pi is an ni × 1 vector of probabilities of response for the ni members of the ith twin
pair,
Xi is a ni × p matrix of covariates and β is the corresponding p × 1 vector of fixed-effect
estimates,
M Zi and DZi are dummy-coded variables indicating twin-pair status such that for

 


 

each pair, M Zi DZi = 1 0 , if MZ and M Zi DZi = 0 1 , if DZ, and
θi is a random effect with a standard normal distribution.
This model includes a single random effect, which contributes to model simplicity and ease
of estimation. The pre-multiplication by the separate MZ and DZ variance terms, however,
allows for different intraclass correlations between MZ and DZ twins. The two variances
terms are not constrained to be unequal, however the specification of the model allows them
to be different.
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We modified this model to apply it to the high-dimensional, ordinal response setting as
follows:



 γ
P (Yi ≤ c|Xi , wi , M Zi , DZi , ui )
ic
= log
log
1 − γ ic
P (Yi > c|Xi , wi , M Zi , DZi , ui )




σu(M Z) 
= αc + Xi β + Wi θ + M Zi DZi 
 ui ,
σu(DZ)

(3.51)

(3.52)

αc , Xi , β, Wi , and θ are defined exactly as in Section 3.3, and the random effects
portion is defined as described in Equation 3.50.
This model may be fit similarly to the original proposed model, with a few modifications.
The random effect, ui , is assumed to be standard normal and its distribution may be given
as follows:
−u2i
1
f (ui ) = √ exp
2
2π

(3.53)

Then the conditional likelihood for family i is:
2

L∗i (α, β, θ, ui , σM Z , σDZ |Xi , Wi , M Zi , DZi )

ni Y
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C
exp(− i ) Y
πc (Xij , Wij , ui , M Zi , DZi )yijc .
= √ 2
2π j=1 c=1

(3.54)
Then as before, the marginal likelihood may be achieved by integrating out the random
effect, to yield:
1
√
2 2π

Z h

exp(−u2i )

ni Y
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i
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(3.55)

j=1 c=1

As before, this integral also has no closed-form solution and we therefore employ adaptive
Gauss-Hermite quadrature to estimate a solution. This is applied in the same manner as
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shown above so that the likelihood may be approximated as follows:

L∗i (α, β, θ, ui , Σi |Xi , Wi , M Zi , DZi ) ≈
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The µ̂i is the mode of g(ti ), the integrand from the approximated likelihood equation above,
for each family. It may be calculated by maximizing g(ti ) or, equivalently, minimizing
− log(g(ti )) as follows:

µ̂i = arg min − log(g(ti ))

(3.57)
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Then, allowing the expression,


σu(M Z) 
 ui to be rexpressed as follows,
DZi 
σu(DZ)

(3.59)

Xi β + Wi θ + (σM Z M Zi + σDZ DZi )ui and represented by ∗,

(3.60)


Xi β + W i θ + M Z i
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the derivative of − log(g(ti )) may be expressed as follows:
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2

Parameter Estimation

The optimx 96 package in R may be used to optimize the expression for the original proposed
model in 3.48 or for the alternate model in 3.57 and find the empirical Bayes estimate
of µ̂. The optimx function will also estimate the Hessian matrix, which may be used to
estimate σ̂. Estimation of the Hessian matrix is possible when the derivative expressions,
as calculated previously in Section 3.3 and Section 3.4, are provided to the function call.
Once the µ̂i ’s and σˆi2 ’s have been found by the optimx function, they may be used in the
Gauss-Hermite quadrature procedure to approximate the marginal likelihood function. This
marginal likelihood may then be optimized to find the α, β, θ, σa2 , σc2 , and σe2 values for
2
2
the original proposed model or the α, β, θ, σu(M
Z) , and σu(DZ) for the alternate model. The

marginal likelihood optimization is performed via the constrOptim function which estimates
parameters according to some set of linear constraints. For the original model, the constraints
are set so that α1 < ... < αC−1 , σa > 0, σc > 0, and σe > 0.001. The constraint on σe is
enforced to prevent the variance/covariance matrix of the random effect from being singular.
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For the alternate model, the constraints are set so that α1 < ... < αC−1 , σu(M Z) > 0, and
σu(DZ) > 0.
The β estimates for the penalized covariates are estimated in a stepwise fashion. The
model is fit using a modified ordinal Generalized Monotone Incremental Forward Stagewise
(GMIFS) regression method. The original GMIFS 64 was previously extended to allow for
ordinal responses and no-penalty subsets of covariates 11 and further extended for ordinal
responses in a mixed-model framework to allow for clustered and longitudinal data 69 . Our
implementation of the GMIFS here includes a further extension which allows a mixed-model
with specified covariance structure to be fit. Before the modified GMIFS procedure begins,
the penalized covariate matrix X is expanded by appending the negative matrix to the
PN
original. Then, for N family clusters,
i=1 ni = Q total observations so that X with
dimensions Q × p becomes {X : −X} with dimensions Q × 2p after the expansion. We
augment the covariate space in this way so that we may avoid calculation of the second
derivative to determine the direction of the β update 64 . Then the fitting process proceeds
as follows:
• Step 0: Set all β estimates to zero, set σa = σc = 1, σe = 0.5 for the original proposed
model, or set σu(M Z) = 1 and σu(DZ) = 1 for the alternate model, set all u estimates
to 1, and set starting values for α and θ.
– Starting values for α, and θ are set via a 2-step process, first, all θ estimates are
Pk

set to 0 and the α-values are set such that αk = log

c=1

PN

i=1

Pnj

j=1

nijc
Q
nijc
Q

P
P
P nj
1− kc=1 N
i=1
j=1

• Step 1: Holding all other parameters fixed, find the Empirical Bayes estimate of u via
maximum likelihood.
• Step 2: Holding all other parameters fixed, estimate α, θ, and the variance parameters, either σa , σc , and σe or σu(M Z) and σu(DZ) , using the adaptive Gauss-Hermite
quadrature procedure.
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• Step 3: Identify the βm associated with the smallest negative gradient of the log likelihood, i.e. m = arg min −
p

∂
logL.
∂βp

• Step 4: If βm to be updated has a current estimate of 0 (i.e., it has not been updated
yet,) then repeat steps 1-3; if step 3 identifies the same β, then update it by adding
some small .
Otherwise, if βm 6= 0, then simply update it by adding some small .
• Step 5: Repeat steps 3-4 until the difference between sequential log likelihoods is
smaller than some small γ or until the total number of variables estimated in the
model exceeds Q/10, whichever comes first.
After the procedure finishes, the final β estimates are obtained by subtracting the estimates
for the {−X} from those for the {X} so that β = {β1 , ..., βp } − {βp+1 , ..., β2p }. The final
model, or the model as estimated by the final fitting step before the procedure was stopped
according to one of the two stopping criteria, may be an overfit model. The best model is
therefore be chosen according to some fit criteria; we chose to use AIC and BIC to select the
best fitting model. The full R code for fitting the ACE, AE, CE, and alternate models may
be found in Appendices A.8, A.9, A.10, and A.11 respectively.

3.5.1

Model Evaluation

Simulation Study Setup
To evaluate the performance of this proposed method, we performed several simulations
studies. For each simulation set-up, model performance was evaluated according to two general aspects, feature selection and prediction. To assess feature selection, we reported the
number of predictors with truly non-zero coefficients that had non-zero coefficient estimates
in addition to the number of predictors with truly zero coefficients that had non-zero coefficient estimates. In this way, we can essentially measure the power and Type I error for the
variable selection procedure. When a particular β has a non-zero estimate, this means that
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the associated covariate has been included in the model but when a β has a zero estimate,
this means that the associated covariate has been omitted from the model. To assess prediction, we performed cross-validation and used the AIC and BIC-selected model parameters
to estimate the predicted class for the left out fold. While the models themselves include
random effects estimated for each cluster, the predicted responses are found using only the
fixed-effect regression parameters since the random effects cannot be estimated when the
response is not known. In this way, the predicted responses are a sort of average or mean
response for an observation with certain, known covariates.
Given the complex nature of SNP data and the correlation structure of such data for
twins, we chose not to generate SNP data for the purpose of our simulation studies. Instead,
we used actual SNP data from the Pathways project to simulate ordinal outcome data. The
subset of 1092 subjects (546 twin pairs) used in the simulation studies is composed of all
complete twin pairs for whom both SNP and drug use data were available. The R code that
created this subset is shown in Appendix Section A.1. The subset is limited to these subjects
since the zygosity of the twin pairs is needed to define the variance/covariance structure of
the twin pair and this zygosity information is available only in the drug use data set. To
simplify calculations, we randomly selected 46 pairs to remove from the training set, leaving
500 pairs (1000 subjects) in the training set. The zygosity of the 500 training pairs is given
in Table 3.1 below.
MZFF
125

MZMM
75

DZFF
99

DZMM
65

DZMF
136

Table 3.1: Zygosity of twin pairs in the simulated dataset where MZFF and MZMM denote
MZ female-female and MZ male-male respectively, DZFF and DZMM likewise indicate samesex DZ pairs and DZMF denotes opposite sex DZ pairs.
The proposed method is penalized in order to handle high-dimensional data, however, the
full SNP dataset is still too large for the model to accomodate. Even fitting the model on a
chromosome-by-chromosome basis is still intractable, considering that hundreds of thousands
of SNPs are measured on each chromosome. We therefore chose to fit the proposed model
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to each chromosome individually, using a filtered set of SNPs from that chromosome. To
filter the data, we used the nearZeroVar() function from the R package caret 51 . This
function assesses variance according to two metrics, a frequency ratio and a distinct value
percentage. The frequency ratio (freqRatio value) is the ratio of the most common value to
the second most common value; the smaller this ratio, the greater the variance. The distinct
value percentage (percentUnique value) is the percentage of unique values out of the total
number of values; the higher this percentage, the greater the variance. Each of these is
calculated for each SNP on the chromosome. We then filtered out (i.e. removed) those SNPs
with both a freqRatio value at or above the 15th percentile and a percentUnique value
at or below the 85th percentile. In this way, the least informative SNPs, those with small
variance across all samples, may be removed. For the simulation studies, chromosome 21
was used. The full code creating this set may be found in Appendix Section A.2.
The original chromosome 21 dataset contains 118, 603 loci; after filtering, the trimmed
set contained 5602 loci, or approximately 4.72% of the original set. Full code for the data
simulation may be found in Appendix Section A.3 for the original model and Appendix
Section A.4 for the alternate model. From this filtered set, we randomly selected one primary
SNP and then several additional SNPs that were moderately correlated with it (correlation
absolute value of between 0.1 and 0.4) to serve as “true” predictors for the simulation study.
A total of 87 SNPs met this threshold for “moderate” correlation and 5 were randomly
chosen; together, these 6 SNPs represented the true parameters. Then, SNPs which were
highly correlated with these 6 SNPs (correlation absolute value of greater than 0.5) were
removed from the set; 38 such loci were removed. The final SNP set for the simulation study
therefore contained 5564, 6 of which were “true” predictors and the remaining 5558 were not
related to the ordinal response. Let these 6 SNPs in a matrix be represented by X∗ Figure
3.1 shows the dosage distribution across these 6 “true”predictor SNPs.
The random effect and the random error were generated differently for simulations testing the original proposed model and the alternate model; denote these simulated random
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Figure 3.1: Simulation SNPs distributions.
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1.5

2.0

variables as u∗ and ∗ . For the original model, they were generated using the rlogis()
function such that the sum of these two random variables (u∗ + ∗ ), each assumed to be logistic distributed, would be approximately standard logistic distributed. Random variables
may be generated with the rlogis() function by specifying the mean, or the location, m,
and the variance, via a scale value, s, such that the variance is equal to

π 2 s2
.
3

For each of

the original model simulations, m was set to 0 for both the random effect and random error
means. The s values were varied according to 15 combinations and are given in Table 3.2
below where sRE corresponds to the scale parameter for u∗ and serror corresponds to the scale
parameter for ∗ . As mentioned, the SNP data used for these simulations has an inherent
and complex correlation structure. These scale parameters were chosen in order to attempt
to approximate a range of ICC values between the MZ and DZ twins.
sRE
serror

0.05
0.9

0.1
0.8

0.4
0.85

0.5
0.9

0.6
0.95

0.65
0.35

0.65
0.3

0.7
0.9

0.7
0.25

0.75
0.25

0.75
0.2

0.75
0.1

0.8
0.9

0.8
0.2

0.8
0.1

Table 3.2: Scale values used in the rlogis() function to generate the random effect and
random error terms for the simulations for the original model.
In order to determine whether or not the sum of these two logistic-distributed variables
were standard logistic distributed, we simulated 1000 random logistic values for each scale
parameter listed above. The histogram of the sum of the random variables (u∗ + ∗ ) for each
sRE and serror combination was then plotted and the overlayed with the standard logistic
pdf. These may be seen in Figures 3.2 and 3.3. Visual inspection indicated that the sum of
these two random variables was reasonably approximately standard logistic distributed.
For the alternate model, the simulated random effect, u∗ , was generated as a standard
normal via the rnorm() function while the simulated error, ∗ , was generated as a standard
logistic via the rlogis() function where the scale parameter, s = 1. The simulated variance
terms, aM Z and aDZ , were varied according to the combinations shown in Table 3.3. These
values were chosen in order to achieve a small range of intracluster correlations between the
MZ and DZ pairs in the simulated datasets. It is important to note that aM Z and aDZ do
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Figure 3.2: Histograms of the simulated logistic distributions of the sRE and serror combinations overlayed with the standard logistic.
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Figure 3.3: Histograms of the simulated logistic distributions of the sRE and serror combinations overlayed with the standard logistic.
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not represent the true variances of the simulated datasets; these contribute to the complex
variance structure inherent in the SNPs chosen to simulate the outcome. The true ICC for
MZ and DZ twins in each dataset may be calculated from the simulated outcomes and are
given in Table 3.12.
aM Z
aDZ

1
0.65

1
0.8

1.25
0.8

1.5
0.9

1.5
1.1

1.65
1

1.8
1.05

1.8
1.15

Table 3.3: Variance parameters for the alternate model formulation simulation studies.
For the simulation studies, all the β values for the 6 SNPs in X∗ were set to the same
value. For each of the 15 combinations of sre and serror in the original formulation and each
of the 8 combinations of aM Z and aDZ in the alternate formulation, the model was assessed
for β = {1, 1, 1, 1, 1, 1}. The linear portion, v∗ of the outcome was calculated as follows:

vi∗ = X∗i β + u∗i + ∗i , for the original model, and,
= X∗i β + (aM Z M Zi + aDZ DZi )u∗i + ∗i , for the alternate model.

(3.61)
(3.62)

Then these v∗ values are approximately evenly divided into three ordered categories using
quantiles such that
Qv∗ (p) = {v ∗ |Pr(V ∗ ≤ v ∗ ) = p},

(3.63)

indicates the pth percentile of v∗ . Then each vi∗ is transformed into an ordinal response, yi∗
as follows:

yi∗ =





3 if vi∗ < Qv∗ (0.33)





2 if Qv∗ (0.33) ≤ vi∗ < Qv∗ (0.66)






1 if vi∗ ≥ Qv∗ (0.66)

(3.64)

The full R code used to generate the simulation data is given in Appendix Section A.3 for
the original model and Appendix Section A.4 for the alternate model.
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Simulation Study Results
Original Proposed Model The numbers of non-zero β parameters for the simulation
studies of the original proposed model are given in Table 3.4. For each combination of sRE
and serror , the number of parameters estimated by the AIC- and BIC-selected full ACE and
restricted AE and CE models are given. The value in each cell shows the total number of
non-zero β parameters estimated by that model and the adjacent value in parentheses shows
how many of the non-zero β’s are true non-zero β’s.
sRE

serror

0.05
0.1
0.4
0.5
0.6
0.65
0.65
0.7
0.7
0.75
0.75
0.75
0.8
0.8
0.8

0.9
0.8
0.85
0.9
0.95
0.35
0.3
0.9
0.25
0.25
0.2
0.1
0.9
0.2
0.1

ACE
3 (3)
29 (4)
5 (4)
16 (5)
6 (2)
29 (4)
23 (4)
2 (0)
28 (4)
1 (0)
18 (2)
41 (4)
2 (0)
1 (0 )
35 (4)

BIC model
AE
2 (2)
6 (5)
2 (2)
1 (1)
2 (2)
6 (5)
7 (5)
1 (1)
6 (5)
5 (4)
6 (4)
8 (4)
1 (1)
5 (4)
7 (5)

CE
3(3)
30 (4)
6 (4)
11 (4)
6 (2)
30 (4)
23 (4)
2 (1)
28 (4)
2 (0)
19 (2)
41 (4)
2 (1)
1 (0)
35 (4)

ACE
3 (3)
45 (5)
5(4)
16 (5)
23 (5)
45 (5)
45 (5)
44 (5)
43 (5)
40 (4)
45 (4)
45 (4)
45 (5)
45 (4)
45 (5)

AIC model
AE
2 (3)
46 (5)
2 (2)
1(1)
2 (2)
46 (5)
36 (5)
1 (1)
30 (5)
46 (5)
44 (5)
46 (5)
1 (1)
36 (5)
45 (5)

CE
3 (3)
45 (5)
45 (5)
18 (4)
24 (5)
45 (5)
45 (5)
44 (5)
43 (5)
40 (4)
45 (4)
45 (5)
45 (5)
44 (4)
43 (5)

Table 3.4: Number of non-zero parameters selected by the BIC- and AIC-selected full ACE
model and the restriced AE and CE models when β = 1. The value in parentheses indicates
how many of those non-zero parameters were true parameters.
From Table 3.4, we can see that none of the models were able to correctly identify all 6
of the true non-zero parameters, although a fair number of models were able to identify 5 of
them. While the AIC-selected models tend to perform better in terms of capturing more of
the true non-zero predictors, in most cases, they are overfit and include too many additional
parameters. The best selection without overfitting generally occurs in the BIC-selected AE
models, at least in cases where sRE is larger and serror is smaller (indicating greater ICC’s.)
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The predicted response for the simulation studies of the original proposed model are
given in Table 3.5. For each combination of sRE and serror , the ordinal outcome predicted
by the AIC- and BIC-selected full ACE and restricted AE and CE models are given. For
each 3 × 3 block of predicted responses, accurate predictions appear on the diagonal.
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sRE

serror

0.05

0.9

0.1

0.8

0.4

0.85

0.5

0.9

0.6

0.95

0.65

0.35

0.65

0.3

0.7

0.9

0.7

0.25

0.75

0.25

0.75

0.2

0.75

0.1

0.8

0.9

0.8

0.2

0.8

0.1

True
Class
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

21
13
8
2
0
0
21
10
6
20
8
5
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0

ACE
3
4
4
29
26
21
5
3
6
5
5
5
31
30
31
29
26
21
21
28
30
31
30
31
20
29
27
31
30
31
31
30
30
28
28
27
31
30
31
31
30
30
28
29
27

7
13
19
0
4
10
5
17
19
6
17
21
0
0
0
0
4
10
0
2
1
0
0
0
1
1
4
0
0
0
0
0
1
1
2
4
0
0
0
0
0
1
3
1
4

BIC model
AE
0 31 0
0 30 0
0 31 0
20 8
3
9
8 13
0
8 23
30 0
1
27 0
1
25 0
1
0 31 0
0 30 0
0 31 0
0 31 0
0 30 0
0 31 0
20 8
3
9
8 13
0
8 23
20 8
3
8
8 14
0
7 24
0 30 1
0 25 5
0 25 6
21 6
4
8 10 12
0
7 24
21 6
4
9
8 13
0
7 24
20 6
5
10 9 11
0
7 24
20 6
5
5 12 13
0
7 24
0 30 1
0 25 5
0 25 6
20 6
5
11 7 12
0
7 24
21 6
4
9
8 13
0
8 23

CE
21 3
13 4
8
3
2 29
0 26
0 21
21 4
8
5
5
8
3 27
0 27
0 25
0 31
0 30
0 31
2 29
0 26
0 21
0 31
0 27
0 29
0 31
0 30
0 31
0 30
0 29
0 27
0 29
0 28
0 29
0 31
0 30
0 30
2 28
0 28
0 27
0 31
0 30
0 31
0 31
0 30
0 31
0 28
0 29
0 27

7
13
20
0
4
10
6
6
18
1
1
6
0
0
0
0
4
10
0
3
2
0
0
0
3
1
4
2
2
2
0
0
1
1
2
4
0
0
0
0
0
0
3
1
4

21
13
8
4
1
0
21
10
6
20
8
5
9
1
0
4
1
0
4
2
0
12
2
1
3
2
0
0
0
0
2
1
0
3
0
0
8
8
0
2
1
0
3
1
0

ACE
3
4
4
27
23
19
5
3
6
5
5
5
19
22
18
27
23
19
27
22
18
16
22
15
26
26
20
31
30
31
26
28
22
27
28
27
22
22
23
27
29
23
25
28
24

7
13
19
0
6
12
5
17
19
6
17
21
3
7
13
0
6
12
0
6
13
3
6
15
2
2
11
0
0
0
3
1
9
1
2
4
1
1
8
2
0
8
3
1
7

AIC model
AE
0 31 0
0 30 0
0 31 0
16 11 4
7 11 12
0
8 23
30 0
1
27 0
1
25 0
1
0 31 0
0 30 0
0 31 0
0 31 0
0 30 0
0 31 0
16 11 4
7 11 12
0
8 23
18 10 3
7 10 13
0
8 23
0 30 1
0 25 5
0 25 6
16 11 4
8 10 12
0
8 23
16 11 4
6 12 12
0
8 23
15 11 5
8 11 11
0
7 24
16 12 3
6 12 12
0
8 23
0 30 1
0 25 5
0 25 6
15 12 4
7 12 11
1
7 23
17 9
5
10 8 12
0
9 22

21
13
8
4
1
0
16
5
2
12
1
0
19
7
4
4
1
0
4
2
0
12
2
1
2
1
0
0
0
0
2
1
0
2
0
0
8
8
0
2
1
0
2
1
0

CE
3
4
3
27
23
19
11
12
8
17
22
18
4
8
6
27
23
19
27
22
18
16
22
15
27
27
21
29
28
29
26
28
22
28
28
27
22
22
23
27
29
23
26
28
25

7
13
20
0
6
12
4
13
21
2
7
13
8
15
21
0
6
12
0
6
13
3
6
15
2
2
10
2
2
2
3
1
9
1
2
4
1
1
8
2
0
8
3
1
6

Table 3.5: Predicted class for the AIC- and BIC-selected full ACE and restricted AE and
CE models when β = 1.
The predicted outcomes for the 92 left-out subjects given in Table 3.5 may be summa77

rized by accuracy, i.e., the proportion of accurate predictions made by each model. These
accuracies are presented in Table 3.6.
sRE

serror

0.05
0.1
0.4
0.5
0.6
0.65
0.65
0.7
0.7
0.75
0.75
0.75
0.8
0.8
0.8

0.9
0.8
0.85
0.9
0.95
0.35
0.3
0.9
0.25
0.25
0.2
0.1
0.9
0.2
0.1

ACE
.370
.413
.467
.500
.326
.413
.315
.326
.359
.326
.326
.370
.326
.326
.359

BIC model
AE
.326
.554
.337
.326
.326
.554
.565
.337
.598
.576
.576
.609
.337
.554
.565

CE
.489
.413
.478
.391
.326
.413
.315
.326
.359
.326
.337
.370
.326
.326
.359

ACE
.478
.424
.467
.500
.478
.424
.424
.533
.435
.326
.424
.380
.413
.424
.413

AIC model
AE
.326
.543
.337
.326
.326
.543
.554
.326
.533
.554
.543
.554
.337
.543
.511

CE
.489
.424
.533
.511
.522
.424
.424
.533
.424
.326
.424
.370
.413
.424
.391

Table 3.6: Proportion of accurately predicted outcomes for the left-out fold for the BIC- and
AIC-selected full ACE model and the restriced AE and CE models when β = 1.
In terms of prediction accuracy, none of the models perform particularly well, however, it
is important to remember that these predictions are made with only the fixed-effect portions
of the estimated models. The intraclass correlation values of the simulated data and the
variance estimates for the simulation studies of the original proposed model are given in
Table 3.7. For each combination of sRE and serror , the variance parameters estimated by the
AIC- and BIC-selected full ACE and restricted AE and CE models are given.
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sRE

serror

ICCM Z

ICCDZ

0.05

0.9

0.372

0.129

0.1

0.8

0.395

0.144

0.4

0.85

0.438

0.183

0.5

0.9

0.446

0.228

0.6

0.95

0.446

0.233

0.65

0.35

0.812

0.450

0.65

0.3

0.832

0.482

0.7

0.9

0.509

0.299

0.7

0.25

0.847

0.515

0.75

0.25

0.861

0.555

0.75

0.2

0.898

0.563

0.75

0.1

0.926

0.632

0.8

0.95

0.556

0.334

0.8

0.2

0.898

0.627

0.8

0.1

0.918

0.649

model
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE
ACE
AE
CE

σ̂a
BIC
0
0.010
0
0.006
0
0.010
0
0.009
0
0.010
0
0.006
0
0.006
0
0.010
0
0.005
0
0.005
0
0.005
0
0.005
0
0.008
0
0.005
0
0.005
-

σ̂c
AIC
0
0.010
0
0.006
0
0.010
0
0.009
0
0.010
0
0.006
0
0.006
0
0.010
0
0.005
0
0.005
0
0.005
0
0.005
0
0.008
0
0.005
0
0.005
-

BIC
0.054
0.011
0.011
1.918
0.045
0.034
0.036
1.027
1.233
1.251
1.897
1.918
2.304
2.271
1.621
1.614
2.407
2.402
3.717
3.714
3.270
3.278
3.181
3.183
1.802
1.780
4.228
4.245
4.404
3.426

σ̂e
AIC
0.054
0.011
0.011
1.640
0.045
0
0.036
0.769
0.874
0.041
1.626
1.640
1.744
1.774
0.091
0.886
2.079
2.138
2.616
2.630
2.648
2.651
3.095
3.106
1.203
1.190
3.086
3.133
3.160
3.227

BIC
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001

AIC
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001

Table 3.7: Intraclass correlation values for the simulated outcomes for MZ and DZ twins and
the estimated variance components of the BIC- and AIC-selected full ACE and restricted
AE and CE models when the true β parameters are all set to equal 1.
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The comparison of intracluster correlations (as described in Equation 1.2) between the
simulated responses for the MZ and DZ twins indicate that either additive genetics or a
combination of additive genetics and shared environmental components are responsible for
the observed correlations in these scenarios. The full ACE models, however, estimate the
additive genetic component of the variance to be nearly zero in every case. The unique
environmental term is also estimated at nearly zero in every case; although it is estimated
at 0.001, this is an artifact of the estimation procedure since the σ̂e is restricted to be at
least 0.001 in order to prevent singularity in the variance/covariance matrix. Without this
restriction, the estimated value of σ̂e would shrink much closer to zero.
Overall, the original proposed model seems not to perform as optimally as hoped. Weighing the six models solutions (BIC- and AIC-selected models for each of the ACE, AE, and
CE formulations) against one another in terms of variable selection, prediction accuracy, and
variance estimation, the BIC-selected AE model appears to perform the best.
[
Given the estimated variance components, the estimated ICC for each model, the ICC
terms, could be calculated. For each model, the estimated ICC may be found as:
σ̂a2 + σ̂c2 + σ̂e2
, for MZs, and
σ̂a2 + σ̂c2 + σ̂e2 + π 2 /3
1/2σ̂a2 + σ̂c2 + σ̂e2
[=
, for DZs.
ICC
1/2σ̂a2 + σ̂c2 + σ̂e2 + π 2 /3

[=
ICC

(3.65)
(3.66)

From the model-estimated variance parameters in Table 3.7, we see that the additive genetic
component of the variance is never very much greater than zero, resulting in a total random
effect variance of approximately zero for all the AE models. The ACE and CE models
estimate similar variances since the common environmental portion of the variance is driving
the estimates in both cases. The model-estimated ICC would therefore be the same for
both MZ and DZ twins because the shared environment is the only component contributing
significantly to the variance and this component is assumed to be the same for both types of
twin clusters. Based on these results, the model appears to be unable to properly parse out
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[ terms were not calculated
and estimate the variance components. For this reason, the ICC
or reported here.

Alternate Proposed Model The numbers of non-zero β parameters for the simulation
studies of the alternate proposed model are given in Table 3.8. For each combination of
aM Z and aDZ , the number of parameters estimated by the AIC- and BIC-selected models
are given. The value in each cell shows the total number of non-zero β parameters estimated
by that model and the adjacent value in parentheses shows how many of the non-zero β’s
are true non-zero β’s. The parameter values for aM Z and aDZ were chosen such that the
simulated ICCs would be similar to those simulation cases for which the original model
performed poorly in terms of variable selection.
aM Z
1
1
1.25
1.5
1.5
1.65
1.8
1.8

aDZ
0.65
0.8
0.8
0.9
1.1
1
1.05
1.15

BIC model
5 (3)
8 (5)
4 (3)
13 (3)
5 (3)
14 (3)
12 (3)
14 (3)

AIC model
35 (5)
20 (5)
35 (5)
41 (5)
46 (5)
46 (5)
45 (5)
46 (5)

Table 3.8: Number of non-zero parameters selected by the BIC- and AIC-selected models
when β = 1. The value in parentheses indicates how many of those non-zero parameters
were true parameters.
As with the original model, we observe from Table 3.8 that the AIC-selected model does
a better job of finding the true non-zero predictors, but it still overfitting in every case.
In comparison to the BIC-selected AE original proposed model, the BIC-selected alternate
model appears to perform variable selection more consistently, although not necessarily more
accurately in every case.
The predicted response for the simulation studies of the alternate proposed model are
given in Table 3.9. For each combination of aM Z and aDZ , the ordinal outcome predicted by
the AIC- and BIC-selected models are given. For each 3 × 3 block of predicted responses,
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accurate predictions appear on the diagonal.
aM Z

aDZ

1

0.65

1

0.8

1.25

0.8

1.5

0.9

1.5

1.1

1.65

1

1.8

1.05

1.8

1.15

True Class
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
1
2
3

BIC model
12 14 5
4 17 9
2 10 19
13 15 3
5 15 10
3 11 17
6 25 0
3 24 3
2 16 13
6 25 0
2 25 3
3 15 13
0 31 0
0 30 0
0 30 1
7 24 0
2 25 3
3 16 12
0 31 0
0 29 1
0 25 6
0 31 0
0 29 1
0 25 6

AIC model
17 9 5
5 12 13
4 8 19
17 9 5
5 13 12
4 8 19
15 11 5
5 12 13
5 8 18
15 11 5
4 15 11
5 8 18
10 15 6
4 14 12
5 9 17
13 13 5
5 13 12
6 7 18
11 15 5
5 14 11
6 8 17
10 15 6
3 15 12
5 9 17

Table 3.9: Predicted class for the AIC- and BIC-selected models when β = 1.
The proportion of accurate predictions from Table 3.9 are summarized in Table 3.10.
aM Z
1
1
1.25
1.5
1.5
1.65
1.8
1.8

aDZ
0.65
0.8
0.8
0.9
1.1
1
1.05
1.15

BIC model
.522
.489
.467
.478
.337
.478
.380
.380

AIC model
.522
.489
.489
.522
.446
.478
.456
.456

Table 3.10: Proportion of accurately predicted outcomes for the left-out fold for the BICand AIC-selected models when β = 1. The value in parentheses indicates how many of those
non-zero parameters were true parameters.
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The proportion of accurately predicted outcomes appear more consistent but not necessarily more accurate than those from the original proposed model.
The intraclass correlation values of the simulated data and the variance estimates for
the simulation studies of the original proposed model are given in Table 3.11. For each
combination of aM Z and aDZ , the variance parameters estimated by the AIC- and BICselected models are given.
aM Z

aDZ

ICCM Z

ICCDZ

1
1
1.25
1.5
1.5
1.65
1.8
1.8

0.65
0.8
0.8
0.9
1.1
1
1.05
1.15

0.324
0.332
0.382
0.441
0.425
0.456
0.500
0.488

0.123
0.153
0.159
0.190
0.221
0.184
0.207
0.245

BIC
σ̂M Z
σ̂DZ
0.859 0.353
0.733 0.360
1.141 0.611
1.226 0.633
1.334 1.028
1.295 0.659
1.687 0.853
1.575 0.976

AIC
σ̂M Z
σ̂DZ
0.351
0
0.416
0
0.669
0
0.895 0.211
0.661 0.491
0.919 0.132
1.212 0.291
1.096 0.594

Table 3.11: Intraclass correlation values for the simulated outcomes for MZ and DZ twins
and the estimated variance components of the BIC- and AIC-selected models when the true
β parameters are all set to equal 1.

aM Z

aDZ

ICCM Z

ICCDZ

1
1
1.25
1.5
1.5
1.65
1.8
1.8

0.65
0.8
0.8
0.9
1.1
1
1.05
1.15

0.324
0.332
0.382
0.441
0.425
0.456
0.500
0.488

0.123
0.153
0.159
0.190
0.221
0.184
0.207
0.245

BIC
[ M Z ICC
[ DZ
ICC
0.183
0.036
0.140
0.038
0.284
0.102
0.313
0.109
0.351
0.243
0.338
0.117
0.464
0.181
0.430
0.225

AIC
[ M Z ICC
[ DZ
ICC
0.036
0
0.050
0
0.120
0
0.196
0.013
0.117
0.068
0.204
0.005
0.309
0.025
0.267
0.097

Table 3.12: Estimated intra-class correlations for MZ and DZ twins and the estimated variance components of the BIC- and AIC-selected models when the true β parameters are all
set to equal 1.
[ terms indicate the model-estimated ICC values. For each model, the estimated
The ICC
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ICCs are given as:

[MZ =
ICC

2
2
σ̂M
σ̂M
Z
Z
[ DZ =
and
ICC
,
2
2
2 /3
σ̂M
σ̂
+
π
+
π 2 /3
Z
MZ

(3.67)

for MZ and DZ twins, respectively. From the results in Table 3.12, it’s clear that the BICselected model performs better in terms of more accurately estimating the ICCs in MZ and
DZ twins. Although the estimates are below the true values in every case, they better
approximate the true values than the AIC-selected model estimates.
In this Chapter, we proposed a novel model formulation that met the requirements for
the data applications: penalization for the high-dimensional nature of the data and inclusion
of a no-penalty subset of covariates in an ordinal response mixed-model that allowed userspecified covariance structures. This original proposed model did not perform optimally in
simulation studies; although variable selection was moderately effective in some cases, the
model was unable to properly parse out the additive genetic, common environmental, and
unique environmental portions of the variance in the random effect and in most cases, did
not predict with much greater than 50% accuracy. An alternate model was also proposed
and this model included all the features of the original model, with the exception of the
flexibility to specify partitioning of the covariance structure between twins. This model
performed better in simulation studies than the original model. Although it had similar
difficulty regarding prediction and BIC-selected models did not correctly identify as many
true predictors, it was more effective for approximating the covariance between twins.
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Chapter 4
Data Application
4.1

Final Analysis Set

As described in Chapter 1, much of the methodological research conducted in this dissertation, specifically the model formulations described in Chapter 3, were motivated by the
Pathways to Cannabis Use and Abuse study described in Section 1.2. This chapter applies
the proposed methods to this study data. A total of 986 subjects were included in the final
analysis set. The distribution of participant sex and zygosity is described in Table 4.1

Female
Male
Total

MZ
218 (59.89%)
146 (40.11%)
364

DZ (same sex)
214 (59.78%)
144 (40.22%)
358

DZ (opposite sex)
132 (50%)
132 (50%)
264

Total
564 (57.20%)
422 (42.80%)
986

Table 4.1: Participants in the final application analysis set sex by zygosity
The imputed dosage data for these subjects included a total of 8,809,012 typed and
imputed loci, generated via the Illumina 610K SNP array, as described in Section 1.2.4.
Although the proposed methods developed here are designed to handle overparameterized
problems, the dimensions of these SNP data are still too large for the model to accomodate.
We therefore implemented variance filtering, similar to the filtering described in Section
3.5.1, in order to trim down the number of predictors. To filter the data, we used the
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nearZeroVar() function from the R package caret 51 . This function assesses variance according to two metrics, a frequency ratio and a distinct value percentage. The frequency
ratio (freqRatio value) is the ratio of the most common value to the second most common value; the smaller this ratio, the greater the variance. The distinct value percentage
(percentUnique value) is the percentage of unique values out of the total number of values; the higher this percentage, the greater the variance. Each of these is calculated for
each SNP on the chromosome. We then filtered out (i.e. removed) those SNPs with both a
freqRatio value at or above the 5th percentile and a percentUnique value at or below the
95th percentile. In this way, the least informative SNPs, those with small variance across all
samples, may be removed. Although this level of filtering seems restrictive, it was necessary
in order to trim larger chromosomes down to a manageable size. Table 4.2 describes the
total number of loci for each chromosome before filtering and the number remaining after
the filtering procedure was implemented. The R code for filtering the SNP data is given in
Appendix A.5 (for chromosomes 9-22) and Appendix A.6 (for chromosomes 1-8).
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Chromosome
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Pre-filtering
SNP count
679,987
740,798
625,883
642,278
571,858
580,647
515,626
492,689
379,567
448,105
437,189
424,387
325,756
290,063
252,138
276,413
232,797
253,621
196,511
199,361
122,176
121,162
8,809,012

Post-Filtering
SNP count
4,519
5,610
3,790
4,542
3,566
3,856
3,949
2,983
2,766
2,855
2,996
2,913
1,858
2,556
1,715
3,756
3,174
1,864
1,354
1,252
942
2,296

Table 4.2: Number of typed and imputed SNPs in each chromosome in the original, unfiltered
dataset and in the variance filtered dataset.
Before applying the proposed models to the application data, we determine which variables should be included in the no-penalty subset. As mentioned in Section 3.1.3, cannabis
use is often correlated with use of other substances such as nicotine and alcohol. Furthermore, these may share some genetic liability 106 . We therefore chose to include the stem
items for nicotine and alcohol in the no-penalty subject. The three stem items for the final
subject of subjects for the application analysis are summarized in Chapter 1, Table 1.7 and
repeated here, in Table 4.3
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Tobacco

Alcohol

Cannabis

0
1
2
0
1
2
0
1
2

Total

Female
258 (45.74%)
196 (34.75%)
110 (19.50%)
13 (2.30%)
247 (43.79%)
304 (53.90%)
302 (53.55%)
152 (26.95%)
110 (19.50%)
564

Male
147 (34.83%)
150 (35.55%)
125 (29.62%)
4 (0.95%)
118 (27.96%)
300 (71.09%)
167 (39.57%)
80 (18.96%)
175 (41.47%)
422

Total
405 (41.08%)
346 (35.09%)
235 (23.83%)
17 (1.72%)
365 (37.02%)
604 (61.26%)
469 (47.57%)
232 (23.53%)
285 (28.90%)
986

Table 4.3: Number of subjects in the final application analysis set reporting level of tobacco,
alcohol, and cannabis use by sex.
Because the “did not use” (0) category in the alcohol stem item contained so few subjects,
we chose to dichotomize this variable and combine ordinal levels of alcohol use into 0:“used
none to moderately”(original ordinal levels 0-1) and 1:“used frequently”(original ordinal level
2). The intracluster correlation between the ordinal level of cannabis use was estimated for
both twin types using the ICCest() function from the ICC R package 133,134 . The formula for
the ICCs are given as:

ICCM Z =

2
2
σDZ
σM
Z
,
and
ICC
=
,
DZ
2
2
2
σM
σDZ
+ π 2 /3
Z + π /3

(4.1)

for either MZ or DZ twins. The estimated ICCs were 0.667 for MZ twins and 0.304 for DZ
twins.
We used the modified alcohol stem item and the nicotine stem items to model the cannabis
stem item with a random intercept ordinal response model. We fit this model using the
clmm() function from the R package ordinal 33 . Although this function does not allow
separate random intercepts to be fit for MZ and DZ twins, it will model the data adequately
enough to obtain an idea of the significance of the association between cannabis and the
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other stem items. The following model is fit using the ordinal package:


logit γ ic = αc − walc1i β1 − wnic1i β2 − wnic2i β3 + ui , where

(4.2)

γ ic is an ni × 1 vector of the ni probabilities that each of the j responses in the ith
cluster will fall at or below the cth ordinal level of cannabis use,
αc are the intercepts,
walc1i β1 represents the binary alcohol use item and its associated coefficient,
wnic1i β2 represents an indicator for ordinal level 1 of nicotine use such that wnic1ij is
1 when nicotine use for the j th member of the ith cluster falls into ordinal category 1,
and 0 otherwise, and β2 is its associated coefficient. Likewise, wnic2i is an indicator
taking the value of 1 if nicotine use falls in the second category, and 0 otherwise, and
β3 is its associated coefficient,
and ui is the random intercept for cluster i.
The fitted model parameters are given in Table 4.4.
Parameter
α0|1
α1|2
β1
β2
β3

Estimate
0.953
2.869
-1.584
2.379
3.877

Standard Error
0.1885
0.2445
0.1951
2.379
0.3081

P-Value

< 0.0001
< 0.0001
< 0.0001

Table 4.4: Parameter estimates and standard errors for a model fitting ordinal level of cannbis
by alcohol and nicotine use.
The variance of the random intercept was estimated at 1.296. From the p-values shown in
Table 4.4, it’s clear that both alcohol use and cannabis use are associated with ordinal level
of cannabis use and we use these results to justify including them in the no-penalty subset
when modeling the application data with the proposed models. Not only are alcohol and
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nicotine of interest when investigating cannabis use, we also see that they are statistically
associated in our present data. It is important to note that the model formulation stipulated
by the ordinal package subtracts the fixed effects from the intercept term. Our proposed
models add the fixed effects to the intercepts so that the signs are reversed.

4.2
4.2.1

Proposed Model Application
Application, without JEPQ measure

The original proposed model and the alternate proposed model were applied to the filtered
SNP data from the Pathways project. For every model application, model-selected genomic
loci were referenced in the Illumina 610 Quad manifest files (available online, from Illumina)
and any corresponding dbSNP indentifier (“rs-number’]rq) noted. Additionally, the Integrative Genomics Viewer software (version 2.4.10) 117,121 was used to lookup all identified
genomic loci and associated genes were listed, where applicable. As discussed in Section
3.5.1, the best performing formulation of the original model was the BIC-selected AE model
and the best performing formulation of the alternate model was the BIC-selected model.
These are therefore the two models we chose to apply. For each chromosome, ordinal level
of cannabis use was modeled with the dichotomized alcohol stem item and the nicotine stem
items included in the no-penalty subset and the SNPs for that chromosome. The R code
that sets up the application data for the models may be found in Appendices A.12 (for the
original proposed model) and A.13 (for the alternate model). The model parameters from
the original BIC-selected AE model are shown in Table 4.5.
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Chr
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

α0|1
0.771
0.771
0.752
0.755
0.765
0.765
0.772
0.945
0.796
0.764
1.249
0.770
0.792
0.751
0.898
0.829
0.928
0.875
0.806
0.756
0.779
0.955

α1|2
2.341
2.341
2.326
2.324
2.332
2.332
2.343
2.517
2.366
2.335
2.821
2.339
2.358
2.321
2.468
2.399
2.496
2.444
2.376
2.320
2.347
2.523

walc
1.393
1.393
1.393
1.395
1.391
1.391
1.340
1.403
1.391
1.394
1.386
1.394
1.394
1.393
1.395
1.398
1.391
1.400
1.395
1.401
1.393
1.389

wnic1
-1.939
-1.939
-1.947
-1.947
-1.926
-1.926
-1.193
-1.931
-1.937
-1.932
-1.927
-1.932
-1.920
-1.939
-1.926
-1.935
-1.916
-1.919
-1.937
-1.911
-1.922
-1.942

wnic2
-3.205
-3.205
-3.219
-3.214
-3.197
-3.197
-3.197
-3.194
-3.203
-3.204
-3.193
-3.204
-3.191
-3.209
-3.194
-3.203
-3.191
-3.185
-3.205
-3.183
-3.193
-3.210

σ̂a
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014
0.014

σ̂e
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001

Table 4.5: BIC-selected original proposed AE model parameters when the personality measures are excluded.
The non-zero parameters chosen by the original proposed AE model are given in Table
4.6. The starred parameters indicate loci that were selected by both the original and the
alternate proposed model, applied below.
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Chr
1
2

No. predictors
2
2

3

2

4
5
6
7
8
9
10

2
2
2
2
2
2
2

11

2

12
13
14
15
16
17
18
19
20

2
2
2
2
2
2
2
2
2

21

2

22

2

Non-zero predictors
1:152310892 (RefSeq Gene FLG-AS1), 1:28638259
2:84058093*, 2:195942691*
3:123415781* (RefSeq Gene MYLK, rs820336),
3:183015258* (RefSeq Gene MCF2L2)
4:4029928, 4:9740325
5:130689713 (RefSeq Gene CDC42SE2), 5:158614607
6:30365740*, 6:2473593
7:72914811 (RefSeq Gene BAZ1B), 7:152415427*
8:47716446, 8:137485507* (rs4909596)
9:38488974*, 9:71344802 (RefSeq Gene PIP5K1B)
10:65796140, 10:98539578
11:199673* (RefSeq Gene ODF3), 11:2415964* (RefSeq Gene CD81),
11:117489521 (RefSeq Gene CD81)
12:10940426, 12:12716764*
13:54698204, 13:22562993 (rs3129601)
14:57027631, 14:103656062*
15:98819843*, 15:48696730
16:212328*, 16:81209920
17:81069185*, 17:29115379
18:77549734*, 18:11109512
19:41339896*, 19:45523459 (RefSeq Gene RELB)
20:56193258 (RefSeq Gene ZBP1), 20:19884764 (RefSeq Gene RIN2)
21:17707722 (RefSeq Gene MIR99AHG),
21:18001708 (RefSeq Gene MIR99AHG)
22:20722220*, 22:23029263

Table 4.6: Non-zero parameters in each BIC-selected original proposed AE model when the
personality measures are excluded.
The alternate proposed model was also applied to the application data. As before, for
each chromosome, ordinal level of cannabis use was modeled with the dichotomized alcohol
stem item and the nicotine stem items included in the no-penalty subset and the SNPs for
that chromosome. The model parameters from the alternate BIC-selected model are shown
in Table 4.7 and the associated selected loci given in Table 4.8.
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Chr
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

α0|1
1.253
1.022
1.015
0.989
0.994
1.073
1.218
1.037
1.037
0.999
1.121
1.152
0.992
1.104
1.080
1.090
0.989
0.989
1.127
1.028
1.094
1.078

α1|2
3.288
3.048
3.041
3.015
3.023
3.098
3.239
3.059
3.062
3.025
3.143
3.179
3.018
3.130
3.105
3.120
3.015
3.015
3.151
3.053
3.119
3.107

walc
1.641
1.632
1.632
1.633
1.635
1.628
1.657
1.628
1.634
1.634
1.628
1.632
1.633
1.632
1.632
1.636
1.633
1.633
1.628
1.633
1.637
1.632

wnic1
-2.488
-2.474
-2.476
-2.478
-2.478
-2.468
-2.471
-2.468
-2.471
-2.475
-2.471
-2.468
-2.475
-2.475
-2.472
-2.482
-2.478
-2.475
-2.465
-2.474
-2.473
-2.479

wnic2
-4.055
-4.053
-4.054
-4.057
-4.061
-4.045
-4.036
-4.047
-4.045
-4.054
-4.046
-4.053
-4.054
-4.051
-4.051
-4.063
-4.058
-4.054
-4.047
-4.052
-4.055
-4.061

σ̂M Z
1.727
1.737
1.733
1.739
1.752
1.751
1.723
1.735
1.737
1.739
1.731
1.751
1.740
1.746
1.735
1.748
1.739
1.739
1.733
1.736
1.747
1.755

σ̂DZ
1.177
1.165
1.166
1.168
1.169
1.150
1.137
1.150
1.158
1.165
1.150
1.156
1.165
1.154
1.159
1.170
1.168
1.166
1.155
1.160
1.152
1.163

[MZ
ICC
0.476
0.478
0.477
0.479
0.483
0.482
0.474
0.478
0.478
0.479
0.477
0.482
0.479
0.481
0.478
0.482
0.479
0.479
0.477
0.478
0.481
0.484

[ DZ
ICC
0.296
0.292
0.292
0.293
0.293
0.287
0.282
0.287
0.290
0.292
0.287
0.289
0.292
0.288
0.290
0.294
0.293
0.292
0.289
0.290
0.287
0.291

Table 4.7: BIC-selected alternate proposed model parameters when the personality measures
are excluded.
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Chr
1
2

No. predictors
2
2

3

2

4
5
6
7
8
9
10
11
12

2
1
2
2
2
2
1
2
2

13

2

14
15
16
17
18
19
20
21
22

2
2
2
2
1
2
2
2
2

Non-zero predictors
1:88298721, 1:98965621
2:84058093*, 2:195942691*
3:123415781* (RefSeq Gene MYLK, rs820336),
3:183015258* (RefSeq Gene MCF2L2)
4:84288014, 4:169991977
5:123768154 (RefSeq Gene LINC01170)
6:30365740*, 6:9020700
7:152415427*, 7:152420044
8:137485507* (rs4909596), 8:16729585
9:38488974*, 9:9903078 (RefSeq Gene PTPRD)
10:122746804 (rs10886827)
11:199673 (RefSeq Gene ODF3), 11:2415964 (RefSeq Gene CD81)
12:51769773 (RefSeq Gene GALNT6), 12:12716764
13:112636548 (RefSeq Gene LINC00403),
13:113744139 (RefSeq Gene MCF2L)
14:103656062*, 14:44545808
15:23039087, 15:98819843*
16:212328*, 16:5889790
17:80594 (RefSeq Gene RPH3AL), 17:81069185*
18:77549734*
19:41339896*, 19:20915452
20:17837939, 20:22116226
21:21426525, 21:35226135 (RefSeq Gene ITSN1, rs2249221)
22:47648670, 22:20722220*

Table 4.8: Non-zero parameters in each BIC-selected alternate proposed model when the
personality measures are excluded.
Of interest, the rs820336 variant within the MYLK gene on chromosome 3 has been previously associated with lung disease and asthma 63 . On chromosome 5, the BAZ1B gene was
identified as associated with some of the neurological symptoms in patients with Williams
Beuren syndrome 53 . The PTPRD gene on chromosome 9 has been associated with social conformity behavior 31 . Differential methylation of a CpG site within the MCF2L gene
on chromosome 13 was found to be associated with borderline personality disorder among
childhood mistreatment survivors 112 . Additionally, a rare deletion of a portion of a ring chromosome 13 including the MCF2L gene was discovered in one case of a child with autism 30 .
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4.2.2

Application, with JEPQ measures

It was of interest to include the JEPQ personality measures in the penalized set to determine
if these features were related to ordinal level of cannabis use. Both the original (BIC-selected
AE) and alternate (BIC-selected) models were applied in the same manner as described in
Section 4.2.1. Table 4.9 gives the model parameters for the original proposed BIC-selected
AE model when the JEPQ measures are included with the SNPs in the penalized set. For
this application, the models running on chromosomes 2, 7, 10, 12, 16-17, and 19-22 failed
to converge. Although a precise reason for failed convergence could not be determined, the
optimization procedure was unable to find a solution for the no-penalty subset and variance
parameters after several updates had been made to one or more of the β values for a variable
in the penalized set.
Chr
1
3
4
5
6
8
9
11
12
14
15
18

α0|1
1.968
2.201
2.167
1.968
1.874
1.968
1.874
1.874
2.003
1.968
1.874
2.003

α1|2
3.568
3.824
3.767
3.568
3.470
3.568
3.470
3.470
3.599
3.568
3.470
3.599

walc
1.302
1.270
1.283
1.302
1.316
1.302
1.316
1.316
1.302
1.302
1.316
1.302

wnic1
−1.881
-1.848
-1.868
-1.881
-1.859
-1.881
-1.859
-1.859
-1.859
-1.881
-1.859
-1.859

wnic2
−3.131
-3.068
-3.109
-3.101
-3.102
-3.131
-3.102
-3.102
-3.098
-3.131
-3.102
-3.098

σ̂a
0.015
0.013
0.013
0.013
0.013
0.013
0.013
0.013
0.013
0.013
0.013
0.013

σ̂e
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001

Table 4.9: BIC-selected AE original proposed model parameters.
Table 4.10 lists the non-zero predictors selected by the BIC-selected original proposed
AE model for each chromosome. The covariates listed in Table 4.10 are those selected by
the models shown in Table 4.9. The abbreviations “psy” and “ext” refer to the JEPQ
psychoticism and extroversion scores, respectively. The starred variables indicate loci that
were selected by both the original proposed model and the alternate proposed model (results
shown in Tables 4.11 and 4.12.) The loci indicated by “†” designate positions indicated in
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both the penalized proposed model and the single locus tests (See Section 4.3).
Chr
1

No. predictors
2

3

4

4
5
6
8
9
11
12
14
15
18

2
2
2
2
2
2
2
2
2
2

Non-zero predictors
psy, ext
psy, ext, 3 : 142842195† ∗ (RefSeq Gene CHST2, rs4149496),
3:8652993 (rs2324665)
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext
psy, ext

Table 4.10: Non-zero parameters in each BIC-selected original proposed AE model.
The alternate proposed model was applied to the same data with the JEPQ measures
included in the penalized set. The BIC-selected alternate model parameter estimates are
shown for each chromosome in Table 4.11. Models for chromosomes 1-2, 7-8, 13, 16-17, and
21 failed to convergence in the same manner as the failed models shown in Table 4.9 above.
Chr
3
4
5
6
9
10
11
12
14
15
18
19
20
22

α0|1
2.121
2.279
2.279
2.294
2.309
2.210
2.294
2.288
2.309
2.289
2.284
2.303
2.294
2.309

α1|2
4.137
4.320
4.320
4.335
4.352
4.248
4.335
4.330
4.352
4.330
4.326
4.347
4.335
4.352

walc
1.518
1.555
1.556
1.556
1.556
1.545
1.556
1.556
1.556
1.556
1.557
1.557
1.556
1.556

wnic1
-2.308
-2.379
-2.379
-2.379
-2.380
-2.352
-2.380
-2.379
-2.381
-2.379
-2.380
-2.380
-2.380
-2.381

wnic2
-3.795
-3.911
-3.910
-3.911
-3.912
-3.861
-3.911
-3.910
-3.912
-3.910
-3.911
-3.911
-3.911
-3.912

σ̂M Z
1.599
1.664
1.663
1.664
1.665
1.617
1.664
1.663
1.665
1.663
1.663
1.664
1.664
1.665

σ̂DZ
1.025
1.145
1.146
1.148
1.150
1.121
1.148
1.147
1.150
1.147
1.147
1.150
1.148
1.150

[MZ
ICC
0.437
0.457
0.457
0.457
0.457
0.443
0.457
0.457
0.457
0.457
0.457
0.457
0.457
0.457

[ DZ
ICC
0.242
0.285
0.285
0.286
0.287
0.276
0.286
0.286
0.287
0.286
0.286
0.287
0.286
0.287

Table 4.11: BIC-selected alternate proposed model parameters.
Table 4.12 lists the non-zero predictors selected by the BIC-selected alternate model for
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each chromosome. The covariates listed in Table 4.12 are those selected by the models
shown in Table 4.11. The abbreviations “psy” and “ext” refer to the JEPQ psychoticism
and extroversion scores, respectively.
Chr
3
4
5
6
9
10
11
12
14
15
18
19
20
22

No. predictors
4
3
3
3
3
4
3
3
3
3
3
3
3
3

Non-zero predictors
psy, ext, 3 : 142842195† ∗ (RefSeq Gene CHST2, rs4149496), 3:147615285
psy, ext, 4:124557772
psy, ext, 5:54177511
psy, ext, 6:40641816
psy, ext, 9:98845512
psy, ext, 10:82568684, 10:98529002
psy, ext, 11:38779116
psy, ext, 12:3454736
psy, ext, 14:105636587
psy, ext, 15:24576149
psy, ext, 18:1955951
psy, ext, 19:53076618 (RefSeq Gene ZNF701)
psy, ext, 20:3435427
psy, ext, 22:20246081

Table 4.12: Non-zero parameters in each BIC-selected alternate proposed model.
The model results shown in Tables 4.10 and 4.12 seem to indicate that the JEPQ measures
may be overwhelming the SNP effects. Furthermore, many of the models failed to converge so
further investigation into the association between the JEPQ measures, SNPs, and cannabis
use in this setting is warranted.

4.2.3

Discussion of Proposed Model Results

The true intracluster correlations, as calculated from the cannabis use data for the 986
subjects in the analysis set, were estimated at 0.667 for MZ twins and 0.304 for DZ twins.
As seen in the simulation studies, the original proposed model estimates the random effect
variance components to be nearly zero and the ICCs could therefore not be accurately
measured. Also as seen in the simulation studies, the alternate proposed model estimates the
intracluster correlations consistently, but tends to underestimates these values. Excluding
the JEPQ features, the two model forms selected some, but not all of the same variables
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from each chromosome. When the personality features were included in the penalized set,
the model chose extroversion and psychoticism as the primary features, however not all the
models on every chromosome converged when the problem was framed in this way.

4.3

Single Locus Tests

Because the proposed models did not perform as well as expected during simulation studies,
we chose to apply the single locus association test (SLAT) methodology to the application
dataset. Similar to the model fit in Equation 4.2, the SLATs are fit using the ordinal
package 33 in R as follows:


logit γ ic = αc − walc1i β1 − wnic1i β2 − wnic2i β3 + snpabi β4 + ui , where

(4.3)

all parameters carry the same interpretation as in Equation 4.2, and
snpabi represents the bth SNP from the ath chromosome for subject i and β4 is its
associated coefficient.
The model above was fit once for each SNP on each chromosome. Because these models
were fit many times for each chromosome, it was necessary to correct for multiple testing.
(The exact number of tests performed for each chromosome may be seen in Table 4.2) A
p-value adjustment was made to the resulting p-values from every chromosome using both
the Benjamini and Hochberg 20 (BH) and the Benjamini and Yekuttieli 21 (BY) methods.
These adjustment methods control the false discovery rate (FDR), or the false positive rate,
and control it at a user-specified level. These adjustment methods are similar, although the
BY method is better suited to correlated variables. The FDR was set at 0.01 and Table
4.13 gives the significant hits from each of the chromosomes; only the chromosomes with
significant hits are included in the table.
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Chr
3

16

17

significant loci
BY: BH: 3 : 142842195† (RefSeq Gene CHST2, rs4149496), 3:142844453
BY: 16:268548701, 16:268553561, 16:19944471, 16:19953191, 16:19960751,
16:84376551, 16:843765511
BH: 16:26854329, 16:268543291, 16:268548701, 16:268553561, 16:291188651,
16:1996075 (RefSeq Gene RPL3L), 16:19944471, 16:19953191, 16:19960751,
16:84376551, 16:843765511
BY: 17:252682671, 17:25334803:1
BH: 17:805941 (RefSeq Gene NXN), 17:774678211, 17:252651301, 17:252682671,
17:252769831, 17:25281651:1, 17:25284681:2, 17:252858031, 17:25334803:1

Table 4.13: Significant loci from the single locus association tests performed on each chromosome, as determined by both Benjamini and Hochberg and Benjamini and Yekuttieli FDR
correction methods.
Significant loci appeared only on chromosomes 3, 16, and 17 and 3:142842195 (RefSeq
Gene CHST2, rs4149496) was the only loci indentified by both the penalized methods and
the SLATs.
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Chapter 5
Conclusion
In Chapter 1, we described the Pathways to Cannabis Use, Abuse and Dependence project,
which utilized data from the Bisbane Longitudinal Twin Study in order to investigate the
associations between substance use (particularly, the ordinal level of cannabis use) and SNPs
and personality features. A penalized regression-type model capable of handling the highdimensional data, the ordinal response, and the specific correlation pattern observed between
twins was not available to apply to the data. In Chapter 2, we described a penalized ordinal
regression fitting procedure that included a no-penalty subset, allowing the user to specify
some group of variable which may be coerced into the model. In Chapter 3, this model was
expanded in order to allow for user-specified covariance patterns between MZ and DZ twin
pairs so that different intracluster correlations might be calculated for each type of twin pair.
Finally, in Chapter 4, we applied the proposed models to the Pathways dataset and provide
some interpretation of the findings.

5.1

Model Limitations

The application of the proposed models to the Pathways data revealed some suggestive loci
of interest. None of the suggestive SNPs have previously been implicated in drug or alcohol
use studies. Given exploratory nature of the penalized regression analysis, it will of course
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be necessary to further investigate and verify any findings. Additionally, when SNP effects
are small, as is typically seen for complex traits, sample sizes of tens of thousands or more
are needed in order to detect these effects. With a sample size of less than 1000 subjects in
our application, it is even more important to regard the results as suggestive, but impotant
initial pilot work into the study of genetic variants associated with drug use.

5.2

Future Directions

In its current form, the proposed model is applicable only to a single set of twins from
each family. The original proposed model form, however, was conceived as a general familycluster method. It will be straightforward to extend the model to allow for general kinship
matrices (of any size) to be used to specify the correlation structure within each family.
For application to the Pathways data, the first extension will be to include the sampled
siblings of the twin pairs from the BLTS data. The inclusion of additional family members
in the analysis will allow for more precise calculations of additive genetic and environmental
proportions of the variance.
The original proposed model was designed to model additive genetic, shared environmental, and individual environmental components of the variance with a single random effect.
The purpose of this choice was to keep the model as parsimonious and easily estimable as
possible. As discussed in Section 3.2.2 however, many other implementations of the mixed
model for behavior genetic applications fit a separate random effect for each of the partitions
of the total variance, additive genetic, shared environmental, and individual environmental.
Fitting additional random effects is more complex and requires more computing resources
but may result in better performance. Comparative performance may be evaluated by fitting
the same simulated dataset using our proposed, single random effect model and an extended,
multiple effect model, to see if addition random effects improve fit.
Multiple software programs have been developed which use measured genotypes to es-
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timate the genetic relatedness matrix (GRM) between subjects in a sample. This GRM
may be regarded as a measured kinship matrix. Since the GRMs are calculated based on
the SNPs across the sample, they more accurately reflect the genetic relatedness between
subjects than the theoretical kinship matrix. It would be of interest to apply the proposed
methods using the estimated GRMs for each family cluster, as opposed to the theoretical
double coancestry matrices.
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Appendix A
R Code
A.1

Code for creating the twinlist snp.RData object

The following code creates the object, a list of complete twin pairs appearing in both the drug use and SNP
datasets.
### Makes the "twinlist_snp.RData" object which contains:
# a list of complete twin pairs with drug AND snp data (not personality data)
# Runs on the Beowolf cluster
setwd("/home/ARCHIVE/ngillespie/Release6_1000G_20101123_v3/PLINK_dosage")
# Read the SNP data, skipping the first line
chr<-read.table("1000G_20101123_v3_281K_plinkdosage_QCpass_chr20.dose.gz",
header=FALSE,skip=1)
# Column 1 gives the SNP identifier, so we make these the row names
rownames(chr)<-chr[,1]
# drop the first three columns, after the row names have been assigned
# columns 2-3 list the major and minor alleles for the SNP
chr<-chr[,4:dim(chr)[2]]
# Read the first line only which contains just the patient identifiers
chr.header<-read.table("1000G_20101123_v3_281K_plinkdosage_QCpass_chr20.dose.gz",
header=FALSE,nrows=1)
#To get just the list of patients
chr.header<-chr.header[1,4:dim(chr.header)[2]]
chr.subjects<-chr.header[c(FALSE,TRUE)]
# In chr, the patients are in columns and SNPs are in rows
# Assign the subject list as the column names
colnames(chr)<-chr.subjects
# Load the object that contains the list of the complete twin pairs
# (derived from the drug data)
setwd("/home/gentryae/myR")
load("twinlist.RData")
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# Drop the subjects that don't appear in the SNP set
twinpairs.only <- twinpairs.only[ twinpairs.only$subid %in% colnames(chr), ]
# Then we have to remove singletons again
identifier <- logical()
for (i in 1:dim(twinpairs.only)[1]){
identifier[i]<- sum(twinpairs.only$familyid ==
twinpairs.only$familyid[i]) == 2
}
twinpairs.only.snp <- twinpairs.only[identifier, ]
# Drop the subjects from the SNP set that aren't in the drug set
chr <- chr[ , colnames(chr) %in% twinpairs.only.snp$subid]
### And now, there is a list of complete twin pairs with SNP data
### We can output this list in order to use it in SNP filtering code
save(twinpairs.only.snp, file="twinlist_snp.RData")

A.2

Code for creating the chr21filt.RData object

The following code creates the object, a list of complete twin pairs appearing in both the drug use and SNP
datasets.
# Use the nearZerVar() function to filter chr 21 for the purpose of simulations
# Use the "twinlist_snp.RData" file to load the twinpairs.only.snp object
# that has the list of the complete twin pairs in both the drug and SNP data files
### Runs on the Beowolf cluster
###
setwd("/home/ARCHIVE/ngillespie/Release6_1000G_20101123_v3/PLINK_dosage")
# Read the SNP data, skipping the first line
chr<-read.table("1000G_20101123_v3_281K_plinkdosage_QCpass_chr21.dose.gz",
header=FALSE,skip=1)
# this object has dim 118,606 X 4,541
# Column 1 gives the SNP identifier, so we make these the row names
rownames(chr)<-chr[,1]
# drop the first three columns, after the row names have been assigned
# columns 2-3 list the major and minor alleles for the SNP
chr<-chr[,4:dim(chr)[2]]
# Read the first line only which contains just the patient identifiers
chr.header<-read.table("1000G_20101123_v3_281K_plinkdosage_QCpass_chr21.dose.gz",
header=FALSE,nrows=1)
#To get just the list of patients
chr.header<-chr.header[1,4:dim(chr.header)[2]]
chr.subjects<-chr.header[c(FALSE,TRUE)]
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# In chr, the patients are in columns and SNPs are in rows
# Assign the subject list as the column names
colnames(chr)<-chr.subjects
# Load the subject list
setwd("/home/gentryae/myR")
load("twinlist_snp.RData")
# Subset the SNP data
chr <- chr[ , colnames(chr) %in% twinpairs.only.snp$subid]
# Run the filtering, outputting the metrics matrix
library(caret)
nzvchr21 <- nearZeroVar(t(chr), saveMetrics=TRUE)
save(nzvchr21, file="nzvchr21.Rdata")
# Keep the SNPs with freqRatio values in the bottom 15th percentile
# and percentUnique values in the top 85th percentile
# This will result in keeping approximately 5% of the SNPs on the chromosome
keep <- (nzvchr21$freqRatio < quantile(nzvchr21$freqRatio, 0.15) &
nzvchr21$percentUnique > quantile(nzvchr21$percentUnique, 0.85))
chr21filt <- chr[keep, ]
# Output the filtered SNP set
save(chr21filt, file="chr21filt.RData")

A.3

Code for creating the simulated data for the original model

This particular example sets the σRE = 0.6 and σerror = 0.95, but these may be changed to produce the
data for any of the simulations for the original proposed model.
### Simulation Set-up
#setwd("/Users/taylorgentry/Documents/Amanda")
setwd("/home/gentryae/myR")
#setwd("/Users/AmandaGentry/Documents/Thesis")
# load the filtered chr21 SNP set
load("chr21filt.RData")
# load the object with the twin id's and zygosity info. from the list
load("twinlist_snp.RData")
# number of complete twin pairs for which there is SNP AND drug use data
# we have to use this subset because the zygosity information is contained
# within the drug use dataset the twinpairs.only.snp list has already been
# filtered to return this subset of subjects
no.sim.sub <- dim(twinpairs.only.snp)[1]
no.sim.pair <- no.sim.sub/2
### There are 1092 subjects in this set, we remove 46 random pairs for the
### simple purpose of working with a round number for the simulation
set.seed(1635)
# randomly select 46 family ID's and remove these from the training data
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# We can use those 46 pairs as a test set
# subset the twinpairs.only.snp and the filtered chromosome objects
no.remove <- 46
no.train.sub <- no.sim.sub - (no.remove *2)
no.train.pair <- no.sim.pair - no.remove
keep <- !(twinpairs.only.snp$familyid %in%
sample(unique(twinpairs.only.snp$familyid), no.remove))
test <- !(keep)
twinpairs.only.test <- twinpairs.only.snp[test,]
chr21filt.test <- chr21filt[, colnames(chr21filt) %in%
twinpairs.only.test$subid]
twinpairs.only.snp <- twinpairs.only.snp[keep,]
chr21filt <- chr21filt[, colnames(chr21filt) %in% twinpairs.only.snp$subid]
# can double check that there's no overlap between the test and training sets
# sum(twinpairs.only.snp£subid %in% twinpairs.only.test£subid)
# the original SNP set from chromosome 21 contained 118603 SNPs
no.snps <- dim(chr21filt)[1]
prop.snps <- no.snps/118603
# to see the new distribution of zygosity in the training set
# table(twinpairs.only.snp£zygosity)
# no of MZFF
MZFF.sim <- sum(twinpairs.only.snp$zygosity == 1)/2
MZMM.sim <- sum(twinpairs.only.snp$zygosity == 2)/2
DZFF.sim <- sum(twinpairs.only.snp$zygosity == 3)/2
DZMM.sim <- sum(twinpairs.only.snp$zygosity == 4)/2
DZMF.sim <- (sum(twinpairs.only.snp$zygosity == 5) +
sum(twinpairs.only.snp$zygosity == 6))/2
# Original coding designates zygosity of 1 or 2 as MZ twins
# and zygosity of 3, 4, 5, or 6 as DZ twins
# For convenience, add an abbreviated zygosity column designating 0
# for MZ and 1 for DZ
twinpairs.only.snp$zyg.abr <- ifelse(twinpairs.only.snp$zygosity < 3,
0, 1)
# SNP 4000 has a nice distribution so we will choose it as the primary SNP
# see the distribution of this SNP
#hist(as.numeric(chr21filt[4000,]))
snp.choice<-4000
# Find the correlation between this SNP and every other SNP on the chromosome
cor.choice <- apply(chr21filt, 1, cor, as.numeric(chr21filt[snp.choice,]))
# Randomly select 5 other SNPs with abs(correlation) of between 0.1 and 0.4
set.seed(81092)
cor.with.4000 <- sample(which(abs(cor.choice)>0.1 & abs(cor.choice)<0.4), 5)
no.cor <- length(which(abs(cor.choice)>0.1 & abs(cor.choice)<0.4))
# see the correlations themselves
cor.choice[names(cor.choice) %in% rownames(chr21filt[cor.with.4000,])]
# Put these 6 SNPs in a matrix
selected<-c(rownames(chr21filt[4000,]),names(cor.with.4000))
# Find the correlations between each of these SNPs and every
# other SNP in the set
cor.mat<-matrix(data=NA, ncol=length(selected), nrow=dim(chr21filt[1]))
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for (i in 1:length(selected)){
cor.mat[, i] <- apply(chr21filt, 1, cor,
as.numeric(chr21filt[rownames(chr21filt) == selected[i],]))
}
# assign rownames
rownames(cor.mat) <- rownames(chr21filt)
# Find SNPs highly correlated with the selected SNPs
cor.mat.ind <- abs(cor.mat) > 0.5
# Sum across to find the SNPs with correlation to any of the selected
# SNPs of greater than .5
cor.mat.ind2 <- apply(cor.mat.ind, 1, sum)
# Find the names of these SNPs
remove.snps <- names(which(cor.mat.ind2 >= 1))
# find the list of these correlated SNPs, minus the names of the 6
# "selected" SNPs
remove.snps1 <- !(remove.snps %in% selected)
# Find a subset of the SNPs to be removed, by name
remove.snps <- remove.snps[remove.snps1]
# Find the row numbers of these
remove.snps.rows <- which(rownames(chr21filt) %in% remove.snps)
# Remove these SNPs from the test and training sets
chr21filt <- chr21filt[-remove.snps.rows, ]
chr21filt.test <- chr21filt.test[-remove.snps.rows, ]
# the SNP table has subjects in columns, so we take the transpose
t.chr <- t(chr21filt)
t.chr.test <- t(chr21filt.test)
# reorder the SNP object so that it matches the
# twinpairs.only.snp object
# (the twinpairs.only.snp object is ordered according
# to ascending subject id)
t.chr <- t.chr[order(as.numeric(rownames(t.chr))), ]
t.chr.test <- t.chr.test[order(as.numeric(rownames(t.chr.test))), ]
# check that the twinpairs.only.snp object and the t.chr object
# are ordered the same
# all.equal(rownames(t.chr), as.character(twinpairs.only.snp£subid))
# all.equal(rownames(t.chr.test), as.character(twinpairs.only.test£subid))
# define the X matrix with the selected SNPs
no.final.snps <- dim(t.chr)[2]
no.false.pred <- dim(t.chr)[2] -6
X <- t.chr[, colnames(t.chr)%in%selected]
X.test <- t.chr.test[, colnames(t.chr.test)%in%selected]
# check that the ordering of X matches the twinpairs.only.snp ordering
# all.equal(rownames(X), as.character(twinpairs.only.snp£subid))
# all.equal(rownames(X.test), as.character(twinpairs.only.test£subid))
# Set the beta values
snp.betas <- rep(1,6)
# Generate the random intercept
u1mean <- 0
u1sd <- 0.6
set.seed(6981)
#u1 <- rnorm(500, u1mean, u1sd)
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u1<- rlogis(500, u1mean, u1sd)
set.seed(6339)
#u1.test <- rnorm(46, u1mean, u1sd)
u1.test <- rlogis(46, u1mean, u1sd)
# append u to itself and add a temporary index from 1-500
u <- cbind(rep(1:500, 2), c(u1,u1))
u.test <- cbind(rep(1:46, 2), c(u1.test,u1.test))
# then order u according to the index and remove the index
# this is just the dumbest way I could think of to repeat each
# random intercept twice
u <- u[order(u[,1]),2 ]
u.test <- u.test[order(u.test[,1]),2 ]
sim <- cbind(twinpairs.only.snp, u)
sim.test <- cbind(twinpairs.only.test, u.test)
## Generate the random error/perturbations
sigmamean <- 0
sigmasd <- 0.95
set.seed(6480)
sigma = rlogis(dim(sim)[1], location = sigmamean, scale = sigmasd)
set.seed(6340)
sigma.test = rlogis(dim(sim.test)[1], location = sigmamean, scale = sigmasd)
z <- as.matrix(X) %*% snp.betas +
as.matrix(sim$u) +sigma
z.test <- as.matrix(X.test) %*% snp.betas +
as.matrix(sim.test$u.test) +sigma.test
y <- z
y[z < quantile(z,0.33)] <- 3
y[z >= quantile(z,0.33) & z < quantile(z,0.66)] <- 2
y[z >= quantile(z,0.66)] <- 1
ord.lev <- y
y.test <- z.test
y.test[z.test < quantile(z.test,0.33)] <- 3
y.test[z.test >= quantile(z.test,0.33) & z.test < quantile(z.test,0.66)] <- 2
y.test[z.test >= quantile(z.test,0.66)] <- 1
ord.lev.test <- y.test
############################################################DATA##
sim.training <- sim
ord.lev.training <- ord.lev
X.training <- X
t.chr.training <- t.chr
sim.test <- sim.test
ord.lev.test <- ord.lev.test
X.test <- X.test
t.chr.test <- t.chr.test
############################################################DATA##
# list the subjects individually
family.id <- as.numeric(sim.training$familyid)
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# list the families (clusters)
family.list <- as.numeric(unique(sim.training$familyid))
family.size <- numeric(length=length(family.list))
for (i in 1:length(family.list)){
family.size[i] <- sum(family.id == family.list[i])
}
zygosity <- sim.training$zygosity
response <- ord.lev.training
### Define the penalized and unpenalized covariates
# Unpenalized
#w.mat <- as.matrix(sim£age)
#rownames(w.mat) <- sim£sim.subid
#colnames(w.mat) <- "age"
#Penalized
x.mat <- as.matrix(t.chr.training)
rownames(x.mat) <- sim.training$subid
colnames(x.mat) <- colnames(t.chr.training)
##################################################################
### Initialize the important stuff ###
epsilon <- 0.001
ordinal.level <- as.numeric(levels(as.factor(response)))
num.cat <- nlevels(as.factor(response))
# LATER - add an error message so that the function will not proceed
# if num.cat < 3
levels.response <- sort(unique(response))
# set the starting alpha and theta values
alpha <- vector(length=(num.cat-1), mode="numeric")
# set the alphas using the empirical values
for (ii in 1:(num.cat-1)){
alpha[ii] <- sum(response == levels.response[ii]) / length(response)
}
alpha <- log(cumsum(alpha)/(1 - cumsum(alpha)))[1:(num.cat - 1)]
#Theta <- rep(0, dim(w.mat)[2])
library(ordinal)
ord.model <- clm(as.factor(response) ~ 1, start=alpha)
alpha <- ord.model$alpha
#Theta <- ord.model£beta
# set the starting value for sigma.a and sigma.c, the variance of
# the random effect
sigma.a <- 1
sigma.c <- 1
sigma.e <- 0.5
# set starting beta values
beta <- rep(0, dim(x.mat)[2])
### Zygosity is defined: 1=MZFF, 2=MZMM, 3=DZFF, 4=DZMM, 5-6=DZFM
add.gens <- list()
com.env <- list()
uni.env <- list()
for (i in 1:length(family.list)) {
com.env[[i]] <- matrix(1, nrow=family.size[i], ncol=family.size[i])
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uni.env[[i]] <- diag(1, nrow=family.size[i], ncol=family.size[i])
add.gens[[i]] <- diag(1, nrow=family.size[i], ncol=family.size[i])
zyg <- zygosity[family.id == family.list[i]]
no.DZ.twins1 <- sum(zyg == 1)
no.DZ.twins2 <- sum(zyg == 2)
if (no.DZ.twins1 == 2){
add.gens[[i]][which(zyg==1)[1], which(zyg==1)[2]] <- 1
add.gens[[i]][which(zyg==1)[2], which(zyg==1)[1]] <- 1
} else {
add.gens[[i]]<- add.gens[[i]]
}
if (no.DZ.twins2 == 2){
add.gens[[i]][which(zyg==2)[1], which(zyg==2)[2]] <- 1
add.gens[[i]][which(zyg==2)[2], which(zyg==2)[1]] <- 1
} else {
add.gens[[i]]<- add.gens[[i]]
}
add.gens[[i]][add.gens[[i]]==0] <- 0.5
}
levels <- sort(unique(response))
k <- length(unique(response))
# build the response matrix
Ymat <- matrix(0, nrow = length(response), ncol = k)
for (i in levels) {
Ymat[which(response == i), which(levels == i)] <- 1
}
z <- matrix(0, nrow = length(response), ncol = length(family.list))
for (i in (1:length(family.id))) {
for (j in (1:length(family.list))){
z[i,j] <- ifelse(family.id[i] == family.list[j], 1, 0)
}
}
n.GHQ.points <- 7

A.4

Code for creating the simulated data for the alternate model

This particular example sets the aM Z = 1.5 and aDZ = 1.1, but these may be changed to produce the data
for any of the simulations for the alternate proposed model.
### Simulation Set-up
#setwd("/Users/taylorgentry/Documents/Amanda")
setwd("/home/gentryae/myR")
#setwd("/Users/AmandaGentry/Documents/Thesis")
# load the filtered chr21 SNP set
load("chr21filt.RData")
# load the object with the twin id's and zygosity info. from the list
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load("twinlist_snp.RData")
delta <- matrix(c(1.5, 1.1), nrow=2)
snp.betas <- rep(1,6)
# number of complete twin pairs for which there is SNP AND drug use data
# we have to use this subset because the zygosity information is contained
# within the drug use dataset
# the twinpairs.only.snp list has already been filtered to return this
#subset of subjects
no.sim.sub <- dim(twinpairs.only.snp)[1]
no.sim.pair <- no.sim.sub/2
### There are 1092 subjects in this set, we remove 46 random pairs for the
# simple purpose of working with a round number for the simulation
set.seed(1635)
# randomly select 46 family ID's and remove these from the training data
# We can use those 46 pairs as a test set
# subset the twinpairs.only.snp and the filtered chromosome objects
no.remove <- 46
no.train.sub <- no.sim.sub - (no.remove *2)
no.train.pair <- no.sim.pair - no.remove
keep <- !(twinpairs.only.snp$familyid %in% sample(unique(twinpairs.only.snp$familyid),
no.remove))
test <- !(keep)
twinpairs.only.test <- twinpairs.only.snp[test,]
chr21filt.test <- chr21filt[, colnames(chr21filt) %in% twinpairs.only.test$subid]
twinpairs.only.snp <- twinpairs.only.snp[keep,]
chr21filt <- chr21filt[, colnames(chr21filt) %in% twinpairs.only.snp$subid]
# can double check that there's no overlap between the test and training sets
# sum(twinpairs.only.snp£subid %in% twinpairs.only.test£subid)
# Original coding designates zygosity of 1 or 2 as MZ twins
# and zygosity of 3, 4, 5, or 6 as DZ twins
# For convenience, add an abbreviated zygosity column designating 0 for
# MZ and 1 for DZ
twinpairs.only.snp$zyg.abr <- ifelse(twinpairs.only.snp$zygosity < 3,
0, 1)
# SNP 4000 has a nice distribution so we will choose it as the primary SNP
# see the distribution of this SNP
#hist(as.numeric(chr21filt[4000,]))
snp.choice<-4000
# Find the correlation between this SNP and every other SNP on the chromosome
cor.choice <- apply(chr21filt, 1, cor, as.numeric(chr21filt[snp.choice,]))
# Randomly select 5 other SNPs with abs(correlation) of between 0.1 and 0.4
set.seed(81092)
cor.with.4000 <- sample(which(abs(cor.choice)>0.1 & abs(cor.choice)<0.4), 5)
no.cor <- length(which(abs(cor.choice)>0.1 & abs(cor.choice)<0.4))
# see the correlations themselves
cor.choice[names(cor.choice) %in% rownames(chr21filt[cor.with.4000,])]
# Put these 6 SNPs in a matrix
selected<-c(rownames(chr21filt[4000,]),names(cor.with.4000))
# Find the correlations between each of these SNPs and every other SNP in the set
cor.mat<-matrix(data=NA, ncol=length(selected), nrow=dim(chr21filt[1]))
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for (i in 1:length(selected)){
cor.mat[, i] <- apply(chr21filt, 1, cor,
as.numeric(chr21filt[rownames(chr21filt) == selected[i],]))
}
# assign rownames
rownames(cor.mat) <- rownames(chr21filt)
# Find SNPs highly correlated with the selected SNPs
cor.mat.ind <- abs(cor.mat) > 0.5
# Sum across to find the SNPs with correlation to any of the selected SNPs of
# greater than .5
cor.mat.ind2 <- apply(cor.mat.ind, 1, sum)
# Find the names of these SNPs
remove.snps <- names(which(cor.mat.ind2 >= 1))
# find the list of these correlated SNPs, minus the names of the 6 "selected" SNPs
remove.snps1 <- !(remove.snps %in% selected)
# Find a subset of the SNPs to be removed, by name
remove.snps <- remove.snps[remove.snps1]
# Find the row numbers of these
remove.snps.rows <- which(rownames(chr21filt) %in% remove.snps)
# Remove these SNPs from the test and training sets
chr21filt <- chr21filt[-remove.snps.rows, ]
chr21filt.test <- chr21filt.test[-remove.snps.rows, ]
# the SNP table has subjects in columns, so we take the transpose
t.chr <- t(chr21filt)
t.chr.test <- t(chr21filt.test)
# reorder the SNP object so that it matches the twinpairs.only.snp object
# (the twinpairs.only.snp object is ordered according to ascending subject id)
t.chr <- t.chr[order(as.numeric(rownames(t.chr))), ]
t.chr.test <- t.chr.test[order(as.numeric(rownames(t.chr.test))), ]
# check that the twinpairs.only.snp object and the t.chr object are ordered the same
# all.equal(rownames(t.chr), as.character(twinpairs.only.snp£subid))
# all.equal(rownames(t.chr.test), as.character(twinpairs.only.test£subid))
# define the X matrix with the selected SNPs
no.final.snps <- dim(t.chr)[2]
no.false.pred <- dim(t.chr)[2] -6
X <- t.chr[, colnames(t.chr)%in%selected]
X.test <- t.chr.test[, colnames(t.chr.test)%in%selected]
# check that the ordering of X matches the twinpairs.only.snp ordering
# all.equal(rownames(X), as.character(twinpairs.only.snp£subid))
# all.equal(rownames(X.test), as.character(twinpairs.only.test£subid))
# Create a zygosity vector that shows zygosity by INDIVIDUAL
zygosity <- twinpairs.only.snp$zygosity
zygosity.test <- twinpairs.only.test$zygosity
# create the zygosity indicator vector for each individual
zyg.ind2 <- matrix(nrow=length(zygosity), ncol=2)
zyg.ind2.test <- matrix(nrow=length(zygosity.test), ncol=2)
zyg.ind2[,1] <- ifelse(zygosity < 3, 1, 0)
zyg.ind2[,2] <- ifelse(zygosity > 2, 1, 0)
zyg.ind2.test[,1] <- ifelse(zygosity.test < 3, 1, 0)
zyg.ind2.test[,2] <- ifelse(zygosity.test > 2, 1, 0)
# Then create a zygosity vector that lists zygosity by FAMILY
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zygosity.fam <- zygosity[c(TRUE, FALSE)]
zygosity.fam.test <- zygosity.test[c(TRUE, FALSE)]
### Zygosity is defined: 1=MZFF, 2=MZMM, 3=DZFF, 4=DZMM, 5-6=DZFM
# create the zygosity indicator vector for each family
zyg.ind <- matrix(nrow=length(zygosity.fam), ncol=2)
zyg.ind.test <- matrix(nrow=length(zygosity.fam.test), ncol=2)
zyg.ind[,1] <- ifelse(zygosity.fam < 3, 1, 0)
zyg.ind[,2] <- ifelse(zygosity.fam > 2, 1, 0)
zyg.ind.test[,1] <- ifelse(zygosity.fam.test < 3, 1, 0)
zyg.ind.test[,2] <- ifelse(zygosity.fam.test > 2, 1, 0)
# Generate the random intercept
u1mean <- 0
u1sd <- 1
set.seed(6981)
u1 <- rnorm(500, u1mean, u1sd)
#u1<- rlogis(500, u1mean, u1sd)
set.seed(6339)
u1.test <- rnorm(46, u1mean, u1sd)
#u1.test <- rlogis(46, u1mean, u1sd)
# append u to itself and add a temporary index from 1-500
u <- cbind(rep(1:500, 2), c(u1,u1))
u.test <- cbind(rep(1:46, 2), c(u1.test,u1.test))
# then order u according to the index and remove the index
# this is just the dumbest way I could think of to repeat each random intercept twice
u <- u[order(u[,1]),2 ]
u.test <- u.test[order(u.test[,1]),2 ]
sim <- cbind(twinpairs.only.snp, u)
sim.test <- cbind(twinpairs.only.test, u.test)
# Generate the sigma values
## Generate the random error/perturbations
sigmamean <- 0
sigmasd <- 1
set.seed(6480)
sigma = rlogis(dim(sim)[1], location = sigmamean, scale = sigmasd)
set.seed(6340)
sigma.test = rlogis(dim(sim.test)[1], location = sigmamean, scale = sigmasd)
z <- as.matrix(X) %*% snp.betas +
(zyg.ind2 %*% delta) * as.matrix(sim$u) + sigma
z.test <- as.matrix(X.test) %*% snp.betas +
(zyg.ind2.test %*% delta) * as.matrix(sim.test$u.test) +sigma.test
y <- z
y[z < quantile(z,0.33)] <- 3
y[z >= quantile(z,0.33) & z < quantile(z,0.66)] <- 2
y[z >= quantile(z,0.66)] <- 1
ord.lev <- y
y.test <- z.test
y.test[z.test < quantile(z.test,0.33)] <- 3
y.test[z.test >= quantile(z.test,0.33) & z.test < quantile(z.test,0.66)] <- 2
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y.test[z.test >= quantile(z.test,0.66)] <- 1
ord.lev.test <- y.test
############################################################DATA##
sim.training <- sim
ord.lev.training <- ord.lev
X.training <- X
t.chr.training <- t.chr
sim.test <- sim.test
ord.lev.test <- ord.lev.test
X.test <- X.test
t.chr.test <- t.chr.test
############################################################DATA##
# list the subjects individually
family.id <- as.numeric(sim.training$familyid)
# list the families (clusters)
family.list <- as.numeric(unique(sim.training$familyid))
family.size <- numeric(length=length(family.list))
for (i in 1:length(family.list)){
family.size[i] <- sum(family.id == family.list[i])
}
response <- ord.lev.training
x.mat <- as.matrix(t.chr.training)
rownames(x.mat) <- sim.training$subid
colnames(x.mat) <- colnames(t.chr.training)
##################################################################
### Initialize the important stuff ###
epsilon <- 0.001
ordinal.level <- as.numeric(levels(as.factor(response)))
num.cat <- nlevels(as.factor(response))
# LATER - add an error message so that the function will not proceed
# if num.cat < 3
levels.response <- sort(unique(response))
# set the starting alpha and theta values
alpha <- vector(length=(num.cat-1), mode="numeric")
# set the alphas using the empirical values
for (ii in 1:(num.cat-1)){
alpha[ii] <- sum(response == levels.response[ii]) / length(response)
}
alpha <- log(cumsum(alpha)/(1 - cumsum(alpha)))[1:(num.cat - 1)]
#Theta <- rep(0, dim(w.mat)[2])
library(ordinal)
ord.model <- clm(as.factor(response) ~ 1, start=alpha)
alpha <- ord.model$alpha
#Theta <- ord.model£beta
# set the starting value for sigma.mz and sigma.dz, the variance
# of the random effects
sigma <- matrix(c(2,1), nrow=2)
# set starting beta values
beta <- rep(0, dim(x.mat)[2])
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levels <- sort(unique(response))
k <- length(unique(response))
# build the response matrix
Ymat <- matrix(0, nrow = length(response), ncol = k)
for (i in levels) {
Ymat[which(response == i), which(levels == i)] <- 1
}
z <- matrix(0, nrow = length(response), ncol = length(family.list))
for (i in (1:length(family.id))) {
for (j in (1:length(family.list))){
z[i,j] <- ifelse(family.id[i] == family.list[j], 1, 0)
}
}
n.GHQ.points <- 7

A.5

Code for the application SNP data filtering, Chr
9-22

This code runs on the QIMR HPC cluster when the SNP data is stored. This piece of code was used to filter
the chromosome 16 SNP data, but it was modified slightly in order to filter any one of chromosomes 9-22.
The SNP data was stored in blocks on the HPC cluster; SNP data for chromosomes 9-22 were small enough
that they could be read and filtered in a single group. Appendix Section A.6 shows the code used to filter
SNP data for chromosomes 1-8.
# Runs on the QIMR HPC cluster
# Load the list of twins with outcome information
load("/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/twinlist.RData")
# SNP Data Folder
setwd("/mnt/lustre/reference/genepi/GWAS_release/Release8/Release8_HRCr1.1/PLINK_dosage")
# temp <- list.files(pattern="*poly.dose.gz")
temp <- list.files(pattern="^BlockPLINK_chr16[.].*poly.dose.gz$")
# Read the SNP data from the first block, skipping the first line
chr.header <- read.table("BlockPLINK_chr16.1_poly.dose.gz",header=FALSE,nrows=1)
#To get just the list of subjects, remove the first three columns
chr.header<-chr.header[1,4:dim(chr.header)[2]]
#The header line contains two fields for each subject, one field for family ID and the
# second for subject ID, so we remove the family ID field
chr.subjects<-chr.header[c(FALSE,TRUE)]
chr.subjects<-apply(chr.subjects, 2, as.character)
# Subset the list of subjects to include only the twins with this outcome information
# This will create a logical vector that can be used to subset the Block SNP files
subj.keep <- chr.subjects[chr.subjects %in% as.character(twinpairs.only$subid)]
rm(chr.header)
# Create the empty chrm object
chrm <- NULL
# Create the loop to read in each block, subset it, and append it
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for (f in temp){
chr<-read.table(f,header=FALSE,skip=1)
# Column 1 gives the SNP identifier, so we make these the row names
rownames(chr)<-chr[,1]
# drop the first three columns, after the row names have been assigned
# columns 2-3 list the major and minor alleles for the SNP
chr<-chr[,4:dim(chr)[2]]
# In chr, the subjects are in columns and SNPs are in rows
# Assign the subject list as the column names
colnames(chr)<-chr.subjects
# Subset the chromosome object to contain the same subjects
chr.subset <- chr[, colnames(chr) %in% subj.keep]
rm(chr)
chrm <- rbind(chrm, chr.subset)
rm(chr.subset)
}
# load the caret library
library(caret)
# Run the filtering, outputting the metrics matrix
nzvchr16 <- nearZeroVar(t(chrm), saveMetrics=TRUE)
save(nzvchr16, file="/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/nzvchr16.Rdata")
# Keep the SNPs with freqRatio values in the bottom 15th percentile and percentUnique
# values in the top 85th percentile
### This will result in keeping approximately 5% of the SNPs on the chromosome
keep <- (nzvchr16$freqRatio < quantile(nzvchr16$freqRatio, 0.05) &
nzvchr16$percentUnique > quantile(nzvchr16$percentUnique, 0.95))
chr16filt <- chrm[keep, ]
# Output the filtered SNP set
save(chr16filt, file="/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/chr16filt.RData")

A.6

Code for the application SNP data filtering, Chr
1-8

This code runs on the QIMR HPC cluster when the SNP data is stored. This piece of code was used to
filter the chromosome 2 SNP data, but it was modified slightly in order to filter any one of chromosomes 1-8.
The SNP data was stored in blocks on the HPC cluster; SNP data for chromosomes 1-8 were too large to
be filtered in a single group and two scripts were therefore needed in order to filter the data in two batches.
Appendix Section A.5 shows the code used to filter SNP data for chromosomes 9-22.
# Runs on the QIMR HPC cluster
# Load the list of twins with outcome information
# Load the list of twins with outcome information
load("/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/twinlist.RData")
# SNP Data Folder
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setwd("/mnt/lustre/reference/genepi/GWAS_release/Release8/Release8_HRCr1.1/PLINK_dosage")
# temp <- list.files(pattern="*poly.dose.gz")
temp <- list.files(pattern="^BlockPLINK_chr2[.].*poly.dose.gz$")
# chr2 has 68 blocks
temp <- temp[1:34]
# change to temp <- temp[35:68] for the second group
# Read the SNP data from the first block, skipping the first line
chr.header <- read.table("BlockPLINK_chr2.1_poly.dose.gz",header=FALSE,nrows=1)
#To get just the list of subjects, remove the first three columns
chr.header<-chr.header[1,4:dim(chr.header)[2]]
#The header line contains two fields for each subject, one field for family ID and the
# second for subject ID, so we remove the family ID field
chr.subjects<-chr.header[c(FALSE,TRUE)]
chr.subjects<-apply(chr.subjects, 2, as.character)
# Subset the list of subjects to include only the twins with this outcome information
# This will create a logical vector that can be used to subset the Block SNP files
subj.keep <- chr.subjects[chr.subjects %in% as.character(twinpairs.only$subid)]
rm(chr.header)
# Create the empty chrm object
chrm <- NULL
# Create the loop to read in each block, subset it, and append it
for (f in temp){
chr<-read.table(f,header=FALSE,skip=1)
# Column 1 gives the SNP identifier, so we make these the row names
rownames(chr)<-chr[,1]
# drop the first three columns, after the row names have been assigned
# columns 2-3 list the major and minor alleles for the SNP
chr<-chr[,4:dim(chr)[2]]
# In chr, the subjects are in columns and SNPs are in rows
# Assign the subject list as the column names
colnames(chr)<-chr.subjects
# Subset the chromosome object to contain the same subjects
chr.subset <- chr[, colnames(chr) %in% subj.keep]
rm(chr)
chrm <- rbind(chrm, chr.subset)
rm(chr.subset)
}
# load the caret library
library(caret)
# Run the filtering, outputting the metrics matrix
nzvchr2 <- nearZeroVar(t(chrm), saveMetrics=TRUE)
save(nzvchr2, file="/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/nzvchr2p1.Rdata")
# Keep the SNPs with freqRatio values in the bottom 15th percentile and percentUnique
# values in the top 85th percentile
### This will result in keeping approximately 5% of the SNPs on the chromosome
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keep <- (nzvchr2$freqRatio < quantile(nzvchr2$freqRatio, 0.05) &
nzvchr2$percentUnique > quantile(nzvchr2$percentUnique, 0.95))
chr2filt <- chrm[keep, ]
# Output the filtered SNP set
save(chr2filt,
file="/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/chr2filtp1.RData")
# If the second group, save as:
#save(chr2filt,
#
file="/mnt/lustre/working/lab_nickm/nathanG/AmandaThesis/chr2filtp2.RData")

A.7

Code to create the final set.RData object

# Runs locally
library(memisc)
# load the drug data from the .sav file
drug <- as.data.set(spss.system.file(
"/Users/AmandaGentry/Documents/Brisbane/NU321_8_16_16.sav"))
# save the data as a dataframe
drug <- as.data.frame(drug)
### Create a unique id field for each subject
# make a vector of possible twinid values, use up to 60 just to be safe
allowed.twinid <- c("01", "02", as.character(seq(from=50, to=60)))
# keep only the entries for which there is a valid twinid
drug <- drug[drug$twinid %in% allowed.twinid,]
# to get rid of any empty (invalid) factor levels, reapply the factor() function
drug$twinid <- factor(drug$twinid)
### For now, consider only twins
drug <- drug[drug$twinid %in% c("01","02"), ]
# and then get rid of the empty levels of twinid
drug$twinid <- factor(drug$twinid)
# Remove the subjects without any stem item
drug <- drug[ !is.na(drug$stem_ca), ]
drug <- drug[ !is.na(drug$stem_alc), ]
drug <- drug[ !is.na(drug$stem_nic), ]
# combine the familyid and twinid fields for a unique subject id
# these ID's are what already exist in the SNP data files
drug$subid <- as.numeric(paste(drug$familyid, drug$twinid, sep=""))
# To filter out singletons, we can just count the number of times each familyid appears,
# since sibs have already been removed
identifier <- logical()
for (i in 1:dim(drug)[1]){
identifier[i]<- sum(drug$familyid == drug$familyid[i]) == 2
}
# Then use the identifier field to remove the singletons
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drug <- drug[identifier, ]
dim(drug)
# load the personality data from the .sav file
jepq <- as.data.set(spss.system.file(
"/Users/AmandaGentry/Documents/Brisbane/JEPQ_170215_unlocked.sav"))
jepq <- as.data.frame(jepq)
# keep only the first visit data for now
jepq_v1<-jepq[jepq$visit==1,]
# Organize the JEPQ data
# 1=YES 2=NO
converter <- function(x){
x<-ifelse(x==1, 1, ifelse(x==9, NA, 0))
return(x)
}
#library(DescTools)
# psychoticism
psy <- c(3,7,12,15,19,23,30,32,35,39,42,46,50,54,57,63,72)
psy <- psy+2
jepq_v1[, psy] <- apply(jepq_v1[,psy], 2, converter)
sum.na.psy <- apply(is.na(jepq_v1[, psy]), 1, sum)
prop.na.psy <- sum.na.psy/length(psy)
max.na.psy <- max(prop.na.psy)
jepq_v1$psy.med <- round(apply(jepq_v1[, psy], 1, median, na.rm=TRUE))
for (i in 1:dim(jepq_v1)[1]){
jepq_v1[i, psy][is.na(jepq_v1[i, psy])] <- jepq_v1$psy.med[i]
}
jepq_v1$psy.score <- apply(jepq_v1[,psy], 1, sum)
# extroversion
ext <- c(1,5,9,13,17,21,25,28,33,37,41,44,48,52,56,58,61,65,67,70,74,76,79,81)
ext <- ext+2
jepq_v1[, ext] <- apply(jepq_v1[,ext], 2, converter)
sum.na.ext <- apply(is.na(jepq_v1[, ext]), 1, sum)
prop.na.ext <- sum.na.ext/length(ext)
max.na.ext <- max(prop.na.ext)
jepq_v1$ext.med <- round(apply(jepq_v1[, ext], 1, median, na.rm=TRUE))
for (i in 1:dim(jepq_v1)[1]){
jepq_v1[i, ext][is.na(jepq_v1[i, ext])] <- jepq_v1$ext.med[i]
}
jepq_v1$ext.score <- apply(jepq_v1[,ext], 1, sum)
# neuroticism
neu <- c(2,6,10,14,18,22,26,29,34,38,45,49,53,59,62,66,68,71,77,80)
neu <- neu+2
jepq_v1[, neu] <- apply(jepq_v1[,neu], 2, converter)
sum.na.neu <- apply(is.na(jepq_v1[, neu]), 1, sum)
prop.na.neu <- sum.na.neu/length(neu)
max.na.neu <- max(prop.na.neu)
jepq_v1$neu.med <- round(apply(jepq_v1[, neu], 1, median, na.rm=TRUE))
for (i in 1:dim(jepq_v1)[1]){
jepq_v1[i, neu][is.na(jepq_v1[i, neu])] <- jepq_v1$neu.med[i]
}
jepq_v1$neu.score <- apply(jepq_v1[,neu], 1, sum, na.rm=TRUE)
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# lie
lie <- c(4,8,11,16,20,24,27,31,36,40,43,47,51,55,60,64,69,73,75,78)
lie <- lie+2
jepq_v1[, lie] <- apply(jepq_v1[,lie], 2, converter)
sum.na.lie <- apply(is.na(jepq_v1[, lie]), 1, sum)
prop.na.lie <- sum.na.lie/length(lie)
max.na.lie <- max(prop.na.lie)
jepq_v1$lie.med <- round(apply(jepq_v1[, lie], 1, median, na.rm=TRUE))
for (i in 1:dim(jepq_v1)[1]){
jepq_v1[i, lie][is.na(jepq_v1[i, lie])] <- jepq_v1$lie.med[i]
}
jepq_v1$lie.score <- apply(jepq_v1[,lie], 1, sum, na.rm=TRUE)
### Merge the drug and personality datasets keeping only the subjects in both
jepq_v1$subid <- jepq_v1$id
drug.jepq <- merge(drug, jepq_v1, by="subid")
# To filter out singletons, we can just count the number of times each familyid appears,
# since sibs have already been removed
identifier <- logical()
for (i in 1:dim(drug.jepq)[1]){
identifier[i]<- sum(drug.jepq$familyid == drug.jepq$familyid[i]) == 2
}
#check
sum(identifier) == dim(drug.jepq)[1]
load("/Users/AmandaGentry/Documents/Thesis/HPCdata/chr22filt.RData")
keep.dj <- as.character(drug.jepq$subid) %in% colnames(chr22filt)
drug.jepq <- drug.jepq[keep.dj, ]
identifier <- logical()
for (i in 1:dim(drug.jepq)[1]){
identifier[i]<- sum(drug.jepq$familyid == drug.jepq$familyid[i]) == 2
}
drug.jepq <- drug.jepq[identifier, ]
save(drug.jepq, file="final_set.RData")

A.8

Code to run the original proposed ACE model

This code fits the ACE original proposed model, without a no-penalty subset, a was applied only to simulated
data.
###########################################
### Function to find g(t) for each family i
### this representation of the g(t) function returns a scalar
### This technically finds the -log(g(t))
g.t <- function(u1, alpha, x.mat, beta, Ymat, add.gens, com.env,
uni.env, sigma.a, sigma.c, sigma.e, j){
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bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- x.mat %*% beta + u1
bb[,1]<- exp(alpha[1] + aa)/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <(exp(alpha[2:(length(alpha))] + aa)/
(1 + exp(alpha[2:(length(alpha))] + aa)) exp(alpha[1:(length(alpha)-1)] + aa)/
(1 + exp(alpha[1:(length(alpha)-1)] + aa)))
bb[,(length(alpha)+1)] <(1 - exp(alpha[length(alpha)] + aa)/(1 + exp(alpha[length(alpha)] + aa)))
sigmas <- (sigma.a^2 * add.gens + sigma.c^2 * com.env + sigma.e^2 * uni.env)
as.numeric( as.vector(((u1)^2)/2) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply(Ymat * log(bb), 1, sum)))
}
###########################################
### Function to find derivative(g(t))
### function returning a scalar
d.g.t <- function(u1, alpha, x.mat, beta, Ymat, add.gens, com.env,
uni.env, sigma.a, sigma.c, sigma.e, j){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- x.mat %*% beta + u1
bb[,1]<- 1/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- (
(exp(alpha[2:(length(alpha))] + aa) *
(1 + exp(alpha[1:(length(alpha)-1)] + aa))^2) (exp(alpha[1:(length(alpha)-1)] + aa) *
(1 + exp(alpha[2:(length(alpha))] + aa))^2) ) /
((
exp(alpha[2:(length(alpha))] + aa) exp(alpha[1:(length(alpha)-1)] + aa) ) *
( (1 + exp(alpha[1:(length(alpha)-1)] + aa)) *
(1 + exp(alpha[2:(length(alpha))] + aa))) )
bb[,(length(alpha)+1)] <(-exp(alpha[length(alpha)] + aa)) / (1 + exp(alpha[length(alpha)] + aa))
sigmas <- (sigma.a^2 * add.gens + sigma.c^2 * com.env + sigma.e^2 * uni.env)
as.numeric( as.vector((u1)) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply((bb * Ymat), 1, sum)))
}
###########################################
### Calculate the empirical Bayes estimates of the u1's
library(numDeriv)
library(optimx)
starting.u <- rep(1, length(family.list))
EB.u1 <- vector("numeric", length=length(family.list))
EB.Hessian <- vector("numeric", length=length(family.list))
EB.sigma.hat <- vector("numeric", length=length(family.list))
E.Bayes <- function(family.list, x.mat, Ymat, alpha, beta, sigma.a,
sigma.c, sigma.e, add.gens, com.env, uni.env, starting.u){
optim.output <- vector("list", length=length(family.list))
for (i in 1:length(family.list)){
# new.w.mat <- as.matrix(w.mat[which(z[ ,i] != 0),])
new.x.mat <- x.mat[which(z[ ,i] != 0),]
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new.Ymat <- Ymat[which(z[ ,i] != 0),]
new.add.gens <- add.gens[[i]]
new.com.env <- com.env[[i]]
new.uni.env <- uni.env[[i]]
new.j <- rep(1, length=dim(new.add.gens)[1])
new.starting.u <- starting.u[i]
optim.output[[i]] <- optimx(par=new.starting.u, g.t, gr=d.g.t,
method="BFGS", hessian=TRUE,
alpha=alpha, x.mat=new.x.mat, beta=beta, Ymat=new.Ymat,
sigma.a=sigma.a, sigma.c=sigma.c, sigma.e=sigma.e,
add.gens=new.add.gens, com.env=new.com.env,
uni.env=new.uni.env, j=new.j)
EB.u1[i] <- optim.output[[i]]$p1
EB.Hessian[i] <- as.numeric(attr(optim.output[[i]],"details")[,"nhatend"])
EB.sigma.hat[i] <- 1/EB.Hessian[i]
}
return(list(EB.u1 = EB.u1, EB.Hessian = EB.Hessian,
EB.sigma.hat = EB.sigma.hat))
}
### Get the initial EB u1 values
E.Bayes.out <- E.Bayes(family.list=family.list, x.mat=x.mat,
Ymat=Ymat, alpha=alpha, beta=beta,
sigma.a=sigma.a, sigma.c=sigma.c, sigma.e=sigma.e,
add.gens=add.gens, com.env=com.env, uni.env=uni.env,
starting.u=starting.u)
###########################################
### Calculate the likelihood
library(glmmML)
library(Matrix)
nodes <- ghq(n.points = n.GHQ.points, modified = FALSE)$zeros
weights <- ghq(n.points = n.GHQ.points, modified = FALSE)$weights
LL.fxn <function(par, EB.u1, EB.sigma.hat, n.GHQ.points, nodes,
weights, z, x.mat, beta, family.id, family.list, num.cat,
add.gens, com.env, uni.env){
alpha <- par[1:length(alpha)]
sigma.a <- par[(length(alpha) + 1)]
sigma.c <- par[(length(alpha) + 2)]
sigma.e <- par[(length(alpha) + 3)]
### EB.u1 is a column vector of the empirical Bayes estimates of the u1's.
### EB.u1 is appended to itself to create a matrix with EB.u1 in each column and as
### many columns as n.GHQ.points.
### EB.sigma.hat is a column vector of the standard errors of the empirical Bayes
### estimates. After some manipulation, it's appended to itself n.GHQ.points times
### and then each column is multiple by the corresponding node.
### The resulting a matrix has no. of rows equal to the number of families/clusters
### and no. of columns equal to the number of nodes.
a <- (matrix(EB.u1, nrow=length(EB.u1), ncol=n.GHQ.points, byrow=FALSE) +
as.matrix(sqrt(2 * (EB.sigma.hat)^2)) %*% t(as.matrix(nodes)))
### Each column of aa is w*theta + x*beta + u1 for each node
### The large w-matrix, for all subjects, is multiplied by the theta vector and
### then appended to itself (i.e. repeated) n.GHQ.points times.
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###
###
###
###
###
###
###

The z matrix is multiple by the a matrix (from the above step) in order
to repeat the appropriate rows of a so that it will have a row for each
subject. (See that before this step, a has only one row for each family/cluster
and we need to have each family's rows repeated to correspond to the number of
members in that family.)
The resulting matrix has no. of rows equal to number of subjects and no. of
columns equal to the number of nodes.
aa <matrix((x.mat %*% beta), nrow=dim(x.mat)[1],
ncol=n.GHQ.points, byrow=FALSE) +
z %*% a
### Create a matrix of alpha values
### Consider alpha as a row vector that's appended to itself n.GHQ.points-times.
alpha.mat <- matrix(alpha, nrow=length(family.id), ncol=length(alpha), byrow=TRUE)
### Create the sigma matrices
sigma.mats <- list()
for (i in 1:length(family.list)){
sigma.mats[[i]] <- (sigma.a^2 * add.gens[[i]] +
sigma.c^2 * com.env[[i]] +
sigma.e^2 * uni.env[[i]])
}
### Create a new list of the inverse of the sigma matrices.
i.sigmas <- lapply(sigma.mats, solve)
### Create a large, block-diagonal matrix of the inverse sigma matrices.
big.i.sigmas <- bdiag(i.sigmas)
### bb is Robj2
### For the likelihood calculation, we need the j'Sigma^(-1)j term for each
### family/cluster. Notice that regardless of the length of j and the
### dimensions of K, this will be a scalar. This can be
### accomplished by pre and post-multiplying the large block-diagonal
### inverse-kinships matrix by the z matrix.
bb <- diag(t(z) %*% big.i.sigmas %*% z)
### Create empty matrices for the loop calculation
pi.c <- matrix(nrow=length(family.id), ncol=num.cat)
final.pi.c <- vector("numeric", length=length(family.list))
likelihood.i <- matrix(nrow=length(family.list), ncol=n.GHQ.points)
### The loop calculates the individual pi.c's for each family/cluster,
### for each node.
for (i in 1:n.GHQ.points){
### Build the pi.c matrix, with a row for each subject (j) and a column
# for each level (c)
pi.c[ ,1] <exp(alpha.mat[ ,1] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1] + aa[ ,i]))
pi.c[ , 2:(num.cat-1)] <exp(alpha.mat[ ,2:(num.cat-1)] +
aa[ ,i])/(1 + exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])) exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i]))
pi.c[ , num.cat]
<1 - exp(alpha.mat[ , num.cat-1]
+ aa[ ,i])/(1 + exp(alpha.mat[ , num.cat-1] + aa[ ,i]))
### Apply the exponent y_ijc and then take the product across all levels (c)
a.pi.c <apply(pi.c^ Ymat, 1, prod) * z
### Change the zeros to ones so that the next multiplication step will work
a.pi.c[a.pi.c == 0] <- 1
final.pi.c <- apply(a.pi.c, 2, prod)
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likelihood.i[ ,i] <- weights[i] * exp(nodes[i]^2) *
exp( -a[ ,i]^2 / 2 * bb) * final.pi.c
}
### Sum over the nodes
likelihood.i <- apply(likelihood.i, 1, sum)
likelihood <- -sum(log(sqrt(EB.sigma.hat^2)/
(pi * sqrt(2 * as.numeric(lapply(sigma.mats,det)))) * likelihood.i))
return(likelihood)
}
### Estimate alpha, theta, and the sigmas
# build the constraint matrix that will ensure alpha1 < alpha2 < alpha3 < ...
ui <- matrix(0, nrow=(length(alpha)+2), ncol=(length(alpha) + 3 ))
for (j in 1:(length(alpha) - 1)){
ui[j, j] <- -1
ui[j, j+1] <- 1
}
for (j in (length(alpha)):(length(alpha) + 2)) {
ui[j, (j + 1)] <- 1
}
ci <- c(rep(0, (length(alpha) + 1)), 0.001)
unpen.param <- constrOptim(theta=c(alpha, sigma.a, sigma.c, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci, EB.u1=E.Bayes.out$EB.u1,
EB.sigma.hat=E.Bayes.out$EB.sigma.hat, n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat, add.gens=add.gens, com.env=com.env,
uni.env=uni.env)
alpha <- unpen.param$par[1:length(alpha)]
sigma.a <- unpen.param$par[(length(alpha) + 1)]
sigma.c <- unpen.param$par[(length(alpha) + 2)]
sigma.e <- unpen.param$par[(length(alpha) + 3)]
likelihood.val <- unpen.param$value
diff.LL <- 0
beta.selection <- function(alpha, x.mat, beta, z, EB.u1, Ymat){
# put the alphas into a matrix
alpha.mat <- matrix(alpha, nrow=dim(x.mat)[1],
ncol=length(alpha), byrow=TRUE)
# for convenience, construct the xB + wTHETA + zu portion of the equation
aa <- x.mat %*% beta + z %*% EB.u1
# find the negative partial derivative of the likelihood function
# with respect to the p'th variable of the x-matrix
deriv.beta.p <-t(x.mat) %*% (
Ymat[ ,1]/(1 + exp(alpha[1] + aa)) apply(
Ymat[ ,2:(dim(Ymat)[2] - 1)] *
(exp(alpha.mat[ ,2:dim(alpha.mat)[2]] +
alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)] + 2 * aa) - 1 ) /
((1 + exp(alpha.mat[ ,2:dim(alpha.mat)[2]] + aa)) *
(1 + exp(alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)]))), 1, sum) -
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Ymat[ , dim(Ymat)[2]] * exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa) /
(1 + exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa))
)
# find which variable has the smallest negative gradient and save that
# coefficient value and also the position of that variable
update.beta.value
<- min(deriv.beta.p, na.rm=TRUE)
update.beta.position
<- which.min(deriv.beta.p)
# indicate whether or not a NEW beta is being added to the model
update.beta.position.opp <- ifelse(
update.beta.position > (length(beta)/2),
update.beta.position - (length(beta)/2),
update.beta.position + (length(beta)/2))
new.beta <ifelse( (beta[update.beta.position] == 0 &
beta[update.beta.position.opp] == 0),
1,
0)
# save these in a list to be output by the function
return(list(
update.beta.value = update.beta.value,
update.beta.position = update.beta.position,
new.beta = new.beta))
}
# append the negative of x to itself
orig.x <- x.mat
x.mat <- cbind(x.mat, -1 * x.mat)
# initialize the betas
beta <- rep(0, dim(x.mat)[2])
# initialize step to 0
step <- 0
# set the number of unpenalized parameters
n.unpen <- length(alpha) + 3
# initialize a path matrices
beta.path <- matrix(c(beta,step), ncol=(dim(x.mat)[2] + 1), byrow=TRUE)
param.path <- matrix(c(alpha, sigma.a, sigma.c, sigma.e, n.unpen,
likelihood.val, diff.LL, step), nrow=1, byrow=TRUE)
alpha.names <- paste("alpha", as.character(c(1:length(alpha))), sep="")
colnames(param.path) <- c(alpha.names, "sigma.a", "sigma.c", "sigma.e",
"no. of param", "-log(L)", "diff in -LL", "step")
u1.path <- matrix(E.Bayes.out$EB.u1, nrow=1, byrow=TRUE)
sigma.hat.path <- matrix(E.Bayes.out$EB.sigma.hat, nrow=1, byrow=TRUE)
n.var.total <- n.unpen
### begin iterative portion
repeat{
# define the object updt (don't want to use "update" bc that's a function in R)
# to be the list of the beta value and position of the beta to be updated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta,
z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
if (updt$update.beta.value < 0) {
# Is the beta to be added new?
# If yes, then re-estimate the alpha, Theta, sigma.u, and u's
# Then, update beta
if (updt$new.beta == 1){
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# set the location of the beta that is to be added
# (the "maybe" beta)
maybe.beta <- updt$update.beta.position
# collapse beta back to the original
collapsed.beta <- beta[1:(dim(orig.x)[2])] beta[(dim(orig.x)[2] + 1):length(beta)]
# re-estimate unpenalized parameters alpha, Theta, and sigma.u
# append the new estimates to the matrix of the old estimates
unpen.param <- constrOptim(theta=c(alpha, sigma.a, sigma.c, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat, add.gens=add.gens, com.env=com.env,
uni.env=uni.env)
param.path <- rbind(param.path, c(unpen.param$par, n.var.total,
unpen.param$value,
(param.path[dim(param.path)[1],
(dim(param.path)[2] - 2)] - unpen.param$value),
step))
alpha <- unpen.param$par[1:length(alpha)]
sigma.a <- unpen.param$par[(length(alpha) + 1)]
sigma.c <- unpen.param$par[(length(alpha) + 2)]
sigma.e <- unpen.param$par[(length(alpha) + 3)]
# re-estimate the u1's (random effects)
# append the new estimates to the matrix of old estimates
starting.u <- E.Bayes.out$EB.u1
E.Bayes.out <- E.Bayes(family.list=family.list, x.mat=orig.x,
Ymat=Ymat, add.gens=add.gens, com.env=com.env,
uni.env=uni.env, alpha=alpha,
beta=collapsed.beta, sigma.a=sigma.a, sigma.c=sigma.c,
sigma.e=sigma.e,
starting.u = starting.u)
u1.path <- rbind(u1.path, E.Bayes.out$EB.u1)
sigma.hat.path <- rbind(sigma.hat.path, E.Bayes.out$EB.sigma.hat)
# NOW, re-asess to see if the same beta will be indicated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta,
z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
# If the beta to be added is the same beta, then update that beta
if( updt$update.beta.position == maybe.beta ) {
# update beta
beta[updt$update.beta.position] <beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta, step))
# increment the step since a new beta has been added
step <- step + 1
}
} else {
# Otherwise, if the beta to be added is NOT new, then just add the beta
# update beta
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beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta,step))
# increment the step since a new beta has been added
step <- step + 1
}
collapsed.beta <- beta[1:(dim(orig.x)[2])] +
beta[(dim(orig.x)[2] + 1):length(beta)]
n.var.total <- sum(collapsed.beta != 0) + n.unpen
if ( n.var.total >= length(family.list)/10 |
step == 10000 |
(param.path[dim(param.path)[1],
(dim(param.path)[2] - 1)] < 0.0001 & step > 10000)) {
break
}
} else {
break
}
}

A.9

Code to run the original proposed AE model

This code fits the original proposed AE model, with a no-penalty subset, and what is shown here was applied
to the application dataset.
###########################################
### Function to find g(t) for each family i
### this representation of the g(t) function returns a scalar
### This technically finds the -log(g(t))
g.t <- function(u1, alpha, w.mat, Theta, x.mat, beta, Ymat,
add.gens, uni.env, sigma.a, sigma.e, j){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- w.mat %*% Theta + x.mat %*% beta + u1
bb[,1]<- exp(alpha[1] + aa)/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- (exp(alpha[2:(length(alpha))] + aa)/
(1 + exp(alpha[2:(length(alpha))] + aa)) exp(alpha[1:(length(alpha)-1)] + aa)/
(1 + exp(alpha[1:(length(alpha)-1)] + aa)))
bb[,(length(alpha)+1)] <- (1 - exp(alpha[length(alpha)] + aa)/
(1 + exp(alpha[length(alpha)] + aa)))
sigmas <- (sigma.a^2 * add.gens + sigma.e^2 * uni.env)
as.numeric( as.vector(((u1)^2)/2) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply(Ymat * log(bb), 1, sum)))
}
###########################################
### Function to find derivative(g(t))
### function returning a scalar
d.g.t <- function(u1, alpha, w.mat, Theta, x.mat, beta,
Ymat, add.gens, uni.env, sigma.a, sigma.e, j){
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bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- w.mat %*% Theta + x.mat %*% beta + u1
bb[,1]<- 1/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- ( (exp(alpha[2:(length(alpha))] + aa) *
(1 + exp(alpha[1:(length(alpha)-1)] + aa))^2) (exp(alpha[1:(length(alpha)-1)] + aa) *
(1 + exp(alpha[2:(length(alpha))] + aa))^2) ) /
((
exp(alpha[2:(length(alpha))] + aa) exp(alpha[1:(length(alpha)-1)] + aa) ) *
( (1 + exp(alpha[1:(length(alpha)-1)] + aa)) *
(1 + exp(alpha[2:(length(alpha))] + aa))) )
bb[,(length(alpha)+1)] <- (-exp(alpha[length(alpha)] + aa)) /
(1 + exp(alpha[length(alpha)] + aa))
sigmas <- (sigma.a^2 * add.gens + sigma.e^2 * uni.env)
as.numeric( as.vector((u1)) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply((bb * Ymat), 1, sum)))
}
###########################################
### Calculate the empirical Bayes estimates of the u1's
library(numDeriv)
library(optimx)
starting.u <- rep(1, length(family.list))
EB.u1 <- vector("numeric", length=length(family.list))
EB.Hessian <- vector("numeric", length=length(family.list))
EB.sigma.hat <- vector("numeric", length=length(family.list))
E.Bayes <- function(family.list, w.mat, x.mat, Ymat, alpha, Theta, beta, sigma.a,
sigma.e, add.gens, uni.env, starting.u){
optim.output <- vector("list", length=length(family.list))
for (i in 1:length(family.list)){
new.w.mat <- w.mat[which(z[ ,i] != 0),]
new.x.mat <- x.mat[which(z[ ,i] != 0),]
new.Ymat <- Ymat[which(z[ ,i] != 0),]
new.add.gens <- add.gens[[i]]
new.uni.env <- uni.env[[i]]
new.j <- rep(1, length=dim(new.add.gens)[1])
new.starting.u <- starting.u[i]
optim.output[[i]] <- optimx(par=new.starting.u, g.t, gr=d.g.t,
method="BFGS", hessian=TRUE,
alpha=alpha, w.mat=new.w.mat, x.mat=new.x.mat, Theta=Theta,
beta=beta, Ymat=new.Ymat,
sigma.a=sigma.a, sigma.e=sigma.e,
add.gens=new.add.gens, uni.env=new.uni.env, j=new.j)
EB.u1[i] <- optim.output[[i]]$p1
EB.Hessian[i] <- as.numeric(attr(optim.output[[i]],"details")[,"nhatend"])
EB.sigma.hat[i] <- 1/EB.Hessian[i]
}
return(list(EB.u1 = EB.u1, EB.Hessian = EB.Hessian, EB.sigma.hat = EB.sigma.hat))
}
### Get the initial EB u1 values
E.Bayes.out <- E.Bayes(family.list=family.list, w.mat=w.mat, x.mat=x.mat,
Ymat=Ymat, alpha=alpha, Theta=Theta, beta=beta,
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sigma.a=sigma.a, sigma.e=sigma.e,
add.gens=add.gens, uni.env=uni.env, starting.u=starting.u)
###########################################
### Calculate the likelihood
library(glmmML)
library(Matrix)
nodes <- ghq(n.points = n.GHQ.points, modified = FALSE)$zeros
weights <- ghq(n.points = n.GHQ.points, modified = FALSE)$weights
LL.fxn <-

function(par, EB.u1, EB.sigma.hat, n.GHQ.points, nodes, weights, w.mat,
z, x.mat, beta, family.id, family.list, num.cat, add.gens,
uni.env){
alpha <- par[1:length(alpha)]
Theta <- par[(length(alpha) + 1):(length(alpha) + dim(w.mat)[2])]
sigma.a <- par[(length(alpha) + dim(w.mat)[2] + 1)]
sigma.e <- par[(length(alpha) + dim(w.mat)[2] + 2)]

###
###
###
###
###
###
###
###

###
###
###
###
###
###
###
###
###
###

###
###

EB.u1 is a column vector of the empirical Bayes estimates of the u1's.
EB.u1 is appended to itself to create a matrix with EB.u1 in each column and as
many columns as n.GHQ.points.
EB.sigma.hat is a column vector of the standard errors of the empirical Bayes
estimates. After some manipulation, it's appended to itself n.GHQ.points times
and then each column is multiple by the corresponding node.
The resulting a matrix has no. of rows equal to the number of families/clusters
and no. of columns equal to the number of nodes.
a <- (matrix(EB.u1, nrow=length(EB.u1), ncol=n.GHQ.points, byrow=FALSE) +
as.matrix(sqrt(2 * (EB.sigma.hat)^2)) %*% t(as.matrix(nodes)))
Each column of aa is w*theta + x*beta + u1 for each node
The large w-matrix, for all subjects, is multiplied by the theta vector and
then appended to itself (i.e. repeated) n.GHQ.points times.
The z matrix is multiple by the a matrix (from the above step) in order
to repeat the appropriate rows of a so that it will have a row for each
subject. (See that before this step, a has only one row for each family/cluster
and we need to have each family's rows repeated to correspond to the number of
members in that family.)
The resulting matrix has no. of rows equal to number of subjects and no. of
columns equal to the number of nodes.
aa <matrix((w.mat %*% Theta + x.mat %*% beta), nrow=dim(w.mat)[1],
ncol=n.GHQ.points, byrow=FALSE) +
z %*% a
Create a matrix of alpha values
Consider alpha as a row vector that's appended to itself n.GHQ.points-times.
alpha.mat <- matrix(alpha, nrow=length(family.id), ncol=length(alpha), byrow=TRUE)
### Create the sigma matrices
sigma.mats <- list()
for (i in 1:length(family.list)){
sigma.mats[[i]] <- (sigma.a^2 * add.gens[[i]] +
sigma.e^2 * uni.env[[i]])
}
### Create a new list of the inverse of the sigma matrices.
i.sigmas <- lapply(sigma.mats, solve)
### Create a large, block-diagonal matrix of the inverse sigma matrices.
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big.i.sigmas <- bdiag(i.sigmas)
### bb is Robj2
### For the likelihood calculation, we need the j'Sigma^(-1)j term for each
### family/cluster. Notice that regardless of the length of j and the
### dimensions of K, this will be a scalar. This can be
### accomplished by pre and post-multiplying the large block-diagonal
### inverse-kinships matrix by the z matrix.
bb <- diag(t(z) %*% big.i.sigmas %*% z)
### Create empty matrices for the loop calculation
pi.c <- matrix(nrow=length(family.id), ncol=num.cat)
final.pi.c <- vector("numeric", length=length(family.list))
likelihood.i <- matrix(nrow=length(family.list), ncol=n.GHQ.points)
### The loop calculates the individual pi.c's for each family/cluster,
### for each node.
for (i in 1:n.GHQ.points){
### Build the pi.c matrix, with a row for each subject (j) and
# a column for each level (c)
pi.c[ ,1] <exp(alpha.mat[ ,1] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1] + aa[ ,i]))
pi.c[ , 2:(num.cat-1)] <exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])) exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i]))
pi.c[ , num.cat]
<1 - exp(alpha.mat[ , num.cat-1]
+ aa[ ,i])/(1 + exp(alpha.mat[ , num.cat-1] + aa[ ,i]))
### Apply the exponent y_ijc and then take the product across all levels (c)
a.pi.c <apply(pi.c^ Ymat, 1, prod) * z
### Change the zeros to ones so that the next multiplication step will work
a.pi.c[a.pi.c == 0] <- 1
final.pi.c <- apply(a.pi.c, 2, prod)
likelihood.i[ ,i] <- weights[i] * exp(nodes[i]^2) *
exp( -a[ ,i]^2 / 2 * bb) * final.pi.c
}
### Sum over the nodes
likelihood.i <- apply(likelihood.i, 1, sum)
likelihood <- -sum(log(sqrt(EB.sigma.hat^2)/
(pi * sqrt(2 * as.numeric(lapply(sigma.mats,det)))) * likelihood.i))
return(likelihood)
}
### Estimate alpha, theta, and the sigmas
# build the constraint matrix that will ensure alpha1 < alpha2 < alpha3 < ...
ui <- matrix(0, nrow=(length(alpha)+1), ncol=(length(alpha) +
length(Theta) + 2 ))
for (j in 1:(length(alpha) - 1)){
ui[j, j] <- -1
ui[j, j+1] <- 1
}
for (j in (length(alpha)):(length(alpha) + 1)) {
ui[j, (j + length(Theta) + 1)] <- 1
}
ci <- c(rep(0, (length(alpha))), 0.001)
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unpen.param <- constrOptim(theta=c(alpha, Theta, sigma.a, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights, w.mat=w.mat,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat, add.gens=add.gens, uni.env=uni.env)
alpha <- unpen.param$par[1:length(alpha)]
Theta <- unpen.param$par[(length(alpha) + 1):(length(Theta) +
length(alpha))]
sigma.a <- unpen.param$par[(length(alpha) + length(Theta) + 1)]
sigma.e <- unpen.param$par[(length(alpha) + length(Theta) + 2)]
likelihood.val <- exp(-unpen.param$value)
diff.LL <- 0
beta.selection <- function(alpha, x.mat, beta, w.mat, Theta, z, EB.u1, Ymat){
# put the alphas into a matrix
alpha.mat <- matrix(alpha, nrow=dim(x.mat)[1], ncol=length(alpha), byrow=TRUE)
# for convenience, construct the xB + wTHETA + zu portion of the equation
aa <- x.mat %*% beta + w.mat %*% Theta + z %*% EB.u1
# find the negative partial derivative of the likelihood function
# with respect to the p'th variable
# of the x-matrix
deriv.beta.p <-t(x.mat) %*% (
Ymat[ ,1]/(1 + exp(alpha[1] + aa)) apply(
Ymat[ ,2:(dim(Ymat)[2] - 1)] *
(exp(alpha.mat[ ,2:dim(alpha.mat)[2]] +
alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)] + 2 * aa) - 1 ) /
((1 + exp(alpha.mat[ ,2:dim(alpha.mat)[2]] + aa)) *
(1 + exp(alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)]))),
1, sum) Ymat[ , dim(Ymat)[2]] * exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa) /
(1 + exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa))
)
# find which variable has the smallest negative gradient and save
# that coefficient value
# and also the position of that variable
update.beta.value
<- min(deriv.beta.p, na.rm=TRUE)
update.beta.position
<- which.min(deriv.beta.p)
# indicate whether or not a NEW beta is being added to the model
update.beta.position.opp <- ifelse(
update.beta.position > (length(beta)/2),
update.beta.position - (length(beta)/2),
update.beta.position + (length(beta)/2))
new.beta <ifelse(
(beta[update.beta.position] == 0 & beta[update.beta.position.opp] == 0),
1,
0)
# save these in a list to be output by the function
return(list(
update.beta.value = update.beta.value,
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update.beta.position = update.beta.position,
new.beta = new.beta))
}
# append the negative of x to itself
orig.x <- x.mat
x.mat <- cbind(x.mat, -1 * x.mat)
# initialize the betas
beta <- rep(0, dim(x.mat)[2])
# initialize step to 0
step <- 0
# set the number of unpenalized parameters
n.unpen <- length(alpha) + 2
# initialize a path matrices
beta.path <- matrix(c(beta,step), ncol=(dim(x.mat)[2] + 1), byrow=TRUE)
param.path <- matrix(c(alpha, Theta, sigma.a, sigma.e, n.unpen, likelihood.val,
diff.LL, step), nrow=1, byrow=TRUE)
alpha.names <- paste("alpha", as.character(c(1:length(alpha))), sep="")
colnames(param.path) <- c(alpha.names, colnames(w.mat), "sigma.a", "sigma.e",
"no. of param", "-log(L)", "diff in -LL", "step")
u1.path <- matrix(E.Bayes.out$EB.u1, nrow=1, byrow=TRUE)
sigma.hat.path <- matrix(E.Bayes.out$EB.sigma.hat, nrow=1, byrow=TRUE)
n.var.total <- n.unpen
### begin iterative portion
repeat{
# define the object updt (don't want to use "update" bc that's a function in R)
# to be the list of the beta value and position of the beta to be updated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta, w.mat=w.mat,
Theta=Theta, z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
if (updt$update.beta.value < 0) {
# Is the beta to be added new?
# If yes, then re-estimate the alpha, Theta, sigma.u, and u's
# Then, update beta
if (updt$new.beta == 1){
# set the location of the beta that is to be added
# (the "maybe" beta)
maybe.beta <- updt$update.beta.position
# collapse beta back to the original
collapsed.beta <- beta[1:(dim(orig.x)[2])] beta[(dim(orig.x)[2] + 1):length(beta)]
# re-estimate unpenalized parameters alpha, Theta, and sigma.u
# append the new estimates to the matrix of the old estimates
unpen.param <- constrOptim(theta=c(alpha, Theta, sigma.a, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights, w.mat=w.mat,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat, add.gens=add.gens, uni.env=uni.env)
param.path <- rbind(param.path, c(unpen.param$par, n.var.total,
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unpen.param$value,
(param.path[dim(param.path)[1],
(dim(param.path)[2] - 2)] unpen.param$value),
step))
alpha <- unpen.param$par[1:length(alpha)]
Theta <- unpen.param$par[(length(alpha) + 1):(length(Theta) +
length(alpha))]
sigma.a <- unpen.param$par[(length(alpha) + length(Theta) + 1)]
sigma.e <- unpen.param$par[(length(alpha) + length(Theta) + 2)]
# re-estimate the u1's (random effects)
# append the new estimates to the matrix of old estimates
starting.u <- E.Bayes.out$EB.u1
E.Bayes.out <- E.Bayes(family.list=family.list, w.mat=w.mat, x.mat=orig.x,
Ymat=Ymat, add.gens=add.gens, uni.env=uni.env, alpha=alpha,
Theta=Theta, beta=collapsed.beta, sigma.a=sigma.a,
sigma.e=sigma.e,
starting.u = starting.u)
u1.path <- rbind(u1.path, E.Bayes.out$EB.u1)
sigma.hat.path <- rbind(sigma.hat.path, E.Bayes.out$EB.sigma.hat)
# NOW, re-asess to see if the same beta will be indicated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta, w.mat=w.mat,
Theta=Theta, z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
# If the beta to be added is the same beta, then update that beta
if( updt$update.beta.position == maybe.beta ) {
# update beta
beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta, step))
# increment the step since a new beta has been added
step <- step + 1
}
} else {
# Otherwise, if the beta to be added is NOT new, then just add the beta
# update beta
beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta,step))
# increment the step since a new beta has been added
step <- step + 1
}
collapsed.beta <- beta[1:(dim(orig.x)[2])] +
beta[(dim(orig.x)[2] + 1):length(beta)]
n.var.total <- sum(collapsed.beta != 0) + n.unpen
if ( n.var.total >= length(family.list)/10 |
step == 500000 ) {
break
}
} else {
break
}
}
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A.10

Code to run the original proposed CE model

This code fits the original proposed CE model, without a no-penalty subset, as was applied only to the
simulated data.
###########################################
### Function to find g(t) for each family i
### this representation of the g(t) function returns a scalar
### This technically finds the -log(g(t))
g.t <- function(u1, alpha, x.mat, beta, Ymat, com.env, uni.env, sigma.c, sigma.e, j){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- x.mat %*% beta + u1
bb[,1]<- exp(alpha[1] + aa)/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- (exp(alpha[2:(length(alpha))] + aa)/
(1 + exp(alpha[2:(length(alpha))] + aa)) exp(alpha[1:(length(alpha)-1)] + aa)/
(1 + exp(alpha[1:(length(alpha)-1)] + aa)))
bb[,(length(alpha)+1)] <- (1 - exp(alpha[length(alpha)] + aa)/
(1 + exp(alpha[length(alpha)] + aa)))
sigmas <- (sigma.c^2 * com.env + sigma.e^2 * uni.env)
as.numeric( as.vector(((u1)^2)/2) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply(Ymat * log(bb), 1, sum)))
}
###########################################
### Function to find derivative(g(t))
### function returning a scalar
d.g.t <- function(u1, alpha, x.mat, beta, Ymat, com.env,
uni.env, sigma.c, sigma.e, j){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- x.mat %*% beta + u1
bb[,1]<- 1/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- ( (exp(alpha[2:(length(alpha))] + aa) *
(1 + exp(alpha[1:(length(alpha)-1)] + aa))^2) (exp(alpha[1:(length(alpha)-1)] + aa) *
(1 + exp(alpha[2:(length(alpha))] + aa))^2) ) /
((
exp(alpha[2:(length(alpha))] + aa) exp(alpha[1:(length(alpha)-1)] + aa) ) *
( (1 + exp(alpha[1:(length(alpha)-1)] + aa)) *
(1 + exp(alpha[2:(length(alpha))] + aa))) )
bb[,(length(alpha)+1)] <- (-exp(alpha[length(alpha)] + aa)) /
(1 + exp(alpha[length(alpha)] + aa))
sigmas <- (sigma.c^2 * com.env + sigma.e^2 * uni.env)
as.numeric( as.vector((u1)) %*% (t(j) %*% solve(sigmas) %*% j) sum(apply((bb * Ymat), 1, sum)))
}
###########################################
### Calculate the empirical Bayes estimates of the u1's
library(numDeriv)
library(optimx)
starting.u <- rep(1, length(family.list))
EB.u1 <- vector("numeric", length=length(family.list))
EB.Hessian <- vector("numeric", length=length(family.list))
EB.sigma.hat <- vector("numeric", length=length(family.list))
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E.Bayes <- function(family.list, x.mat, Ymat, alpha, beta,
sigma.c, sigma.e, com.env, uni.env, starting.u){
optim.output <- vector("list", length=length(family.list))
for (i in 1:length(family.list)){
new.x.mat <- x.mat[which(z[ ,i] != 0),]
new.Ymat <- Ymat[which(z[ ,i] != 0),]
new.com.env <- com.env[[i]]
new.uni.env <- uni.env[[i]]
new.j <- rep(1, length=dim(new.com.env)[1])
new.starting.u <- starting.u[i]
optim.output[[i]] <- optimx(par=new.starting.u, g.t, gr=d.g.t,
method="BFGS", hessian=TRUE,
alpha=alpha, x.mat=new.x.mat, beta=beta, Ymat=new.Ymat,
sigma.c=sigma.c, sigma.e=sigma.e,
com.env=new.com.env, uni.env=new.uni.env, j=new.j)
EB.u1[i] <- optim.output[[i]]$p1
EB.Hessian[i] <- as.numeric(attr(optim.output[[i]],"details")[,"nhatend"])
EB.sigma.hat[i] <- 1/EB.Hessian[i]
}
return(list(EB.u1 = EB.u1, EB.Hessian = EB.Hessian,
EB.sigma.hat = EB.sigma.hat))
}
### Get the initial EB u1 values
E.Bayes.out <- E.Bayes(family.list=family.list, x.mat=x.mat,
Ymat=Ymat, alpha=alpha, beta=beta,
sigma.c=sigma.c, sigma.e=sigma.e,
com.env=com.env, uni.env=uni.env,
starting.u=starting.u)
###########################################
###########################################
### Calculate the likelihood
library(glmmML)
library(Matrix)
nodes <- ghq(n.points = n.GHQ.points, modified = FALSE)$zeros
weights <- ghq(n.points = n.GHQ.points, modified = FALSE)$weights
LL.fxn <function(par, EB.u1, EB.sigma.hat, n.GHQ.points, nodes, weights,
z, x.mat, beta, family.id, family.list, num.cat, com.env, uni.env){
alpha <- par[1:length(alpha)]
# Theta <- par[(length(alpha) + 1):(length(alpha) + dim(w.mat)[2])]
#sigma.a <- par[(length(alpha) + 1)]
sigma.c <- par[(length(alpha) + 1)]
sigma.e <- par[(length(alpha) + 2)]
### EB.u1 is a column vector of the empirical Bayes estimates of the u1's.
### EB.u1 is appended to itself to create a matrix with EB.u1 in each column and as
### many columns as n.GHQ.points.
### EB.sigma.hat is a column vector of the standard errors of the empirical Bayes
### estimates. After some manipulation, it's appended to itself n.GHQ.points times
### and then each column is multiple by the corresponding node.
### The resulting a matrix has no. of rows equal to the number of families/clusters
### and no. of columns equal to the number of nodes.
a <- (matrix(EB.u1, nrow=length(EB.u1), ncol=n.GHQ.points, byrow=FALSE) +
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as.matrix(sqrt(2 * (EB.sigma.hat)^2)) %*% t(as.matrix(nodes)))
Each column of aa is w*theta + x*beta + u1 for each node
The large w-matrix, for all subjects, is multiplied by the theta vector and
then appended to itself (i.e. repeated) n.GHQ.points times.
The z matrix is multiple by the a matrix (from the above step) in order
to repeat the appropriate rows of a so that it will have a row for each
subject. (See that before this step, a has only one row for each family/cluster
and we need to have each family's rows repeated to correspond to the number of
members in that family.)
The resulting matrix has no. of rows equal to number of subjects and no. of
columns equal to the number of nodes.
aa <matrix((x.mat %*% beta), nrow=dim(x.mat)[1], ncol=n.GHQ.points,
byrow=FALSE) +
z %*% a
### Create a matrix of alpha values
### Consider alpha as a row vector that's appended to itself n.GHQ.points-times.
alpha.mat <- matrix(alpha, nrow=length(family.id), ncol=length(alpha), byrow=TRUE)
### Create the sigma matrices
sigma.mats <- list()
for (i in 1:length(family.list)){
sigma.mats[[i]] <- (#sigma.a^2 * add.gens[[i]] +
sigma.c^2 * com.env[[i]] +
sigma.e^2 * uni.env[[i]])
}
### Create a new list of the inverse of the sigma matrices.
i.sigmas <- lapply(sigma.mats, solve)
### Create a large, block-diagonal matrix of the inverse sigma matrices.
big.i.sigmas <- bdiag(i.sigmas)
### bb is Robj2
### For the likelihood calculation, we need the j'Sigma^(-1)j term for each
### family/cluster. Notice that regardless of the length of j and the
### dimensions of K, this will be a scalar. This can be
### accomplished by pre and post-multiplying the large block-diagonal
### inverse-kinships matrix by the z matrix.
bb <- diag(t(z) %*% big.i.sigmas %*% z)
### Create empty matrices for the loop calculation
pi.c <- matrix(nrow=length(family.id), ncol=num.cat)
final.pi.c <- vector("numeric", length=length(family.list))
likelihood.i <- matrix(nrow=length(family.list), ncol=n.GHQ.points)
### The loop calculates the individual pi.c's for each family/cluster,
### for each node.
for (i in 1:n.GHQ.points){
### Build the pi.c matrix, with a row for each subject (j)
#and a column for each level (c)
pi.c[ ,1] <exp(alpha.mat[ ,1] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1] + aa[ ,i]))
pi.c[ , 2:(num.cat-1)] <exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])) exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i]))
pi.c[ , num.cat]
<1 - exp(alpha.mat[ , num.cat-1]
+ aa[ ,i])/
(1 + exp(alpha.mat[ , num.cat-1] + aa[ ,i]))
###
###
###
###
###
###
###
###
###
###
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### Apply the exponent y_ijc and then take the product across all levels (c)
a.pi.c <apply(pi.c^ Ymat, 1, prod) * z
### Change the zeros to ones so that the next multiplication step will work
a.pi.c[a.pi.c == 0] <- 1
final.pi.c <- apply(a.pi.c, 2, prod)
likelihood.i[ ,i] <- weights[i] * exp(nodes[i]^2) *
exp( -a[ ,i]^2 / 2 * bb) * final.pi.c
}
### Sum over the nodes
likelihood.i <- apply(likelihood.i, 1, sum)
likelihood <- -sum(log(sqrt(EB.sigma.hat^2)/
(pi * sqrt(2 * as.numeric(lapply(sigma.mats,det)))) * likelihood.i))
return(likelihood)
}
### Estimate alpha, theta, and the sigmas
# build the constraint matrix that will ensure alpha1 < alpha2 < alpha3 < ...
ui <- matrix(0, nrow=(length(alpha)+1), ncol=(length(alpha) + 2 ))
for (j in 1:(length(alpha) - 1)){
ui[j, j] <- -1
ui[j, j+1] <- 1
}
for (j in (length(alpha)):(length(alpha) + 1)) {
ui[j, (j + 1)] <- 1
}
ci <- c(rep(0, (length(alpha))), 0.001)
unpen.param <- constrOptim(theta=c(alpha, sigma.c, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights,
z=z, x.mat=x.mat, beta=beta, family.id=family.id, family.list=family.list,
num.cat=num.cat, com.env=com.env, uni.env=uni.env)
alpha <- unpen.param$par[1:length(alpha)]
sigma.c <- unpen.param$par[(length(alpha) + 1)]
sigma.e <- unpen.param$par[(length(alpha) + 2)]
likelihood.val <- unpen.param$value
diff.LL <- 0
beta.selection <- function(alpha, x.mat, beta, z, EB.u1, Ymat){
# put the alphas into a matrix
alpha.mat <- matrix(alpha, nrow=dim(x.mat)[1], ncol=length(alpha), byrow=TRUE)
# for convenience, construct the xB + wTHETA + zu portion of the equation
aa <- x.mat %*% beta + z %*% EB.u1
# find the negative partial derivative of the likelihood function with
# respect to the p'th variable
# of the x-matrix
deriv.beta.p <-t(x.mat) %*% (
Ymat[ ,1]/(1 + exp(alpha[1] + aa)) apply(
Ymat[ ,2:(dim(Ymat)[2] - 1)] *
(exp(alpha.mat[ ,2:dim(alpha.mat)[2]] +
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alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)] + 2 * aa) - 1 ) /
((1 + exp(alpha.mat[ ,2:dim(alpha.mat)[2]] + aa)) *
(1 + exp(alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)]))),
1, sum) Ymat[ , dim(Ymat)[2]] * exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa) /
(1 + exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa))
)
# find which variable has the smallest negative gradient and
# save that coefficient value and also the position of that variable
update.beta.value
<- min(deriv.beta.p, na.rm=TRUE)
update.beta.position
<- which.min(deriv.beta.p)
# indicate whether or not a NEW beta is being added to the model
update.beta.position.opp <- ifelse(
update.beta.position > (length(beta)/2),
update.beta.position - (length(beta)/2),
update.beta.position + (length(beta)/2))
new.beta <ifelse(
(beta[update.beta.position] == 0 & beta[update.beta.position.opp] == 0),
1,
0)
# save these in a list to be output by the function
return(list(
update.beta.value = update.beta.value,
update.beta.position = update.beta.position,
new.beta = new.beta))
}
# append the negative of x to itself
orig.x <- x.mat
x.mat <- cbind(x.mat, -1 * x.mat)
# initialize the betas
beta <- rep(0, dim(x.mat)[2])
# initialize step to 0
step <- 0
# set the number of unpenalized parameters
n.unpen <- length(alpha) + 2
# initialize a path matrices
beta.path <- matrix(c(beta,step), ncol=(dim(x.mat)[2] + 1), byrow=TRUE)
param.path <- matrix(c(alpha, sigma.c, sigma.e, n.unpen,
likelihood.val, diff.LL, step),
nrow=1, byrow=TRUE)
alpha.names <- paste("alpha", as.character(c(1:length(alpha))), sep="")
colnames(param.path) <- c(alpha.names, "sigma.c", "sigma.e","no. of param",
"-log(L)", "diff in -LL", "step")
u1.path <- matrix(E.Bayes.out$EB.u1, nrow=1, byrow=TRUE)
sigma.hat.path <- matrix(E.Bayes.out$EB.sigma.hat, nrow=1, byrow=TRUE)
n.var.total <- n.unpen
### begin iterative portion
repeat{
# define the object updt (don't want to use "update" bc that's a function in R)
# to be the list of the beta value and position of the beta to be updated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta,
z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
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if (updt$update.beta.value < 0) {
# Is the beta to be added new?
# If yes, then re-estimate the alpha, Theta, sigma.u, and u's
# Then, update beta
if (updt$new.beta == 1){
# set the location of the beta that is to be added
# (the "maybe" beta)
maybe.beta <- updt$update.beta.position
# collapse beta back to the original
collapsed.beta <- beta[1:(dim(orig.x)[2])] beta[(dim(orig.x)[2] + 1):length(beta)]
# re-estimate unpenalized parameters alpha, Theta, and sigma.u
# append the new estimates to the matrix of the old estimates
unpen.param <- constrOptim(theta=c(alpha, sigma.c, sigma.e),
f=LL.fxn, grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat, com.env=com.env, uni.env=uni.env)
param.path <- rbind(param.path, c(unpen.param$par, n.var.total,
unpen.param$value,
(param.path[dim(param.path)[1], (dim(param.path)[2] - 2)] unpen.param$value),
step))
alpha <- unpen.param$par[1:length(alpha)]
sigma.c <- unpen.param$par[(length(alpha) + 1)]
sigma.e <- unpen.param$par[(length(alpha) + 2)]
# re-estimate the u1's (random effects)
# append the new estimates to the matrix of old estimates
starting.u <- E.Bayes.out$EB.u1
E.Bayes.out <- E.Bayes(family.list=family.list, x.mat=orig.x,
Ymat=Ymat, com.env=com.env, uni.env=uni.env, alpha=alpha,
beta=collapsed.beta, sigma.c=sigma.c, sigma.e=sigma.e,
starting.u = starting.u)
u1.path <- rbind(u1.path, E.Bayes.out$EB.u1)
sigma.hat.path <- rbind(sigma.hat.path, E.Bayes.out$EB.sigma.hat)
# NOW, re-asess to see if the same beta will be indicated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta,
z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
# If the beta to be added is the same beta, then update that beta
if( updt$update.beta.position == maybe.beta ) {
# update beta
beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta, step))
# increment the step since a new beta has been added
step <- step + 1
}
} else {
# Otherwise, if the beta to be added is NOT new, then just add the beta
# update beta
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beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta,step))
# increment the step since a new beta has been added
step <- step + 1
}
collapsed.beta <- beta[1:(dim(orig.x)[2])] +
beta[(dim(orig.x)[2] + 1):length(beta)]
n.var.total <- sum(collapsed.beta != 0) + n.unpen
if ( n.var.total >= length(family.list)/10 |
step == 10000 |
(param.path[dim(param.path)[1], (dim(param.path)[2] - 1)] <
0.0001 & step > 10000)) {
break
}
} else {
break
}
}

A.11

Code to run the alternate proposed model

This code fits the alternate proposed model, with a no-penalty subset, and was applied to the application
dataset.
###########################################
### Function to find g(t) for each family i
### this representation of the g(t) function returns a scalar
### This technically finds the -log(g(t))
g.t <- function(u1, alpha, w.mat, Theta, x.mat, beta, Ymat, sigma, zyg.ind){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- w.mat %*% Theta + x.mat %*% beta + as.numeric(zyg.ind %*% sigma * u1)
bb[,1]<- exp(alpha[1] + aa)/(1 + exp(alpha[1] + aa))
bb[,2:(length(alpha))] <- (exp(alpha[2:(length(alpha))] + aa)/
(1 + exp(alpha[2:(length(alpha))] + aa)) exp(alpha[1:(length(alpha)-1)] + aa)/
(1 + exp(alpha[1:(length(alpha)-1)] + aa)))
bb[,(length(alpha)+1)] <- (1 - exp(alpha[length(alpha)] + aa)/
(1 + exp(alpha[length(alpha)] + aa)))
as.numeric( as.vector(((u1)^2)/2) sum(apply(Ymat * log(bb), 1, sum)))
}
###########################################
### Function to find derivative(g(t))
### function returning a scalar
d.g.t <- function(u1, alpha, w.mat, Theta, x.mat, beta, Ymat, sigma, zyg.ind){
bb <- matrix(nrow=dim(Ymat)[1], ncol=dim(Ymat)[2])
aa <- w.mat %*% Theta + x.mat %*% beta + as.numeric(zyg.ind %*% sigma * u1)
bb[,1]<- as.numeric(zyg.ind %*% sigma)/(1 + exp(alpha[1] + aa))
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bb[,2:(length(alpha))] <- as.numeric(zyg.ind %*% sigma) *
( (exp(alpha[2:(length(alpha))] + aa) *
(1 + exp(alpha[1:(length(alpha)-1)] + aa))^2) (exp(alpha[1:(length(alpha)-1)] + aa) *
(1 + exp(alpha[2:(length(alpha))] + aa))^2) ) /
((
exp(alpha[2:(length(alpha))] + aa) exp(alpha[1:(length(alpha)-1)] + aa) ) *
( (1 + exp(alpha[1:(length(alpha)-1)] + aa)) *
(1 + exp(alpha[2:(length(alpha))] + aa))) )
bb[,(length(alpha)+1)] <- (as.numeric(zyg.ind %*% sigma) *
-exp(alpha[length(alpha)] + aa)) /
(1 + exp(alpha[length(alpha)] + aa))
as.numeric( u1 - sum(apply((bb * Ymat), 1, sum)))
}
###########################################
### Calculate the empirical Bayes estimates of the u1's
library(numDeriv)
library(optimx)
starting.u <- rep(1, length(family.list))
EB.u1 <- vector("numeric", length=length(family.list))
EB.Hessian <- vector("numeric", length=length(family.list))
EB.sigma.hat <- vector("numeric", length=length(family.list))
E.Bayes <- function(family.list, w.mat, x.mat, Ymat, alpha, Theta, beta, sigma,
zyg.ind, starting.u){
optim.output <- vector("list", length=length(family.list))
for (i in 1:length(family.list)){
new.w.mat <- w.mat[which(z[ ,i] != 0),]
new.x.mat <- x.mat[which(z[ ,i] != 0),]
new.Ymat <- Ymat[which(z[ ,i] != 0),]
new.zyg.ind <- zyg.ind[i, ]
new.starting.u <- starting.u[i]
optim.output[[i]] <- optimx(par=new.starting.u, g.t, gr=d.g.t,
method="BFGS", hessian=TRUE,
alpha=alpha, w.mat=new.w.mat, x.mat=new.x.mat,
zyg.ind=new.zyg.ind,
Theta=Theta, beta=beta, Ymat=new.Ymat, sigma=sigma)
EB.u1[i] <- optim.output[[i]]$p1
EB.Hessian[i] <- as.numeric(attr(optim.output[[i]],"details")[,"nhatend"])
EB.sigma.hat[i] <- 1/EB.Hessian[i]
}
return(list(EB.u1 = EB.u1, EB.Hessian = EB.Hessian,
EB.sigma.hat = EB.sigma.hat))
}
### Get the initial EB u1 values
E.Bayes.out <- E.Bayes(family.list=family.list, w.mat=w.mat, x.mat=x.mat,
Ymat=Ymat, alpha=alpha, Theta=Theta, beta=beta,
sigma=sigma, zyg.ind=zyg.ind, starting.u=starting.u)
###########################################
### Calculate the likelihood
library(glmmML)
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library(Matrix)
nodes <- ghq(n.points = n.GHQ.points, modified = FALSE)$zeros
weights <- ghq(n.points = n.GHQ.points, modified = FALSE)$weights
LL.fxn <-

function(par, EB.u1, EB.sigma.hat, n.GHQ.points, nodes, weights, w.mat,
z, x.mat, beta, zyg.ind, family.id, family.list, num.cat){
alpha <- par[1:length(alpha)]
Theta <- par[(length(alpha) + 1):(length(alpha) + dim(w.mat)[2])]
sigma <- par[(length(alpha) + dim(w.mat)[2] + 1):length(par)]

###
###
###
###
###
###
###
###

EB.u1 is a column vector of the empirical Bayes estimates of the u1's.
EB.u1 is appended to itself to create a matrix with EB.u1 in each column and as
many columns as n.GHQ.points.
EB.sigma.hat is a column vector of the standard errors of the empirical Bayes
estimates. After some manipulation, it's appended to itself n.GHQ.points times
and then each column is multiple by the corresponding node.
The resulting a matrix has no. of rows equal to the number of families/clusters
and no. of columns equal to the number of nodes.
a <- (matrix(EB.u1, nrow=length(EB.u1), ncol=n.GHQ.points, byrow=FALSE) +
as.matrix(sqrt(2 * (EB.sigma.hat)^2)) %*% t(as.matrix(nodes)))
### Each column of aa is w*theta + x*beta + u1 for each node
### The large w-matrix, for all subjects, is multiplied by the theta vector and
### then appended to itself (i.e. repeated) n.GHQ.points times.
### The z matrix is multiple by the a matrix (from the above step) in order
### to repeat the appropriate rows of a so that it will have a row for each
### subject. (See that before this step, a has only one row for each family/cluster
### and we need to have each family's rows repeated to correspond to the number of
### members in that family.)
### The resulting matrix has no. of rows equal to number of subjects and no. of
### columns equal to the number of nodes.
aa <matrix((w.mat %*% Theta + x.mat %*% beta), nrow=dim(w.mat)[1],
ncol=n.GHQ.points, byrow=FALSE) +
z %*% (a * matrix(zyg.ind %*% sigma,
nrow=dim(zyg.ind)[1], ncol=n.GHQ.points, byrow=FALSE))
### Create a matrix of alpha values
### Consider alpha as a row vector that's appended to itself n.GHQ.points-times.
alpha.mat <- matrix(alpha, nrow=length(family.id), ncol=length(alpha), byrow=TRUE)
### Create empty matrices for the loop calculation
pi.c <- matrix(nrow=length(family.id), ncol=num.cat)
final.pi.c <- vector("numeric", length=length(family.list))
likelihood.i <- matrix(nrow=length(family.list), ncol=n.GHQ.points)
### The loop calculates the individual pi.c's for each family/cluster,
### for each node.
for (i in 1:n.GHQ.points){
### Build the pi.c matrix, with a row for each subject (j)
# and a column for each level (c)
pi.c[ ,1] <exp(alpha.mat[ ,1] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1] + aa[ ,i]))
pi.c[ , 2:(num.cat-1)] <exp(alpha.mat[ ,2:(num.cat-1)] +
aa[ ,i])/
(1 + exp(alpha.mat[ ,2:(num.cat-1)] + aa[ ,i])) exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i])/
(1 + exp(alpha.mat[ ,1:(num.cat-2)] + aa[ ,i]))
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pi.c[ , num.cat]
<1 - exp(alpha.mat[ , num.cat-1] +
aa[ ,i])/
(1 + exp(alpha.mat[ , num.cat-1] + aa[ ,i]))
### Apply the exponent y_ijc and then take the product across all levels (c)
a.pi.c <apply(pi.c^ Ymat, 1, prod) * z
### Change the zeros to ones so that the next multiplication step will work
a.pi.c[a.pi.c == 0] <- 1
final.pi.c <- apply(a.pi.c, 2, prod)
likelihood.i[ ,i] <- weights[i] * exp(nodes[i]^2) * exp( -a[ ,i]^2 / 2 ) *
final.pi.c
}
### Sum over the nodes
likelihood.i <- apply(likelihood.i, 1, sum)
likelihood <- -sum(log(sqrt(EB.sigma.hat^2)/(sqrt(pi)) * likelihood.i))
return(likelihood)
}
### Estimate alpha, theta, and the sigmas
# build the constraint matrix that will ensure alpha1 < alpha2 < alpha3 < ...
# and the sigmas are non-negative
ui <- matrix(0, nrow=(length(alpha)+1), ncol=(length(alpha) +
length(Theta) + 2 ))
for (j in 1:(length(alpha) - 1)){
ui[j, j] <- -1
ui[j, j+1] <- 1
}
for (j in (length(alpha)):(length(alpha) + 1)) {
ui[j, (j + length(Theta) + 1)] <- 1
}
ci <- c(rep(0, (length(alpha) + 1)))
unpen.param <- constrOptim(theta=c(alpha, Theta, sigma), f=LL.fxn,
grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights, w.mat=w.mat, zyg.ind=zyg.ind,
z=z, x.mat=x.mat, beta=beta, family.id=family.id,
family.list=family.list,
num.cat=num.cat)
alpha <- unpen.param$par[1:length(alpha)]
Theta <- unpen.param$par[(length(alpha) + 1):(length(Theta) +
length(alpha))]
sigma <- unpen.param$par[(length(alpha) +
length(Theta) + 1):length(unpen.param$par)]
likelihood.val <- exp(-unpen.param$value)
diff.LL <- 0
beta.selection <- function(alpha, x.mat, beta, w.mat, Theta,
sigma, zyg.ind, z, EB.u1, Ymat){
# put the alphas into a matrix
alpha.mat <- matrix(alpha, nrow=dim(x.mat)[1],
ncol=length(alpha), byrow=TRUE)
# for convenience, construct the xB + wTHETA + zu portion of the equation
aa <- x.mat %*% beta + w.mat %*% Theta + z %*%
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(EB.u1 * matrix(zyg.ind %*% sigma, nrow=dim(zyg.ind)[1],
ncol=1, byrow=FALSE))
# find the negative partial derivative of the likelihood function with
# respect to the p'th variable of the x-matrix
deriv.beta.p <-t(x.mat) %*% (
Ymat[ ,1]/(1 + exp(alpha[1] + aa)) apply(
Ymat[ ,2:(dim(Ymat)[2] - 1)] *
(exp(alpha.mat[ ,2:dim(alpha.mat)[2]] +
alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)] + 2 * aa) - 1 ) /
((1 + exp(alpha.mat[ ,2:dim(alpha.mat)[2]] + aa)) *
(1 + exp(alpha.mat[ ,1:(dim(alpha.mat)[2] - 1)]))),
1, sum) Ymat[ , dim(Ymat)[2]] * exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa) /
(1 + exp(alpha.mat[ ,dim(alpha.mat)[2]] + aa))
)
# find which variable has the smallest negative gradient and save that
# coefficient value and also the position of that variable
update.beta.value
<- min(deriv.beta.p, na.rm=TRUE)
update.beta.position
<- which.min(deriv.beta.p)
# indicate whether or not a NEW beta is being added to the model
update.beta.position.opp <- ifelse(
update.beta.position > (length(beta)/2),
update.beta.position - (length(beta)/2),
update.beta.position + (length(beta)/2))
new.beta <ifelse(
(beta[update.beta.position] == 0 & beta[update.beta.position.opp] == 0),
1,
0)
# save these in a list to be output by the function
return(list(
update.beta.value = update.beta.value,
update.beta.position = update.beta.position,
new.beta = new.beta))
}
# append the negative of x to itself
orig.x <- x.mat
x.mat <- cbind(x.mat, -1 * x.mat)
# initialize the betas
beta <- rep(0, dim(x.mat)[2])
# initialize step to 0
step <- 0
# set the number of unpenalized parameters
n.unpen <- length(alpha) +length(Theta) + 2
# initialize a path matrices
beta.path <- matrix(c(beta,step), ncol=(dim(x.mat)[2] + 1), byrow=TRUE)
param.path <- matrix(c(alpha, Theta, sigma, n.unpen,
likelihood.val, diff.LL, step),
nrow=1, byrow=TRUE)
alpha.names <- paste("alpha", as.character(c(1:length(alpha))), sep="")
colnames(param.path) <- c(alpha.names, colnames(w.mat), "sigma.MZ", "sigma.DZ",
"no. of param", "-log(L)", "diff in -LL", "step")
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u1.path <- matrix(E.Bayes.out$EB.u1, nrow=1, byrow=TRUE)
sigma.hat.path <- matrix(E.Bayes.out$EB.sigma.hat, nrow=1, byrow=TRUE)
n.var.total <- n.unpen

### begin iterative portion
repeat{
# define the object updt (don't want to use "update" bc that's a function in R)
# to be the list of the beta value and position of the beta to be updated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta, w.mat=w.mat,
Theta=Theta, z=z, zyg.ind=zyg.ind, sigma=sigma,
EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat)
if (updt$update.beta.value < 0) {
# Is the beta to be added new?
# If yes, then re-estimate the alpha, Theta, sigma.u, and u's
# Then, update beta
if (updt$new.beta == 1){
# set the location of the beta that is to be added
# (the "maybe" beta)
maybe.beta <- updt$update.beta.position
# collapse beta back to the original
collapsed.beta <- beta[1:(dim(orig.x)[2])] beta[(dim(orig.x)[2] + 1):length(beta)]
# re-estimate unpenalized parameters alpha, Theta, and sigma.u
# append the new estimates to the matrix of the old estimates
unpen.param <- constrOptim(theta=c(alpha, Theta, sigma), f=LL.fxn,
grad=NULL, ui=ui, ci=ci,
EB.u1=E.Bayes.out$EB.u1, EB.sigma.hat=E.Bayes.out$EB.sigma.hat,
n.GHQ.points=n.GHQ.points,
nodes=nodes, weights=weights, w.mat=w.mat,
z=z, x.mat=x.mat, beta=beta, family.id=family.id, family.list=family.list,
num.cat=num.cat, zyg.ind=zyg.ind)
param.path <- rbind(param.path, c(unpen.param$par, n.var.total, unpen.param$value,
(param.path[dim(param.path)[1], (dim(param.path)[2] - 2)] - unpen.param$value),
step))
alpha <- unpen.param$par[1:length(alpha)]
Theta <- unpen.param$par[(length(alpha) + 1):(length(Theta) + length(alpha))]
sigma <- unpen.param$par[(length(alpha) +
length(Theta) + 1):(length(alpha) + length(Theta) + 2)]
# re-estimate the u1's (random effects)
# append the new estimates to the matrix of old estimates
starting.u <- E.Bayes.out$EB.u1
E.Bayes.out <- E.Bayes(family.list=family.list, w.mat=w.mat, x.mat=orig.x,
Ymat=Ymat, alpha=alpha, Theta=Theta, zyg.ind=zyg.ind,
beta=collapsed.beta, sigma=sigma,
starting.u = starting.u)
u1.path <- rbind(u1.path, E.Bayes.out$EB.u1)
sigma.hat.path <- rbind(sigma.hat.path, E.Bayes.out$EB.sigma.hat)
# NOW, re-asess to see if the same beta will be indicated
updt <- beta.selection(alpha=alpha, x.mat=x.mat, beta=beta, w.mat=w.mat,
Theta=Theta, z=z, EB.u1=E.Bayes.out$EB.u1, Ymat=Ymat,
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sigma=sigma, zyg.ind=zyg.ind)
# If the beta to be added is the same beta, then update that beta
if( updt$update.beta.position == maybe.beta ) {
# update beta
beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta, step))
# increment the step since a new beta has been added
step <- step + 1
}
} else {
# Otherwise, if the beta to be added is NOT new, then just add the beta
# update beta
beta[updt$update.beta.position] <- beta[updt$update.beta.position] +
epsilon
beta.path <- rbind(beta.path, c(beta,step))
# increment the step since a new beta has been added
step <- step + 1
}
collapsed.beta <- beta[1:(dim(orig.x)[2])] +
beta[(dim(orig.x)[2] + 1):length(beta)]
n.var.total <- sum(collapsed.beta != 0) + n.unpen
if ( n.var.total >= length(family.list)/10 |
step == 500000 |
(param.path[dim(param.path)[1], (dim(param.path)[2] - 1)] <
0.0001 & step > 100)) {
break
}
} else {
break
}
}

A.12

Code to setup the application data for the original proposed AE model

This code sets up the data to apply the original proposed AE model to the application data.
# Runs on the Beowolf cluster
# Load the drug and personality data
#load("/Users/AmandaGentry/Documents/Thesis/final_set.RData")
load("/home/gentryae/myR/final_set.RData")
# Load the filtered chromosome object
### For chr 9-22
load("/home/gentryae/myR/FiltChr/chr22filt.RData")
chr.subset <- chr22filt[,colnames(chr22filt) %in% as.character(drug.jepq$subid) ]
### For chr 1-8
load("/home/gentryae/myR/FiltChr/chr1filtp1.RData")
snps1 <- chr1filt
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load("/home/gentryae/myR/FiltChr/chr1filtp2.RData")
snps2 <- chr1filt
snps <- rbind(snps1,snps2)
chr.subset <- snps[,colnames(snps) %in% as.character(drug.jepq$subid) ]
chr.subset <-data.frame(t(chr.subset))
chr.subset$subid <- as.numeric(rownames(chr.subset))
drug.jepq$stem_alc_bin <- ifelse(drug.jepq$stem_alc < 2, 1, 0)
drug.jepq$stem_nic1 <- ifelse(drug.jepq$stem_nic == 1, 1, 0)
drug.jepq$stem_nic2 <- ifelse(drug.jepq$stem_nic == 2, 1, 0)
drug.jepq.subset <- drug.jepq[, c("subid", "familyid", "zygosity",
"stem_ca", "stem_alc_bin", "stem_nic1", "stem_nic2")]
final <- merge(drug.jepq.subset, chr.subset, by="subid")
# list the subjects individually
family.id <- as.numeric(as.character(final$familyid))
# list the families (clusters)
family.list <- as.numeric(as.character(unique(family.id)))
family.size <- numeric(length=length(family.list))
for (i in 1:length(family.list)){
family.size[i] <- sum(family.id == family.list[i])
}
# Create a zygosity vector that shows zygosity by INDIVIDUAL
zygosity <- final$zygosity
# Then create a zygosity vector that lists zygosity by FAMILY
zygosity.fam <- zygosity[c(TRUE, FALSE)]
names(zygosity.fam) <- family.list
# create the MZ and DZ indicator vectors/columns
### Zygosity is defined: 1=MZFF, 2=MZMM, 3=DZFF, 4=DZMM, 5-6=DZFM
MZ <- ifelse(zygosity < 3, 1, 0)
DZ <- ifelse(zygosity > 2, 1, 0)
names(MZ) <- names(DZ) <- names(zygosity)
# create the zygosity indicator vector for each family
zyg.ind <- matrix(nrow=length(zygosity.fam), ncol=2)
zyg.ind[,1] <- ifelse(zygosity.fam < 3, 1, 0)
zyg.ind[,2] <- ifelse(zygosity.fam > 2, 1, 0)
rownames(zyg.ind) <- family.list
# Create the response vector from the Cannabis stem item
response <- final$stem_ca
names(response) <- final$subid
### Define the penalized and unpenalized covariates
# Unpenalized
w.mat <- as.matrix(final[,c("stem_alc_bin", "stem_nic1", "stem_nic2")])
rownames(w.mat) <- final$subid
#Penalized
x.mat <- as.matrix(final[,8:(dim(final)[2])])
rownames(x.mat) <- final$subid
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##################################################################
### Initialize the important stuff ###
epsilon <- 0.001
ordinal.level <- as.numeric(levels(as.factor(response)))
num.cat <- nlevels(as.factor(response))
# LATER - add an error message so that the function will not proceed
# if num.cat < 3
levels.response <- sort(unique(response))
# set the starting alpha and theta values
alpha <- vector(length=(num.cat-1), mode="numeric")
# set the alphas using the empirical values
for (ii in 1:(num.cat-1)){
alpha[ii] <- sum(response == levels.response[ii]) / length(response)
}
alpha <- log(cumsum(alpha)/(1 - cumsum(alpha)))[1:(num.cat - 1)]
Theta <- rep(0, dim(w.mat)[2])
library(ordinal)
ord.model <- clm(as.factor(response) ~ w.mat, start=c(alpha, Theta))
alpha <- ord.model$alpha
Theta <- ord.model$beta
# set the starting value for sigma.a and sigma.c, the variance of the random effect
sigma.a <- 1
sigma.c <- 1
sigma.e <- 0.5
# set starting beta values
beta <- rep(0, dim(x.mat)[2])
### Zygosity is defined: 1=MZFF, 2=MZMM, 3=DZFF, 4=DZMM, 5-6=DZFM
add.gens <- list()
com.env <- list()
uni.env <- list()
for (i in 1:length(family.list)) {
com.env[[i]] <- matrix(1, nrow=family.size[i], ncol=family.size[i])
uni.env[[i]] <- diag(1, nrow=family.size[i], ncol=family.size[i])
add.gens[[i]] <- diag(1, nrow=family.size[i], ncol=family.size[i])
zyg <- zygosity[family.id == family.list[i]]
no.DZ.twins1 <- sum(zyg == 1)
no.DZ.twins2 <- sum(zyg == 2)
if (no.DZ.twins1 == 2){
add.gens[[i]][which(zyg==1)[1], which(zyg==1)[2]] <- 1
add.gens[[i]][which(zyg==1)[2], which(zyg==1)[1]] <- 1
} else {
add.gens[[i]]<- add.gens[[i]]
}
if (no.DZ.twins2 == 2){
add.gens[[i]][which(zyg==2)[1], which(zyg==2)[2]] <- 1
add.gens[[i]][which(zyg==2)[2], which(zyg==2)[1]] <- 1
} else {
add.gens[[i]]<- add.gens[[i]]
}
add.gens[[i]][add.gens[[i]]==0] <- 0.5
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}
levels <- sort(unique(response))
k <- length(unique(response))
# build the response matrix
Ymat <- matrix(0, nrow = length(response), ncol = k)
for (i in levels) {
Ymat[which(response == i), which(levels == i)] <- 1
}
z <- matrix(0, nrow = length(response), ncol = length(family.list))
for (i in (1:length(family.id))) {
for (j in (1:length(family.list))){
z[i,j] <- ifelse(family.id[i] == family.list[j], 1, 0)
}
}
n.GHQ.points <- 7

A.13

Code to setup the application data for the alternate proposed AE model

This code sets up the data to apply the original proposed AE model to the application data.
# Runs on the Beowolf cluster
# Load the drug and personality data
#load("/Users/AmandaGentry/Documents/Thesis/final_set.RData")
load("/home/gentryae/myR/final_set.RData")
# Load the filtered chromosome object
### For chr 9-22
load("/home/gentryae/myR/FiltChr/chr22filt.RData")
chr.subset <- chr22filt[,colnames(chr22filt) %in% as.character(drug.jepq$subid) ]
### For chr 1-8
load("/home/gentryae/myR/FiltChr/chr1filtp1.RData")
snps1 <- chr1filt
load("/home/gentryae/myR/FiltChr/chr1filtp2.RData")
snps2 <- chr1filt
snps <- rbind(snps1,snps2)
chr.subset <- snps[,colnames(snps) %in% as.character(drug.jepq$subid) ]
chr.subset <-data.frame(t(chr.subset))
chr.subset$subid <- as.numeric(rownames(chr.subset))
drug.jepq$stem_alc_bin <- ifelse(drug.jepq$stem_alc < 2, 1, 0)
drug.jepq$stem_nic1 <- ifelse(drug.jepq$stem_nic == 1, 1, 0)
drug.jepq$stem_nic2 <- ifelse(drug.jepq$stem_nic == 2, 1, 0)
drug.jepq.subset <- drug.jepq[, c("subid", "familyid", "zygosity",
"stem_ca", "stem_alc_bin", "stem_nic1", "stem_nic2")]
final <- merge(drug.jepq.subset, chr.subset, by="subid")
# list the subjects individually
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family.id <- as.numeric(as.character(final$familyid))
# list the families (clusters)
family.list <- as.numeric(as.character(unique(family.id)))
# Create a zygosity vector that shows zygosity by INDIVIDUAL
zygosity <- final$zygosity
# Then create a zygosity vector that lists zygosity by FAMILY
zygosity.fam <- zygosity[c(TRUE, FALSE)]
names(zygosity.fam) <- family.list
# create the MZ and DZ indicator vectors/columns
### Zygosity is defined: 1=MZFF, 2=MZMM, 3=DZFF, 4=DZMM, 5-6=DZFM
MZ <- ifelse(zygosity < 3, 1, 0)
DZ <- ifelse(zygosity > 2, 1, 0)
names(MZ) <- names(DZ) <- names(zygosity)
# create the zygosity indicator vector for each family
zyg.ind <- matrix(nrow=length(zygosity.fam), ncol=2)
zyg.ind[,1] <- ifelse(zygosity.fam < 3, 1, 0)
zyg.ind[,2] <- ifelse(zygosity.fam > 2, 1, 0)
rownames(zyg.ind) <- family.list
# Create the response vector from the Cannabis stem item
response <- final$stem_ca
names(response) <- final$subid
### Define the penalized and unpenalized covariates
# Unpenalized
w.mat <- as.matrix(final[,c("stem_alc_bin", "stem_nic1", "stem_nic2")])
rownames(w.mat) <- final$subid
#Penalized
x.mat <- as.matrix(final[,8:(dim(final)[2])])
rownames(x.mat) <- final$subid
##################################################################
### Initialize the important stuff ###
epsilon <- 0.001
ordinal.level <- as.numeric(levels(as.factor(response)))
num.cat <- nlevels(as.factor(response))
# LATER - add an error message so that the function will not proceed
# if num.cat < 3
levels.response <- sort(unique(response))
# set the starting alpha and theta values
alpha <- vector(length=(num.cat-1), mode="numeric")
# set the alphas using the empirical values
for (ii in 1:(num.cat-1)){
alpha[ii] <- sum(response == levels.response[ii]) / length(response)
}
alpha <- log(cumsum(alpha)/(1 - cumsum(alpha)))[1:(num.cat - 1)]
Theta <- rep(0, dim(w.mat)[2])
library(ordinal)
ord.model <- clm(as.factor(response) ~ w.mat, start=c(alpha, Theta))
alpha <- ord.model$alpha
Theta <- ord.model$beta
# set the starting value for sigma.mz and sigma.dz, the variance of the random effects
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sigma <- matrix(c(1,1), nrow=2)
# set starting beta values
beta <- rep(0, dim(x.mat)[2])
levels <- sort(unique(response))
k <- length(unique(response))
# build the response matrix
Ymat <- matrix(0, nrow = length(response), ncol = k)
for (i in levels) {
Ymat[which(response == i), which(levels == i)] <- 1
}
z <- matrix(0, nrow = length(response), ncol = length(family.list))
for (i in (1:length(family.id))) {
for (j in (1:length(family.list))){
z[i,j] <- ifelse(family.id[i] == family.list[j], 1, 0)
}
}
n.GHQ.points <- 7
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